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Résumé 
La signalisation par l’estrogène a longtemps été considérée comme jouant un rôle 
critique dans le développement et la progression des cancers hormono-dépendants tel que le 
cancer du sein. Deux tiers des cancers du sein expriment le récepteur des estrogènes (ER) 
qui constitue un élément indiscutable dans cette pathologie. L’acquisition d’une résistance 
endocrinienne est cependant devenue un obstacle majeur au traitement des cancers 
hormono-dépendants devenus hormono-indépendants. 
 
L’émergence de cancers hormono-indépendants est décrite comme étant causée par 
une variété de voies telles que l’activation de ER en absence d’estrogène, l’hypersensibilité 
du récepteur aux faibles concentrations plasmique d’estrogène ainsi que l’activation de ER 
par des modulateurs sélectifs. De plus, l’activité du ER est fortement influencée par 
l’environnement cellulaire tel que l’activation de voie de signalisation des facteurs de 
croissances, la disponibilité de protéines co-régulatrices et des séquences promotrices 
ciblées. Présentement, les études ont principalement considéré le rôle de ERα, cependant 
avec la découverte de ERβ, notre compréhension de la diversité des mécanismes potentiels 
impliquant des réponses ER-dépendantes s’est grandement améliorée. L’activation 
hormono-indépendante de ER est retrouvée dans les tumeurs mammaires estrogène-
dépendantes. L’activation des voies des kinases entraîne le développement d’un phénotype 
tumoral résistant aux traitements actuels. Nos connaissances concernant les voies 
impliquées dans l’activation de la signalisation du ER ainsi que le rôle des évènements de 
phosphorylation affectant l’activité du ER sont restreintes. ERα est considéré comme le 
sous-type dominant et corrèle avec la plupart des facteurs de pronostic dans le cancer du 
sein. Par contre, le rôle de ERβ reste imprécis. Les résultats présentés dans cette thèse ont 
pour objectif de  mieux comprendre l’implication de ERβ dans la prolifération cellulaire par 
l’étude du comportement de ERβ et ERα suite à l’activation des voies de signalisation par 
les facteurs de croissance. 
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Nous démontrons que l’activation des récepteurs de surfaces de la famille ErbB, 
spécifiquement ErbB2/ErbB3, inhibe l’activité transcriptionnelle de ERβ, malgré la 
présence du coactivateur CBP, tout en activant ERα. De plus, l’inhibition de ERβ est  
attribuée à un résidu sérine situé dans la région charnière, absente dans chez ERα. Des 
études supplémentaires de ErbB2/ErbB3 ont révélé qu’ils activent la voie PI3K/Akt ciblant 
à son tour la sérine de la région charnière de ERβ. En effet, cette phosphorylation de ERβ 
par PI3K/Akt induit une augmentation de l’ubiquitination du récepteur qui promeut sa 
dégradation par le système ubiquitine-protéasome. Cette dégradation est spécifique pour 
ERβ. De façon intéressante, la dégradation par le protéasome requiert la présence du 
coactivateur CBP normalement requis pour l’activité transcriptionnelle des récepteurs 
nucléaires. Malgré que l’activation de la voie PI3K/Akt corrèle avec une diminution de 
l’expression des gènes sous le contrôle de ERβ, une augmentation de la prolifération des 
cellules cancéreuses est observée. L’inhibition de la dégradation de ERβ réduit cette 
prolifération excessive causée par le traitement avec Hrgβ1, un ligand de ErbB3. 
 
Un nombre croissant d’évidences indique que les voies de signalisations des 
facteurs de croissance peuvent sélectivement réguler l’activité transcriptionnelle des sous-
types de ER. De plus le ratio de ERα/ERβ dans les cancers du sein devient un outil de 
diagnostique populaire afin de déterminer la sévérité d’une tumeur. En conclusion, la 
caractérisation moléculaire du couplage entre la signalisation des facteurs de croissance et 
la fonction des ERs permettra le développement de nouveaux traitements permettant de 
limiter l’apparition de cellules tumorales résistantes aux thérapies endocriniennes actuelles. 
 
Mots-clés : Cancers hormone-dépendant; Récepteurs aux Estrogènes, ER; Facteurs de 
croissances; Récepteur de tyrosine kinase, RTK;  ErbB; CBP/p300; Phosphorylation; 
Ubiquitination; Mdm2; PI3K/Akt 
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Abstract 
It has long been appreciated that estrogenic signaling plays a critical role in the 
development of hormone-dependent cancers such as breast cancer. Two-thirds of breast 
cancers express estrogen receptor (ER) which has been demonstrated to play an irrefutable 
role in tumour development and progression. However the acquisition of endocrine 
resistance has become a major obstacle in the treatment of hormone-dependent cancers that 
have acquired a hormone-independent state.  
 
Hormone-independent cancers emerge from an array of pathways involving ER 
activation in the absence of estrogen, hypersensitivity of ER to low serum levels of 
estrogen and activation by estrogen antagonists. The activity of ER is critically influenced 
by the cellular environment such as growth factor signaling pathways, availability of 
coregulatory proteins and the promoter sequence of target genes. The mechanisms studied 
have mostly considered the role of ERα, however with the discovery of the second subtype, 
ERβ, the understanding on the diversity of potential mechanisms involving ER-dependent 
responses have improved. Hormonal-independent activation of ER can occur in estrogen-
dependent breast tumours, with concomitant rise in kinase signaling pathways, resulting in 
the acquisition of a therapeutic resistant phenotype in treated women. Our knowledge is 
relatively limited on which pathways trigger ER signaling and how these phosphorylation-
coupled events affect ER activity. ERα is considered the dominant subtype and correlates 
with most of the prognostic factors in breast cancers. Conversely the role of ERβ remains 
unclear. The results presented in this thesis were carried out with the objective of gaining a 
better understanding of ERβ’s role in cellular proliferation by examining the behavior of 
ERβ and ERα during the activation of growth factor signaling pathways by cell-surface 
receptor-tyrosine kinases.  
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We demonstrate here that the activation of cell surface receptors of the ErbB family, 
specifically ErbB2/ErbB3, inhibits the transcriptional activity of ERβ despite the presence 
of the coactivator CBP, yet activated ERα. Furthermore the inhibition of ERβ was 
attributed to a specific serine residue located within the hinge region, not present in ERα. 
Additional studies of ErbB2/ErbB3-initiated signaling revealed that it triggered the 
activation of the PI3K/Akt pathway which targeted the serine residue within the hinge 
region of ERβ. In fact, phosphorylation of ERβ by the PI3K/Akt pathway led to an increase 
in receptor ubiquitination which promoted its degradation by the ubiquitin-proteasome 
system which was subtype specific. Interestingly, proteasomal degradation required the 
presence of the coactivator CBP, which is normally involved in assisting nuclear receptor 
transcriptional activity. Although the activation of the PI3K/Akt pathway correlated with a 
decrease in the expression of ERβ target genes it led to an increase in the proliferation of 
breast cancer cells. Inhibiting the degradation of ERβ reduced the enhanced proliferation of 
breast cancer cells brought about by the treatment of ErbB3’s ligand, Hrgβ1. 
 
Increasing evidence indicates that growth factor signaling pathways can selectively 
regulate the transcriptional activity of ER subtypes, and the ratio of ERα/ERβ expression in 
breast tumours is becoming a popular prognostic factor to evaluate the severity of the 
tumour. Therefore the molecular characterization of the coupling between growth factor 
signaling and ER function should provide improved therapeutical approaches to overcome 
or delay the onset of resistance to endocrine therapy in hormone-dependent cancers.  
 
Keywords: Hormone-dependent cancer; Estrogen Receptor, ER; Growth factors; receptor 
tyrosine kinase, RTK; ErbB; CBP/p300; phosphorylation; Ubiquitination; Mdm2; 
PI3K/Akt  
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 CHAPTER 1: INTRODUCTION 
 
1 Hormone-Dependent Cancers  
Steroid-hormone dependent cancers which include those of the breast, ovaries, 
endometrium and prostate are a leading cause of morbidity and mortality amongst 
diagnosed patients. Breast cancer is probably the most common form of cancer in women 
comprising 25% of the total incidence of diagnosed cancer and accounts for approximately 
18% of mortality (Parkin and Fernandez, 2006)(Canadian Cancer Society/National Cancer 
Institute of Canada; Canadian Cancer Statistics, Toronto, Canada 2008) (Parkin et al., 
2005). Public health data show that the global burden of breast cancer in women (measured 
by incidence, mortality and economic costs) is significant and increasing (Mackay J et al., 
2006). The rate of breast cancer incidence is greatest in North America with 99.4 per 
100,000 persons, closely followed by Western Europe (84.6 per 100,000) and Asia 
exhibiting the least number of incidences (roughly 25 per 100,000) (Botha et al., 2003).     
  
Approximately 95% of breast cancers, whether in pre- or postmenopausal women, 
are initially hormone-dependent (Henderson et al., 1988; Soule and McGrath, 1980; 
Osborne et al., 1985; Lippman et al., 1986), however after a period of time (which may last 
several years) the tumour can potentially become hormone-insensitive by mechanisms 
which still need to be clarified. The majority of breast cancers develop during the 
postmenopausal period, when the ovaries are no longer functional. Despite the low levels of 
circulating estrogens, the concentration of estrogen metabolites (estradiol, estrone and their 
sulphates) are several times greater in the affected tissue than those found in the plasma, 
implying that a specific tumoural biosynthesis and accumulation of these hormones occur 
(Pasqualini et al., 1996; Chetrite et al., 2000).  
 
The pathways involved in reaching a state of hormone independence is complex and 
physiologically important, especially when considering that over 30% of all human breast 
tumours which express both estrogen receptors (ERs) and progesterone receptors (PRs) fail 
to regress following anti-estrogen treatments (Clark and McGuire, 1988; Gurpide, 1991). 
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The perception that the interaction between estrogen and ER, by itself, can entirely mediate 
estrogen-target gene transcription is a great oversimplification. In fact, recent progress in 
understanding ER function has revealed a complex signaling cross-talk between ERs and 
other signal transduction pathways, mainly triggered by receptor tyrosine kinases (RTKs) 
and the expression and activity of coregulatory proteins. At least 70% of breast cancers are 
determined to be ER-positive breast cancers (Normanno et al., 2005). Therefore knowing 
that ERs remain present in ligand-resistant tumours it is primordial to fully understand the 
cellular mechanisms which are elicited during the development of ER ligand-independent 
regulation. 
 
2 Steroid Hormones  
Lipophilic hormones such as steroids (sex-steroids, corticosteroids, 
mineralocorticoids and ecdysteroids) as well as non-steroids (such as retinoic acid, thyroid 
hormone and vitamin D3) are molecules implicated in signal transduction in vertebrates and 
invertebrates (Reichel and Jacob, 1993; Beato, 1989). Steroids are widely dispersed 
throughout the animal kingdom functioning as regulators of numerous biochemical and 
physiological processes with their synthesis beginning in the adrenal gland (Figure 1).  
 
Minutes after the hypothalamic adrenocorticotrophic hormone (ACTH) stimulates 
the adrenal glands, we observe steroid hormone production (Figure 1). The first step is the 
conversion of cholesterol which is cleaved to pregnolenone, the steroid precursor to all 
steroidogenesis (Figure 2). Only certain cells in humans are able to convert cholesterol to 
pregnolenone: Leydig cells, placental trophoblast cells, ovarian theca cells, corpus luteum 
cells, the adrenal cortex cells and some neuronal cells in the brain. This is a tightly 
regulated step and it allows for a rapid production of steroids in response to stimuli. Next,  
 
 
 
  
 
3
 
 
 
 
 
 
 
The adrenal gland is made up of the cortex and the medulla. The three functional zones that 
comprise the adrenal cortex each make distinctive steroids and this zone-specific synthesis 
parallels their distinct expression of steroidogenic enzymes. The zona glomerulosa (outer 
zone) produces mineralocorticoids (aldosterone) which monitors salt and water balance. The 
zona fasciculate (middle layer) makes cortisol regulating carbohydrate metabolism and 
vascular response to cathecholamines. The innermost layer, the zona reticularis, makes the 
androgen precursors such as DHEA and its sulfate (DHEA[S]). Neuroendocrine cells which 
make up the medulla synthesize and secrete catecholamines. Image from illustrator Diantha 
Tevis-2006. 
Figure 1 The adrenal gland 
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pregnolenone is converted into the various intermediates and active steroid hormones. Few 
organs are capable of making steroids from cholesterol however many can transform 
circulating steroids, such as adrenal dehydroepiandrosterone DHEA (Figure 2), which is 
converted to testosterone in peripheral tissues, a route generating the major source of 
testosterone in women (Labrie et al., 2003). Hormones can potentially become more 
powerful or activated in target tissues, such as testosterone, which is converted to its active 
form, dihydrotestosterone (DHT) in the prostate gland. A general principle in 
steroidogenesis is that reactions are unidirectional as most are irreversible, and the 
hydroxysteroid dehydrogenase reactions (HSD) (Figure 2), while reversible, predominantly 
proceed in one direction. The enzymes necessary for these steps are 3β-HSD2, 17βHSD 
and the family of P450 enzymes, which include CYP19A1 (aromatase).  
 
 
 
Figure 2 Human steroid biosynthesis. Adapted from (Ghayee and Auchus, 2007). 
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The testis and ovaries have little capacity to synthesize aldosterone and cortisol. 
Alternatively, steroid metabolism in these organs is focused on making androgens and 
estrogens, while the corpus luteum of the ovary produces progesterone. The testis 
efficiently completes the biosynthesis of testosterone and can export this potent androgen 
whereas the ovaries synthesize primarily androstenedione to convert it into estrogens as 
well as variable amounts of testosterone (Figure 2). Steroidogenesis in the ovary is 
compartmentalized in a cell-specific manner, where the theca cells primarily produce 
androstenedione and the granulose cells complete the synthesis of estradiol (E2). In adrenals 
and gonads, ACTH or Luteinizing hormone (LH) mobilize cholesterol into the 
steroidogenic pathways in bursts or pulse. Follicle-stimulating hormone (FSH) is critical in 
promoting granulose cell development and estradiol synthesis during ovulation. In the 
placenta, steroid production is less pulsatile and dependent on chorionic gonadotropin 
(hCG) early in gestation and later is mostly unregulated. 
 
2.1 Estrogen; From Synthesis to Function 
Steroid hormones are among the most powerful and enduring signaling molecules in 
the body. When transported via the circulation, steroids travel great distances from the site 
of synthesis in an endocrine organ to a distant target organ. Alternatively, steroids can act 
as local autocrine or paracrine signals that impact only the microenvironment, including in 
the brain. The half-life of steroids is several-fold greater than that of other blood-borne 
signaling molecules, such as insulin, which disappear within minutes to hours. Estradiol is 
the final end product of 6 enzymatic conversions from its precursor cholesterol (Figure 2), 
and it is the most potent steroid, being active at concentrations in the femtomolar range. 
The critical p450 enzyme aromatase is the rate-limiting step in estradiol synthesis from 
androgen precursors and is a nodal point of regulation (as discussed in chapter 8).  
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2.1.1 Synthesizing Estrogen 
Estradiol production in the ovary is dependent on the action of 17βHSD. In ovarian 
granulose cells of developing follicles in cycling humans and rodents, 17βHSD1 converts 
estrone to estradiol. Upon ovulation, follicles luteinize and transform into corpora lutea 
which continue to secrete estradiol at high concentrations although, during luteinization, 
17βHSD1 expression declines rapidly in the ovary. The expression of 17βHSD1 is mostly 
abundant in the granulose cells and the syncytiotrophoblasts of the placenta (Sawetawan et 
al., 1994; Fournet-Dulguerov et al., 1987) and expressed at lower levels in the breast 
(Miettinen et al., 1999). In the ovary, 17βHSD1 is primarily induced by FSH acting through 
the cAMP-dependent protein Kinase A (PKA) signaling pathway (Kaminski et al., 1997). 
 
In addition to the source of active steroid hormones derived from the circulation, 
there are numerous tissues such as epithelial cells of human breast and endometrium that 
express 17βHSD, 3βHSD and aromatase, having therefore the ability to synthesize active 
steroid hormones from circulating steroid precursors. The expression of these enzymes in 
target tissues is very important especially in humans where the adrenal glands will secrete 
high levels of DHEA. These steroids serve as substrates in peripheral tissues for their 
eventual conversion to testosterone by one of the isoforms of 17βHSD or to estrone or E2 
by aromatase. In these tissues 17βHSD1 catalyzes the conversion of estrone to the more 
potent form E2  (Figure 2) (Penning, 1997).  
 
The peripheral expression of aromatase is critical, especially in men and 
postmenopausal women. A major site of peripheral expression of aromatase is in the 
adipose tissue of men and women (Kamat et al., 2002; Simpson et al., 2002). The 
conversion of androgens to estrogens in adipose tissue increases with age in 
postmenopausal women and in elderly men (Kamat et al., 2002; Simpson et al., 2002). The 
primary site of expression within adipose tissue is in the stromal mesenchymal cells 
(Simpson et al., 2002). Aromatase is also expressed in osteoblasts and chondrocytes in 
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males and females (Sasano et al., 1997). Aromatase can also be observed in the brain being 
primarily expressed in the hypothalamus of male and females as well as in other areas such 
as the retina (Kamat et al., 2002; Simpson et al., 2002). 
 
2.1.2 Importance of Estrogen 
Estrogen has widespread physiological actions, targeting both genomic and non-
genomic mechanisms. Estrogen is a key regulator of growth, differentiation and biological 
function in a wide array of target tissues, including the male and female reproductive tracts, 
mammary gland, skeletal, cardiovascular and central nervous systems. In breast tissue, 
estrogens stimulate the growth and differentiation of the ductal epithelium, induce mitotic 
activity of ductal cylindric cells and stimulate growth of connective tissues (Porter, 1974). 
Estrogens can also exert histamine-like effects on the microcirculation of the breast 
(Soderqvist et al., 1993). Estrogens are also thought to have neuroprotective actions such as 
synaptic and dendritic remodeling (Naftolin et al., 1990) as well as glial activation in brain 
tissue from adult rats (Garcia-Segura et al., 1999). In neurons of the hippocampus, an area 
involved in memory, estrogens increase the density of N-methyl-D-aspartate receptors and 
increase neuronal sensitivity to input mediated by these receptors (Woolley et al., 1997). 
Estrogens can reduce the generation of β-amyloid peptides, which build up in the brains of 
patients with Alzheimer's disease and observed in cultured human neuroblastoma cells 
(Green and Simpkins, 2000).  
 
Estrogens are also known to cause short-term vasodilation by increasing the 
formation and release of nitric oxide (NO) and prostacyclin in endothelial cells (Kim et al., 
1999). A protective role of estrogens against atherosclerosis was suggested by the findings 
that estrogen treatment reduced the progression of coronary-artery atherosclerosis in 
oophorectimized monkeys (Clarkson et al., 1996). Furthermore, estrogens can directly 
inhibit the functions of osteoclasts which express regulators of bone resorption, reducing 
the risk of fracture in women with osteoporosis (Lufkin et al., 1992; Lindsay et al., 1980).  
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It has been recently proposed that estrogen plays a role in insulin resistance leading 
to glucose intolerance and type II diabetes when pancreatic β-cells cannot meet the 
requirement for insulin (Godsland, 2005). A study showed that treatment of E2 was able to 
protect β-cells from oxidative injury in mice resulted in protection from proinflammatory 
cytokine-mediated β-cell death (Le et al., 2006; Contreras et al., 2002).  E2 can also exert 
anti-inflammatory actions in different tissues and animal models (Vegeto et al., 2003; 
Zancan et al., 1999), through the inhibition of inducible nitric oxide synthase (iNOS) 
synthesis.  
 
One of the most important and notable effects of estrogens is a very potent 
mitogenic action in hormone sensitive tissues such as the breast (Evans, 1988; Kumar et al., 
1987; Weisz et al., 1990) and the uterus (Quarmby and Korach, 1984; Martin et al., 1973). 
Prolonged exposure of target tissues or cells to estrogens has long been considered an 
important etiological factor for the induction of estrogen-associated cancers in experimental 
animals (Nandi et al., 1995) as well as in humans (Nandi et al., 1995; Ziel and Finkle, 
1975; Mack et al., 1976; Pike et al., 1993; McDonald et al., 1977; Grady and Ernster, 1997; 
Feigelson and Henderson, 1996; Jick et al., 1979).  
 
2.2 Steroid hormones- ligands to steroid receptors 
Steroid hormones have long been known as essential metabolic regulators, but the 
cloning of their respective hormone receptors was an indispensable prerequisite to 
understand the molecular basis of hormone action transposed into a transcriptional process. 
In vertebrates, the nuclear receptor superfamily contains intracellular receptor proteins 
targets (a group of structurally related receptors) with specific affinity to estrogens, 
androgens, progestins, glucocorticoids, mineralcorticoids and thyroid hormones. (Evans, 
1988; Mangelsdorf et al., 1995; Beato et al., 1995; Glass, 1994).  
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Jensen and coll. in the early 60’s (Jensen and Jacobson, 1962) laid the groundwork 
demonstrating the presence of a binding protein that would mediate the biological effects of 
E2 in the uterus. This has paved the way twenty four years later to the cloning of the 
estrogen receptor, presently known as ERα (Greene et al., 1986; Green et al., 1986). With 
the cloning of the other steroid receptors such as glucocorticoid receptor (GR), 
progesterone receptor (PR) and androgen receptor (AR), a considerable progress has been 
accomplished over the last two decades in understanding the mechanisms of steroid 
hormone action. In addition, the identification of a growing number of interacting factors 
recruited to steroid receptors in order to facilitate transcriptional processes in response to 
hormone stimuli has helped in developing a comprehensive model of cofactor assembly and 
exchange to mediate target gene expression. However, given the complexity of these 
various regulatory aspects involved in steroid receptor functions that have emerged from 
these studies, it became evident that strategies developed to efficiently counteract 
deregulated functions associated to receptors had to consider the model’s intricate network. 
 
 
3 Steroid Receptors 
The neodarwinian theory of evolution describes that new functions emerge as the 
phenotypic outcome due to the natural selection of random mutations. Complex organs and 
functions are believed to be generated from a gradual selective process of elaboration and 
optimization (Dawkins R, 1986). Vertebrate steroid hormones and the intracellular protein 
receptor that mediate their effects elegantly illustrate this theory.  
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3.1 Evolution of Steroid Receptors 
The receptor phylogeny suggests that two serial duplication of an ancestral steroid 
receptor occurred during the interval when vertebrates were evolving from invertebrates. In 
the ancestral vertebrate, the first duplication event created an estrogen receptor (ER) and a 
3-ketosteroid receptor, whereas the second duplication came from the latter gene to produce 
a corticoid receptor and a receptor for 3-ketogonadal steroids (androgens, progestins or 
both) yielding three steroid receptors (Figure 3). At some point in time within the 
gnathostome lineage (jawed vertebrates comprised of fishes, amphibia, reptilia, aves and 
mammalia), each of these three receptors duplicated a second time to yield six steroid 
receptors currently expressed in jawed vertebrates: the ER to create ERα and ERβ, the 
Figure 3 Phylogeny of steroid receptors. The blue circles represent gene duplication 
events. Adapted from (Thornton, 2001). 
ER
Corticoid
3-Ketosteroid
3-Ketogonadal
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corticoid receptor giving the GR and mineralocorticoid receptor (MR) and the 3-
ketogonadal receptor to create the AR and the PR (Figure 3). Although the timing of these 
events has remained unclear due to divergent hypotheses, gene mapping data supports 
serial duplications as the mechanism by which steroid receptors have diversified.  
 
The fundamental role of steroids in regulating vertebrate development, 
reproduction, growth and homeostasis (DeGroot LJ, 1995; Gilbert SF, 1994; Evans, 1988) 
suggests that these steroid receptor duplications provided vertebrates a selective advantage 
over other organisms, which would be important in vertebrate competition with the diverse 
multicellular organisms present in early Cambrian, 540 to 480 million years ago, as well as 
for vertebrate survival during global extinctions that occurred about 440 and 370 million 
years ago (Raup, 1994). Nuclear receptors are an excellent example of how gene 
duplications and divergence can generate a protein family that responds to diverse signals 
to regulate a wide variety of physiological processes. 
 
3.2 The Ancestral Steroid Receptor was an Estrogen Receptor 
An ancestral protein is likely to have resembled in sequence and function to a 
descendent gene which evolved more slowly after the duplication event, compared to one 
with a more rapid evolutionary rate. Relative rate tests based on amino acid distances and 
reconstruction of branch lengths suggest that the ancestral steroid receptor was a functional 
estrogen receptor, the sequence of which was conserved among descendent ERs.  
 
The reconstructed ancestral receptor is 71% identical to the human ERα however 
radically different to the PR, AR, GR and MR. This result indicates that the ancestral 
steroid receptor activated genes with estrogen-response palindromes (AGGTCA-figure 5) 
and bound estrogens. In the synthesis of estradiol and estrogens, progesterone and 
testosterone are synthesized as intermediates. These steroids, and the enzymes that produce 
them, would therefore have been present during the period when only one receptor for 
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estrogen existed. After gene duplications of the ancestral estrogen receptor gene and 
followed by considerable sequence divergence, receptors emerged to give these 
intermediate compounds novel signaling functions.  
 
Redundant receptors created by gene duplication could then diverge in sequence 
from their ancestors and evolve affinity for these steroids, creating signaling functions for 
what were once intermediates. The expansion of the steroid receptor family by gene 
duplication and ligand application allowed a greater specificity in hormone control over 
physiological functions. Estrogen regulation appears to be the most ancient of all modes of 
steroid/receptor control which is supported by the apparent role of estrogen in 
branchiostome and echinoderm reproduction (Fang et al., 1994; Hines et al., 1992). 
Comparisons of the evolution of steroid receptors indicate that land animals show a slow 
sequence divergence. The fish estrogen and glucocorticoid receptors have about 70 and 
60% sequence identity respectively, to their human orthologs. This puts these steroid 
Figure 4 Phylogenetic tree of the evolutionary relationships of ERα and ERβ based on
amino acid sequences. Adapted from (Kelley and Thackray, 1999). 
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receptors in the class of slowly changing proteins (Doolittle et al., 1996). The discovery of 
a second form of ER (Kuiper et al., 1996; Mosselman et al., 1996) termed ERβ, generated 
questions about the biological importance of this newly discovered gene. Previous sequence 
alignments have shown that ERβ sequences share common elements that are distinct from 
ERα sequences (Pettersson et al., 1997) supporting the idea that the ERβ sequences belong 
to a separate monophyletic clade (a group composed of a single ancestor and all its 
descendents) with respect to ERα and have evolved in parallel (Naylor and Brown, 1998) 
(Figure 4). The fact that the ERβ gene is widespread among chordates (animals which are 
either vertebrates or one of several closely related invertebrates) and comprises a separate 
genetic lineage dating back at least 450 million years argues that this gene performs distinct 
biological functions that have been maintained by natural selection for this long period of 
time. 
 
4 Estrogen Receptors 
In the 1950s, Jensen and Jacobson (Jensen and Jacobson, 1962; Jensen EV and 
Jacobson HI, 1960) used tritium labeled E2 to demonstrate that it was specifically retained 
by estrogen target tissues which led them to hypothesize that a receptor must exist for this 
molecule. 
 
4.1 ERα and ERβ: Discovery of two subtypes 
In the next decade an ER was identified by Toft and Gorski (Toft and Gorski, 1966) 
and isolated from several mammalian species, including rat and human (Toft and Gorski, 
1966; Jensen et al., 1968). However, it was not until the mid 1980s that the first ER, now 
called ERα, was cloned by two groups of investigators (Green et al., 1986; Greene et al., 
1986; Walter et al., 1985). In the mid 1990s, a second ER, called ERβ, was identified from 
a library scan of rat prostate cDNA library (Kuiper et al., 1996) and subsequently cloned 
from several species including the mouse, human, and fish (Kuiper et al., 1996; Mosselman 
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et al., 1996; Tremblay et al., 1997) which meant that the biological properties associated to 
ER signaling in terms of subtype selectivity, ligand specificity, and tissue distribution had 
to be reviewed (Giguère et al., 1998; Gustafsson, 1999).  
 
At first, a human ERβ with 477 amino acids was reported (Mosselman et al., 1996). 
A few months later, Enmark et al. (Enmark et al., 1997) identified an ERβ mRNA species 
of 485 amino acids, and it was hypothesized to reflect full-length ERβ. The following year, 
Ogawa et al. (Ogawa et al., 1998b) reported the cloning of an additional ERβ species 
consisting of 530 amino acids, which is now considered to represent full-length ERβ. A few 
months later, Moore et al. (Moore et al., 1998) also identified the same 530-amino acid 
sequence as the full-length ERβ in addition to various isoforms. Similarly to ERα, ERβ 
expression has also been associated with cancers of the breast (Dotzlaw et al., 1997; 
Dotzlaw et al., 1999; Speirs et al., 1999a; Speirs et al., 1999b), colon (Foley et al., 2000; 
Campbell-Thompson et al., 2001), and ovarian tissues (Pujol et al., 1998; Rutherford et al., 
2000).  
 
4.2 ERα and ERβ; Pertinent or redundant?  
Although in vitro studies have demonstrated redundancy in the roles of these two 
receptors, tissue localization has revealed distinct expression patterns for each receptor 
suggesting that each ER subtype might perform specific functions. ERα is expressed in a 
variety of tissues classically associated with estrogenic activity including the uterus, ovaries 
(theca cells), cervix, vagina, breast, bone and several additional target organs such as in the 
prostate (stroma) and brain but to a lesser degree in bladder, liver and thymus. ERβ is 
predominantly expressed in normal colon, prostate (epithelium), ovary (granulosa cells), 
bone marrow and brain, with smaller amounts reported in uterus, bladder, lung and testis 
(Kuiper et al., 1997; Shughrue et al., 1998; Veeneman, 2005) and in the spleen, 
hypothalamus, and thymus (Couse et al., 1997). ER tissue expression is also tied to 
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developmental stage, specifically in both uterus and pituitary where ERβ is expressed 
during development but is later replaced by ERα (Shupnik, 2002; Nishihara et al., 2000).  
 
The development of KO models has helped us to unmask unidentified estrogen 
signaling systems as well as those that are independent of either ERα or ERβ. Studies with 
ERα and ERβ knockout (KO) mice have revealed a role for ERs signaling in bone 
formation, male and female sexual maturation, fertility, cardiovascular and angiogenesis 
effects, and behavior (Bocchinfuso and Korach, 1997; Couse et al., 1995; Eddy et al., 1996; 
Hess et al., 1997; Korach et al., 1996; Krege et al., 1998; Lindberg et al., 2003; Ogawa et 
al., 1996; Ogawa et al., 1997; Ogawa et al., 1998a; Ogawa et al., 1998d; Rubanyi, 2000; 
Schomberg et al., 1999; Windahl et al., 2001; Windahl et al., 2002). Both sexes of the 
αERKO are infertile. In the female αERKO mice, estrogen insensitivity leads to hypoplasia 
in the reproductive tract with enlarged cystic and haemorrhagic follicles in the ovaries. 
Also, lack of pubertal mammary gland development and excess adipose tissue was 
observed in females (Couse and Korach, 1999). In αERKO males, testicular degeneration 
and epididymal dysfunction are the major phenotypes. Conversely, male βERKO mice are 
fertile and show no obvious phenotype. However female βERKO mice exhibit inefficient 
ovarian function and subfertility due to a block in the last step of follicular development. 
This can be overcome when animals are treated with FSH and LH. A recent report 
described an abnormal vascular function resulting in hypertension of βERKO mice (Zhu et 
al., 2002). The generation of mice that do not express either receptor isoform (DERKO) has 
provided additional information on the role of these two receptors in regulating 
physiological and behavioural processes. The adult ovarian phenotype is masculinised, 
coinciding with a reduction in oocyte number. In addition the ovaries do present structures 
that resemble testicular seminiferous tubules (Couse and Korach, 2001). Absence of both 
receptors leads to a significant drop in sexual and aggressive behaviour (Ogawa et al., 
2000; Simpson and Davis, 2000; Zhu et al., 2002).  
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The difference in tissue distribution between ERα and ERβ can only partly explain 
the tissue specific effects of estrogens. Tissue specificity may actually be attributable to the 
type of dimers formed by these two receptors and their interaction with accessory proteins. 
Several groups have reported that ERα and ERβ can form functional heterodimers (Cowley 
et al., 1997; Ogawa et al., 1998b; Pettersson et al., 1997; Tremblay et al., 1999b). 
  
 
Moreover, the ERα/ERβ heterodimer appeared to form preferentially over each 
homodimer when both receptors are expressed, and was shown to bind to the consensus 
estrogen response element (ERE) sequence (Figure 5) with an affinity comparable to that of 
the ERα homodimer and greater than the ERβ homodimer (Tremblay et al., 1999b; Cowley 
Figure 5 Hormone Response Element- Orientation of Hormone response
element and their cognate receptors. 
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et al., 1997). Consequently, profiles in gene expression may diverge upon ER dimerization 
properties, and therefore the ratio of different receptor types in tissues may be an important 
determinant of a biological response.  
 
4.3 Structure and isoforms of the ERs 
ERα and ERβ are each encoded by unique genes localized on chromosome 6 and 14 
in humans respectively (Enmark et al., 1997; Tremblay et al., 1997; Giguère et al., 1998). 
Both ER subtypes share the distinctive modular structure of functional domains 
characteristic of the superfamily of nuclear hormone receptors (Kumar et al., 1987; Evans, 
1988). Nuclear receptors have been clustered into 6 subclasses based on sequence 
comparison and phylogenetic analysis (Laudet, 1997) and a unified nomenclature was 
proposed thereafter (Laudet et al., 1999). Members include receptors for estrogen (ER), 
glucocorticoids (GR), progesterone (PR) and androgens (AR), as well as the orphan 
estrogen-related receptors (ERRs), which are contained within the NR3 subclass, reflecting 
their apparent abilities to bind to response elements organized as inverted repeats (Figure 5) 
(Beato et al., 1995). Receptors that share the heterodimerization partner retinoid X receptor 
(RXR) bind response elements organized as direct repeats, such as for retinoic acids 
(RAR), prostaglandins and fatty acids (PPAR), thyroid hormones (TR), vitamin D (VDR) 
and oxysterols (LXR), and are mostly found in the NR1 subclass (Truss and Beato, 1993; 
Glass, 1994; Mangelsdorf et al., 1995). Members of NR2 subclass are able to bind as 
homodimers on direct repeat elements including RXR, HNF4 and COUP-TF. Subclasses 
NR4-6 are comprised of orphan nuclear receptors for which no specific ligand has yet been 
identified (Laudet, 1997). 
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4.3.1 Structure of ERs 
There are six functional domains that characterize ERα and ERβ termed A through 
F (Figure 6). These consist of a highly conserved (Umesono and Evans, 1989) (97%) DNA-
binding domain (C) containing two Zn2+-finger motifs necessary for dimerization and 
specific binding to genomic response elements (Figure 5), a globular C-terminal region 
(EF) relatively well conserved (60%) (Warnmark et al., 2003) that contains the LBD and an 
activation function (AF-2) that mediates receptor trans-activation. The AF-2 domain is 
characterized by a highly conserved amphipathic α-helix (H12), essential for ligand 
dependent activation of transcription and interaction coregulatory proteins (McKenna et al., 
1999; Heery et al., 1997). The low rate of change and the conservation of critical residues 
within the DBD and the LBD imply that there has been strong selective pressure to 
maintain these functions in both ERα and ERβ. In addition, the amino acids that make 
Figure 6 ERα and ERβ functional domains and sequence homology. Adapted from
Sanchez et al. TEM. 
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direct contacts with the DNA in the crystal structure of the DBD are completely conserved 
(Schwabe et al., 1993). Also the amino acids of the ligand binding cavity, identified in the 
crystal structure of the LBD, involved in the direct and indirect hydrophobic interactions 
with the ligand (Brzozowski et al., 1997), are conserved with only a few changes within the 
clade.  
 
The LBD region is preceded by a flexible hinge region (D) that was previously 
describe to possess signals for nuclear localization and the binding of chaperones such as 
heat shock proteins (hsp), which provide the receptors proper folding and a means to 
interact with protein trafficking systems. However, over the past few years, studies have 
demonstrated the hinge region to play a much more extensive role in the regulation of both 
receptor isoforms, through different post-translational modifications (Sanchez et al., 2007; 
Giordano et al., 2010; Berry et al., 2008; Herynk et al., 2009).  
 
The N-terminal (AB) domain (Figure 6) is the region that differs dramatically 
between both ER subtypes with a feeble 15% homology. Although the N-terminal appears 
to be relatively unconstrained compared with the DBD and the LBD, it plays an important 
role in the transactivation of gene expression. Experiments have shown that transcriptional 
activation functions (AF) in the N-terminal domain (AF-1) and the LBD are both required 
for full receptor activity (Kumar et al., 1987; Tzukerman et al., 1994). From the structure-
function analysis presently available, the apparent differences between AF-1 and the AF-2 
in conformation suggest that the two activation functions have evolved different approaches 
to achieve transcriptional activation (Warnmark et al., 2003). The N-terminal region of ERs 
contains serine residues which have been implicated in cross-talk with various cell 
signaling pathways (Tremblay et al., 1997; Weigel, 1996; McInerney and 
Katzenellenbogen, 1996). The serine phosphorylation sites in the N-terminal domain of 
ERα and ERβ are not conserved, suggesting that ERα and ERβ may be regulated differently 
by cell signaling pathways. Indeed the AF-1 ligand-independent domain which controls the 
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recruitment of coregulators can be both similar and unique from those employed by the AF-
2 (McKenna et al., 1999; Webb et al., 1998).  Finally the F terminal domain comprised of 
the last 30-45 amino acids (depending on the subtype) has approximately 18% homology 
(Gustafsson, 1999) and appears to regulate the conformation of ERs in order to control the 
transcriptional response to its ligand (Yang et al., 2008). 
 
4.3.2 Isoforms/variants of ERα and ERβ 
From the eight total exons that code for ERα, detection of up to five different 
isoforms/variants have been discovered in humans from alternative splicing, intronic exons 
and exonic duplications (Hirata et al., 2003). The full-length ERα is defined as being 595 aa 
(hERα-66 (66KDa)), however shorter transcripts have been observed to be expressed in 
Figure 7 Isoforms of ERs- Schematic representation of the different splicing produtcs 
from the ERα and ERβ Heldring et al Physiol Rev 87:905-931, 2007. 
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different cell lines, such as hERα-36 (36 KDa) and hERα-46 (46KDa) (Flouriot et al., 2000; 
Wang et al., 2005). hERα-36 lacks both AF domains but contains sites that could be 
myristoylated suggesting that it would have the potential of anchoring itself in the plasma 
membrane. hERα-46 (46KDa) lacks the AF-1 but still manages to show antagonizing 
activity on the proliferative effects of the full length hERα-67 in MCF-7 cells (Penot et al., 
2005) (Figure 7). 
 
As for ERβ, five different variants (ERβ1-5) have been cloned (Figure 7) and 
examined. ERβ1 is considered the full-length receptor and is the only variant to contain 
fully functioning helices 11 and 12 (Wurtz et al., 1996) and therefore capable of interacting 
with ligands and recruiting coregulatory complexes (Henttu et al., 1997). Few studies have 
looked at the preference in dimerization partners between ERα and ERβ, however in gel-
shift assays, ERβ4 and ERβ5 heterodimerised with ERα (Poola et al., 2005) which affected 
the response to estrogen signaling, similar to the heterodimerization of ERβ2 (ERβcx) with 
ERα. ERβcx is the only variant to possibly exhibit clinical relevance. Although this protein 
does not respond to any particular ligand, it has a dominant negative effect on ERα 
transcriptional activity (Ogawa et al., 1998c; Zhao et al., 2007). 
 
4.4 Activation of ERs 
Full transcriptional activity of a nuclear receptor is accomplished not only by the 
synergism between its AFs but also relies on a number of events. The transcriptional 
potential of each AF is dependent on external determinants such as cell type, 
posttranslational modifications, promoter context and interaction with coregulatory 
complexes (Berry et al., 1990; Aronica and Katzenellenbogen, 1993; Hadzopoulou-
Cladaras et al., 1997; Tzukerman et al., 1994; McInerney et al., 1998; Pham et al., 1992; 
Cenni and Picard, 1999). 
 
  
 
22
 
 
4.4.1 Ligand-Dependent Activation of ERs 
ERs, in absence of estrogen, are attached to receptor-associated proteins which 
function as chaperones (Figure 8) stabilizing the receptor in an inactivated state by masking 
the DNA binding domain (Couse et al., 1999). Following the binding of E2, an activating 
conformational change is generated within the ERs promoting dimerization and high 
affinity binding to specific DNA response elements found within the regulatory regions of 
target genes (refer to figure 5). ERα and ERβ have been shown to interact with identical 
DNA response elements and exhibit a similar binding affinity profile for naturally 
occurring estrogens such as E2 when assayed in vitro. Both ERs recognize a distinct 
palindromic sequence, normally specific to the type of nuclear receptor. In the case of ERs 
it is an inverted repeat sequence separated by three nucleotides; AGGTCAnnnTGACCT 
(Parker et al., 1993) (Figure 5). However, only a small number of estrogen-responsive 
Figure 8  Ligand-dependent activation of ERs.  
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genes contain the consensus sequence. Several of the genes identified having a functional 
ERE sequence not only consist of one or more changes from the consensus but are made up 
of multiple copies of imperfect EREs (Driscoll et al., 1998). Depending on the cell and 
promoter context, the different combinations of DNA-bound ERs exert either a positive or 
negative effect on the expression of downstream target genes (Wood et al., 1998).  
 
4.4.2 Ligand-Independent Activation of ERs 
The responsiveness of steroid receptors to cell signaling pathways in the absence of 
their hormone can be different. ERs are quite responsive to cell signaling pathways. In fact, 
endogenously expressing ER-positive cells maintained in phenol-red free, charcoal-stripped 
serum used to minimize steroids, frequently display a considerable transcriptional activity 
in the absence of estrogen (Smith et al., 1993). Although ERs belong to a family of ligand-
activated receptors, they are also phosphoproteins and their activity can equally be 
regulated by phosphorylation of specific sites which can occur as part of both the ligand-
induced activity (Ali et al., 1993; Arnold et al., 1994; Kato et al., 1995) and/or ligand-
independent activity (Arnold et al., 1995b; Bunone et al., 1996; Tremblay et al., 1999a; 
Tremblay et al., 1998). Studies from other transcription factors such as CREB and PR, have 
shown that phosphorylation can play roles in nuclear translocation, DNA binding, 
interaction with other proteins and trans-activation (Hill and Treisman, 1995; Denner et al., 
1990a). Polypeptide growth factors can activate ERs and increase the expression of ER 
target genes (Smith, 1998). Phosphorylation occurs predominantly at specific 
serine/threonine or tyrosine residues and is catalyzed by enzymes such as mitogen-activated 
protein kinases (MAPK) (Shao and Lazar, 1999). MAPKs are composed of several serine-
threonine kinases that are activated in response to various cell-growth signals and transduce 
extracellular signals to intracellular targets by way of membrane receptors.  
 
Activation of ERs by signaling pathways (section 5.3) in the absence of E2 was first 
identified in the early 1990s (Ignar-Trowbridge et al., 1992). Ovariectomized mice were 
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treated with epidermal growth factor (EGF), promoting the translocation of ER towards the 
nucleus and stimulating its activity. Furthermore, EGF antibodies were administered to 
ovariectomized mice 3 days prior to hormone treatment resulting in a marked decrease of 
uterine DNA synthesis (Ignar-Trowbridge et al., 1995), leading to believe that EGF had a 
role in the proliferative effects of estrogen in reproductive tissues. Further assessment of the 
cell-surface receptor tyrosine kinases (RTKs) demonstrated their role in the recruitment of 
multiple signal transduction cascades that act to increase the activation of MAPK Erk1/2, 
PKB/Akt, Jnk, p38 and protein kinase C (PKCα and δ), key elements in the regulation of 
cell proliferation and survival signals (Bonni et al., 1999; Campbell et al., 2001; Gibson et 
al., 1999; Stambolic et al., 1999) (Amit et al., 2007). Chapter 5 will focus on the detailed 
description of the different signaling pathways regulating the activity of ERs.  
 
5  Cell-Surface Receptors 
It is now widely documented that the activation of growth factor (GF) signaling 
cascades through a supply of GF ligands via up-regulation and increased activation of their 
target growth factor membrane receptors and their recruited downstream signaling 
elements, can promote hormone-like responses.  
 
5.1 Members of ErbB Clan 
Figure 9 Four types of ErbB receptors 
               and their ligands. 
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Growth factors and their receptors play a fundamental role in the communication 
between outside the cell surface and the inside compartments (Schlessinger and Lemmon, 
2006; Scaltriti and Baselga, 2006). The human epidermal growth factor family (ErbB/HER) 
is comprised of four closely related receptors (Figure 9); epidermal growth factor receptor 
(EGFR, HER1, ErbB1), human EGFR-2 (HER2, ErbB2), ErbB3 and ErbB4. They are 
transmembrane oncoproteins containing an extracellular ligand binding domain and an 
intracellular receptor tyrosine kinase (RTK) domain sharing 40-45% homology to one 
another. This family of proteins has an important role in tumour processes including 
angiogenesis and metastasis and is associated with a poor prognosis in many human 
malignancies due to their overexpression or constitutive activity (Salomon et al., 1995; 
Hemming et al., 1992). Although all the aforementioned receptors share a strong homology 
within their TK domains, they are quite distinct in their extracellular N-terminal and 
cytoplasmic C-terminal domain (Klapper et al., 2000).   
 
The significance of ErbBs in normal development was, as with ERs, obtained from 
knockout-generated mice. Null mutations in individual ErbB loci are lethal demonstrating 
that ErbB receptors play a pivotal role in regulating vertebrate embryogenesis and 
development. ErbB1 KOs are lethal at the embryonic and up to perinatal stages as mice 
develop abnormalities in the brain, lungs, gastrointestinal tract and the skin (Threadgill et 
al., 1995; Sibilia and Wagner, 1995; Sibilia et al., 1998; Miettinen et al., 1995). ErbB2 and 
ErbB4 KOs are lethal at the stage of midgestation due to malformations of the heart 
(Gassmann et al., 1995; Lee et al., 1995). ErbB3 KO mice are embryonically lethal due to 
malformations of the heart valves in addition to neural crest defect and lack of Schwann 
cell precursors (Riethmacher et al., 1997; Erickson et al., 1997).  
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5.2 Activation of ErbB  
Several ligands bind to the ErbB receptors (Figure 9). Members of the EGF 
superfamily include epidermal growth factor (EGF) (Todaro et al., 1980), transforming 
growth factor-α (TGF- α) (Shoyab et al., 1988) and amphiregulin, which specifically bind 
to ErbB1 (EGFR). Heparin-binding EGF and epiregulin (EPR) bind to both EGFR and 
ErbB4 (Figure 10) (Toyoda et al., 1995). Neuregulins 1 and 2 (also known as heregulins 
(HRG) or neu differentiating factor) bind to both ErbB3 and ErbB4 (Falls, 2003). Binding 
of GF to ErbBs induces receptor dimerization and activation of intracellular protein 
tyrosine kinase with subsequent initiation of numerous downstream signaling events 
(Figure 10) (Press and Lenz, 2007). All ErbB ligands exist initially as membrane-anchored 
precursors that require proteolysis to liberate them as soluble mature ligands (Massague and 
Pandiella, 1993; Harris et al., 2003b). 
 
In the absence of ligand, ErbB1, ErbB3 and ErbB4 are monomeric and can be 
partially or completely inhibited (Schlessinger, 2002; Ferguson et al., 2003; Bouyain et al., 
2005). This inhibition is caused by the extracellular portion autoinhibiting the ligand 
surface due to its conformation status. Binding of a ligand leads to an alteration within the 
extracellular domain which creates a ligand-binding pocket and protrusion of a 
dimerization area. This change aids in receptor oligomerisation and the formation of homo- 
and heterodimers (Hynes and Lane, 2005; Citri et al., 2003; Leahy, 2004). Dimerization 
brings the intracellular kinase domains of the two receptors close together encouraging 
transphosphorylation of tyrosine kinase residues in the cytoplasmic tail of one receptor by 
the kinase domain of the adjacent receptor (Figure 10) (Jorissen et al., 2003; Schlessinger, 
1988). Unlike its family counterparts, ErbB2 has not yet had a ligand identified to regulate 
its activity (Yarden and Sliwkowski, 2001) (Klapper et al., 1999; Citri et al., 2003).  
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 Figure 10 ErbB Receptor Activation. 
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ErbB2 is the preferred heterodimerising partner of ligand-bound ErbB3 but can also 
bind ErbB1 and ErbB4 (Karunagaran et al., 1996), (Graus-Porta et al., 1997). Dimers 
containing ErbB2 are known to enhance and prolong the signaling of several ErbB ligands, 
and this may be due to the reduced dissociation of the receptor complex (Karunagaran et 
al., 1996) in addition to the reduction in the rate of internalization of the complex leading to 
recycling rather than degradation (Holbro et al., 2003). ErbB3 harbors a substitution in 
crucial residues of the C-terminal intracellular domain rendering its kinase activity dead 
(Guy et al., 1994) therefore ErbB3 homodimers are inactive. This forces the receptor to 
heterodimerize with other ErbBs to become phosphorylated and trigger an intracellular 
signal (Kim et al., 1998). In addition, ErbB3 contains seven copies of the Tyr-X-X-Met 
motif in its c-terminal motif recognized by phosphatidylinositol 3-Kinase (PI3K) which 
leads to the activation of the Akt pathway (Prigent and Gullick, 1994; Songyang et al., 
1993). ErbB3’s preferred dimerizing partner is ErbB2, in fact, the ErbB2-ErbB3 
heterodimer is the most prevalent receptor complex and one of the most potent signaling 
pathways that regulate cell growth and transformation (Pinkas-Kramarski et al., 1996; 
Karunagaran et al., 1996).  
 
5.3 ErbB Intracellular signaling 
Autophosphorylation of the C-terminal tyrosine residues serving as docking sites for 
cytoplasmic signaling proteins contain Src-homology (SH-2) and phosphotyrosine-binding 
(PTB) domains (Olayioye et al., 2000; Yarden and Sliwkowski, 2001). Each ErbB receptor 
exhibits a phosphotyrosine profile that allows for binding of enzymes such as Src, 
phospholipase Cγ, and the p85 regulatory subunit of PI-3K, or adapter molecules such as 
Shc and Grb2 linking ErbB activity to many downstream effectors (Figure 11) (Olayioye 
et al., 2000; Hynes and Lane, 2005). Although the Ras-Raf-MAPK and PI3K pathways are 
the major signaling pathways by the ErbB family, each dimeric receptor complex can 
activate different combinations of these signaling cascades, resulting in a wide range of 
signaling events (Figure 11). 
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5.3.1 Ras/Raf/MAPK pathway 
The Ras/Raf/MAPK pathway is the major downstream signaling pathway activated 
by the ErbB family (Salomon et al., 1995; Hemming et al., 1992). Initiation of the signaling 
cascade starts with the direct binding of Grb2/Sos complex adaptor to specific docking sites 
on the intracellular portion of EGFR, otherwise an indirect interaction through Shc adaptor 
proteins is observed as well (Batzer et al., 1994). Next, the Grb2 associated guanine 
nucleotide exchange factor Sos activates ras by the exchange of GDP to GTP, which in turn 
activates Raf kinase triggering the kinase cascade involving mitogen-extracellular kinase 
1,2 (MEK1,2 /MAPKK) and Erk1/2 (MAPK) (Figure 11) (Liebmann, 2001). Erk1, 2 can 
subsequently phosphorylate several cytoplasmic and nuclear targets, such as ERα and ERβ 
(Hill and Treisman, 1995). 
 
5.3.2 PI3K/Akt pathway  
The PI3K/Akt pathway regulates cell growth, resistance to chemotherapy, tumour 
invasion and migration (Vivanco and Sawyers, 2002). Its activation occurs through the SH2 
binding motifs of the p85 regulatory subunit of PI3K to the phosphotyrosine residues or 
indirectly through the binding of GTP-Ras to the p110 catalytic subunit of PI3K. Active 
PI3K converts membrane-bound lipid phosphatidylinositol 4, 5-bisphosphate (PIP2) to 
PIP3, which in turn phosphorylates and activated the serine/threonine Akt (Vivanco and 
Sawyers, 2002; Meier and Hemmings, 1999) (Figure 11). Similar to Erk, Akt can 
phosphorylate a variety of cytoplasmic and nuclear targets. Interestingly, while ErbB2 
easily triggers the MAPK pathway through Grb2 and Shc adapters, it cannot, on its own, 
activate Akt, as it cannot recruit the p85 subunit of PI3K unless ErbB3 or ErbB4 is 
expressed (Prigent and Gullick, 1994; Olayioye et al., 2000).  
 
Studies from breast cancer T47D cell line have demonstrated that depending on 
which ErbB ligand is present, such as EGF or Hrgβ1, the signaling cascade and biological 
response will differ accordingly. Hrgβ1 can activate the p38 MAPK pathway which in 
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conjunction with the PI3K/Akt pathway and MAPK can stimulate cell proliferation, 
however EGF treatment on EGFR, activates a robust MAPK response which does not lead 
to cell proliferation (Neve et al., 2002). Therefore, each ErbB can trigger a distinct set of 
signaling proteins generating unique responses that are cell-type and ligand-receptor 
specific. In particular, steroid hormone and growth factor cross-talk acts to modulate 
endocrine response in breast cancer (Nicholson et al., 1999). Abnormalities in GF signaling 
pathways may account for the endocrine-resistant phenotype and thus may represent a 
target for new therapies to overcome resistance and enhance clinical response rate as 
reviewed in chapter 8.  
 
5.3.3 Membrane receptor signaling pathways can regulate ERs activity 
The concept that overexpressed EGFR and ErbB2 plays a role in the development of 
anti-estrogen resistance is supported by data that demonstrates their hyperphosphorylation 
provoked their heterodimerization in resistant MCF-7 cells (Knowlden et al., 2003) leading 
to the recruitment of multiple signal transduction cascades that act to increase the activation 
numerous signaling pathways, such as MAPK, Akt and even Protein Kinase C (PKCα and 
δ), key elements in the regulation of cell proliferation and survival signals (Bonni et al., 
1999; Campbell et al., 2001; Gibson et al., 1999; Stambolic et al., 1999; Coutts and 
Murphy, 1998; Kurokawa and Arteaga, 2003; Oh et al., 2001). 
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Figure 11 Intracellular pathways activated by ErbB receptors. 
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Such signaling would act as a counterbalance to the anti-proliferative and pro-
apoptotic effects of anti-estrogens. MAPK increases are also reported to contribute to the 
growth of ER-positive breast cancer cells during adaptation to long-term estrogen 
deprivation (Martin et al., 2003; Jeng et al., 2000). Similarly, overexpression of PKCα in 
ER-positive breast cancer cells can promote hormone-independent growth through ERα 
(Tonetti et al., 2000). There is now substantial evidence of crosstalk between the ERs and 
growth factor receptor signaling pathways. 
 
5.3.3.1 Impact on ERα 
There are multiple pathways known to regulate hormone-independent activation of 
ERα. One of the best characterized pathways involves the activation of ERα by EGF.  The 
serine 118 residue of the human ERα AF-1 was described as being a target of MAPK 
phosphorylation following treatment with EGF or IGF-1, enabling ERα to activate target 
gene transcription even in the absence of E2 (Figure 12) (Kato, 2001; Kato et al., 1995). 
Point mutation converting this serine into an alanine residue proved to repress the 
activation (Ali et al., 1993). Ser-118 can be targeted by other kinases such as of cyclin-
dependent kinases, cdk7 (Chen et al., 2000). In this case, the presence of Transcription 
Factor II H (TFIIH) which contains cdk7 (part of the RNA Polymerase II initiation 
complex) together with the ERα LBD mediate ERα phosphorylation. Cyclin A/Cdk2 can 
also target ERα phosphorylation which leads to an increase in its transcriptional activation 
(Rogatsky et al., 1999) but does not target ser-118. Instead cdk2 targets two other serine 
residues, ser 104 and 106 also present in the AF-1 domain (Figure 12). Extracellular signal-
regulated kinase, ERK 7, activated by pathways independent of the documented MAPK 
(ERK1/2), targets ERα degradation in a hormone-dependent manner. ERK7 can enhance 
ser-118 phosphorylation nevertheless targeting the receptor for degradation (Henrich et al., 
2003) (Figure 12). In fact cancer cell lines were found to express much less Erk 7 compared 
to levels found in normal tissue.  
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  In another study to demonstrate that ERα activity could be modulated by signals 
other than its specific ligand, the use of 8-bromo-cAMP (a protein kinase activator) was 
employed and PR expression was seen increased (Denner et al., 1990b), a gene target of 
ERs. Although ERα was activated by the cAMP pathway in uterine tissue, activation of 
ERα by cAMP was not observed in ovary and breast tissue in the absence of estrogen (Cho 
and Katzenellenbogen, 1993b) demonstrating that transcriptional activity of ERs can be 
cell-type specific. Similar results on PR gene were observed when stimulating with IGF-1. 
Treatment of IGF-1 promoted the increase of PR levels in rat uterine cells grown in primary 
cultures due to an increase in ERα phosphorylation (Aronica and Katzenellenbogen, 1993). 
Further studies demonstrated that this increase was due to the apparent indirect interaction 
between PKA and PKC in a ligand dependent manner, leading to phosphorylation of ERα 
and hence transcriptional activation (Cho and Katzenellenbogen, 1993a). A later study 
revealed that PKA could, once activated by cAMP, directly phosphorylate serines of ERα 
within AF-1 specifically targeting ser-104, 106 and 118, which demonstrated an increase in 
transcriptional activity that was further potentiated in the presence of its ligand, E2 (Le Goff 
et al., 1994). TGFα which can also bind the EGFR, can increase ERα transcriptional 
activity through the use of MAPK signaling pathways as well as other second messenger 
signaling pathways, such as PKC and PKA (Ignar-Trowbridge et al., 1993). 
 
Further downstream within the N-terminal AF-1 domain of ERα, ser-167 is also 
targeted for phosphorylation in a ligand-dependent manner by a highly specific 
serine/threonine protein kinase, Casein kinase II known to regulate the activity of several 
transcription factors (Edelman et al., 1987). Ser-167 appears to also be the target of the 
PI3K/Akt pathway (Figure 12). Studies have demonstrated that phosphorylation by Akt at 
this particular site activates ERα-mediated transcription in a PI3K dependent manner 
(Shah and Rowan, 2005). An additional kinase activated by the EGF pathway is the 90-
kDa ribosomal S6 Kinase (pp90rsk1), a Ser/Thr Kinase. During growth factor response, 
pp90rsk1 targets the phosphorylation of ser-167, which is necessary in order to regulate the 
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transcriptional activity of the AF-1 in the ERα isoform (Joel et al., 1998). It appears that 
the phosphorylation of ser-167 plays a role in optimal DNA- binding not only in vitro but 
in vivo as well to endogenous promoters (Shah and Rowan, 2005; Likhite et al., 2006).   
 
Recent studies have shown that p21-activated kinase (pak1) can target ERα ser-305 
(Bostner et al., 2010) which can also promote transcriptional activation of cyclin D1 
(Balasenthil et al., 2004).Furthermore, PKA which also targets ser-305 rendered cells less 
resistant to tamoxifen treatment (Kok et al., 2010). In addition targeting ser-305 prevents 
the acetylation of the nearby lysine residue at position 303 (Cui et al., 2004). In fact lys-
303 is often mutated in breast cancer and seems to increase the sensitivity of ERα to E2 
(Fuqua et al., 2000). It has been shown that another MAPK, p38, can directly 
phosphorylate ERα on Thr-311 in ERα-expressing endometrial cancer cells, encouraging 
its nuclear localization and its interaction with transcriptional coactivating complexes (Lee 
and Bai, 2002).  
 
Finally within the C-terminal domain, close to the LBD, lies the residue tyrosine-
537, which when phosphorylated by the src family tyrosine kinases p60c-src and p561ck in 
MCF-7 and sf8 cells, serves to regulate hormone binding to the receptor, trigger 
homodimerization and enhance transcriptional activation on EREs (Arnold et al., 1995a) 
(Weis et al., 1996; Likhite et al., 2006). While it has not yet been described in tumours, the 
corresponding substitution in ERβ bestowed constitutive activity and increased the 
recruitment of coactivators (Tremblay et al., 1998). Multiple phosphorylated forms of ERα 
exist, and more importantly studies have demonstrated the correlation between the several 
phosphorylates sites within the receptor with human breast tumour biopsy samples 
(Murphy et al., 2009) revealing the significance of studying the regulation of ER 
phosphorylation. 
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5.3.3.2 Impact on ERβ 
The identification of ERβ has improved our understanding on the diversity of 
potential mechanisms by which ER-independent and estrogenic responses may be 
achieved. In the absence of estrogen, ERβ has been shown to regulate cycooxygenase-2 
(COX-2) in fetoplacental endothelial cells (Su et al., 2009). The group did show that 
protein expression of COX-2 was not induced following estradiol treatment, however, 
specific knockdown of ERβ lead a decrease in the levels of COX-2. Although no 
signalling pathways were studied, the group was confident non-estrogenic signalling upon 
ERβ was at play. Earlier studies however did identify that by increasing the levels of 
cAMP, the transcriptional activity of ERβ was enhanced. Unlike ERα, this was not due to 
an increase in phosphorylation within the AF-1 region. It appears that the elevated level of 
cAMP, which activated a variety of protein kinases such as PKA and PKC, target the 
carboxy-terminal region, but specific targets have yet to be identified (Coleman et al., 
2003). Also, during estrogen treatment, the expression of TGFβ-inducible early gene 
(TIEG) was regulated by ERβ in an AF-1-dependent manner due to the domain’s ability to 
Figure 12 Schematic representation of experimentally-supported phosphorylation sites
on ERα. 
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recruit coactivators (Hawse et al., 2008).  The MAPK pathway can target and enhance the 
activity of the murine ERβ through stimulating the recruitment of coactivating protein 
complexes to its N-terminus by phosphorylation of Ser-106 and Ser-124 (Figure 13) 
within the AF-1 domain (Tremblay et al., 1999a; Tremblay and Giguere, 2001). 15d-PGJ2 
(prostaglandin J2) induces apoptosis in pancreatic cancer cells by attenuating ERβ-
mediated human telomerase reverse transcriptase (hTERT) gene transcription through a 
reduction in ERβ phosphorylation (Kondoh et al., 2007). Since it has been reported that 
ERβ phosphorylation was mediated by the MAPK signaling pathway (Tremblay et al., 
1999a), treatment of cells with MEK inhibitor PD98059 reduced ERβ phosphorylation 
affecting the binding of ERβ to the hTERT gene promoter and hTERT protein expression 
suggesting that 15d-PGJ2 suppressed the phosphorylation of ERK1/2 which in turn 
affected the activity of ERβ.  
 
Figure 13 Schematic representation of experimentally-supported phosphorylation
sites on ERβ. 
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The p38 pathway can equally activate the transcriptional activity of ERβ in a ligand 
dependent manner although the mechanism, direct or indirect has not been established 
(Driggers et al., 2001). However, the outcome ER phosphorylation by protein kinases not 
only differ according to the identity of the activator but is also cell-type specific. It was 
recently shown that the activation of the p38 pathway by ErbB2/ErbB3 heterodimer was 
able to repress ERβ activity in pathological cell-lines by affecting the recruitment of 
coactivators to the N-terminal region (St Laurent et al., 2005a). Similarly, ErbB2/ErbB3 
was able to repress ERβ through the Akt pathway by phosphorylating the receptor within 
the hinge region on Ser-255 (Figure 13) and leading to a decrease in its transcriptional 
activity (Sanchez et al., 2007). From the studies highlighted, it can be appreciated that ERβ, 
much like ERα, are regulated by several mechanisms either increasing or decreasing their 
activity depending on the activator, the sites targeted and the cell-type in which they are 
expressed.  
 
5.4 GPCR can regulate ERs  
Studies regarding the potential influence of GPCR signaling on ER-responsive 
genes are very few. A negative regulator of Rho-family of GTP-binding proteins, 
RhoGDIα, is able to regulate the activity of ERα transactivation. In fact RhoGDIα 
differentially modulated the expression of PR and pS2 genes, which contain very different 
cis elements and trans-acting factors. While the pS2 gene contains an imperfect ERE that 
interacts with ERα (Berry et al., 1989), the PR gene contains several activator protein-1 
(AP-1) response elements and Sp1 sites through which ERα acts indirectly (Figure 14) 
(Petz et al., 2002; Petz et al., 2004). Thus the ability of RhoGDIα to affect differently the 
activity of ERα depends on the differences in the population of cis-elements and the trans-
acting factors associated with various target genes. 
 
The melatonin receptor is able to inhibit the proliferation of MCF-7 ER positive cell 
line (Hill et al., 1992; Kiefer et al., 2005) through a down-regulation of protein and mRNA 
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levels of ERα (Molis et al., 1994). In addition these effects are receptor specific as 
melatonin decreased the transcriptional activity of ERα both at ERE and AP-1 response 
elements, although these effects were not observed for ERβ. In fact it appears that the 
response to melatonin depends on the ERα /ERβ, as addition of ERβ results in MCF-7 
insensitivity to melatonin (del et al., 2004).  
 
On the other hand, signaling pathways known to be part of GPCR signaling can 
activate ERs. Brx, a guanine nucleotide exchange factor (GEF) can interact and stimulate 
the activity of both ERα and ERβ (Driggers et al., 2001) albeit through different pathways. 
While the cdc42-dependent pathway mediated ERα activation, ERβ’s activity was 
stimulated by the p38 pathway. Moreover the chemokine receptor CXCR4 originally 
identified as an estrogen-regulated gene in ERα positive ovarian and breast cancer cells (Ali 
and Lazennec, 2007), has recently been reported by our laboratory to affect both the 
estrogen-dependent and independent transcriptional activates of ERα and ERβ. Indeed, the 
activation of CXCR4 with its ligand stromal cell-derived factor (SDF-1) promoted ERβ 
activity at ERE and AP-1 sites involving the phosphorylation of the receptor at ser-87 in the 
AF-1 domain by the MAPK pathway (Sauvé et al., 2009) (Figure 13).  
 
5.5 ERs at the chromatin; a direct (ERE) and indirect (AP-1/ 
sp/1) relationship with DNA  
ER genomic signaling can be divided into two distinct categories, the classical and 
the non-classical pathways. Classical signaling involves ERs binding directly to a specific 
DNA sequence and recruiting cofactors in order to initiate transcription (Figure 14). ERE-
induced changes in ER conformation were predicted to alter ER affinity for coregulatory 
complexes (Klinge et al., 2001; Klinge et al., 2004). Although ERα and ERβ have been 
shown to display similar affinity for different EREs (Klinge, 2001) there are however 
conformational differences in ERs depending on both ligand and the bound ERE sequence 
(Klinge, 1999; Klinge et al., 2001; Bowers et al., 2000; Ramsey and Klinge, 2001; 
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Tyulmenkov and Klinge, 2001; Tyulmenkov et al., 2000). The steroidogenic factor-1 
response element (SFRE) was found to interact with ERα not ERβ and even if heterodimers 
are preferential, ERα was not able to drive ERβ to the promoter (Yi et al., 2002) In fact, 
anti-estrogen treatment stimulated ERα, not ERβ, transcription at EREs in uterine cells 
through its N-terminal domain, which contributed to the agonistic activity of the anti-
estrogen (McInerney et al., 1998; Hall and McDonnell, 1999).  
Alternatively non-classical signaling of ERα and ERβ involves altering the 
transcription of genes without directly binding to an ERE (Figure 14). Studies reporting 
estrogen-ER induction of genes containing no apparent ERE-like sequence led to the 
discovery that ligand-activated ERs can be tethered to other transcription factors and 
interact in an indirect manner with the regulatory regions of target genes. Both receptor 
subtypes are able to regulate gene expression indirectly via protein–protein interactions 
with c-Jun and c-Fos complex that bind to AP-1 (Matthews et al., 2006; Teyssier et al., 
2001) as well as Sp1 and NF-κB (Pearce and Jordan, 2004). There are several genes 
regulated by ERα in a non-classical pathway such as EGFR (Salvatori et al., 2003), c-myc 
(Dubik and Shiu, 1992), IGF-1 (Umayahara et al., 1994) and Hsp27 (Porter et al., 1997). 
Figure 14 Classical vs non-classical ERβ pathways of target gene expression. 
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Specifically, ERα-mediated expression of the collagenase and IGF-1 genes is mediated 
through the interaction of the receptor with Fos and Jun at AP-1 binding sites, whereas 
several genes containing GC-rich promoter sequences are activated through ERα-Sp1 
complexes (Figure 14) (Kushner et al., 2000).  The AF-1 domain of each receptor plays a 
vital role in the outcome of their activity, although at times ligands determine their 
biological actions. ERα and ERβ can show opposite effects at AP-1 promoters in the 
presence of anti-estrogens (Webb et al., 1999). 4-hydroxytamoxifen can induce the activity 
of an AP-1 promoter in the presence of ERβ, whereas E2 blocks transcription (Paech et al., 
1997). ERβ was also able to regulate transcription of the quinone reductase gene in 
response to anti-estrogens but not E2 (Montano et al., 1998). ERβ was not able to induce 
reporter activity driven by the hRARα-1 promoter in the presence of estrogen however it did 
elicit transcriptional activation in the presence of 4-hydroxytamoxifen. Other ER 
antagonists including raloxifene, ICI-164,384 and ICI-182,780 also acted as agonists 
through ERβ via the hRARα-1 promoter (Zou et al., 1999).  
The availability and ability for second messenger signaling used to regulate ERα 
and ERβ and the subtype-specific promoter elements of target genes begin to account for 
the differences in ERs action in the various cells. Yet recent evidence has emerged 
establishing coactivators as points of convergence between ERs and growth factor signaling 
pathways by being targets of phosphorylation an event thought to enhance their 
transcriptional activities (Hall et al., 2001). In addition to activating ER protein directly, 
kinase-mediated growth factors signaling also modulate ER activity indirectly by targeting 
coregulatory complexes that interact with ERs. 
 
6 Coregulatory complexes 
In recent years, a large number of nuclear and steroid coregulators have been cloned 
and characterized to regulate receptor transcriptional activity. Following ligand binding to 
the receptor these coregulators are recruited to promoter regions through protein-protein 
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interaction either enhancing or impairing ERs mediated transcription (Klinge, 2000) by 
using their histone-modifying abilities to alter local chromatin structure. Acetylation on 
lysine residues was first discovered as a post-translational modification on histones and has 
long been considered as a direct regulator of chromatin structure and function. In fact the 
rate of gene transcription can be generally correlated with the degree of histone acetylation, 
where hyperacetylated regions of the genome are more actively transcribed than 
hypoacetylated regions (Pazin and Kadonaga, 1997).  
 
Lysine residues are also used as sites for other post-translational modifications, such 
as ubiquitination, methylation, SUMOylation, biotinylation or neddylation (Yang, 2005), 
however their acetylation chemically locks the residue from any other modification. Lysine 
acetylation provides a great regulatory potential by creating a docking site to promote 
protein-protein interaction or interfere with binding of specific partners (Caron et al., 2005; 
Caron et al., 2003; Yang, 2004). Two types of enzymes control acetylation; histone acetyl-
transferases (HATs), which use acetyl-CoA to transfer an acetyl group to the substrate. The 
other type of enzymes is histone deacetyl-transferases, (HDACs) which reverse the 
aforementioned modification. The discovery that mammalian HDAC was a homolog of the 
yeast corepressor, RPD3 (Taunton et al., 1996) gave rise to the hypothesis that regulated 
activation events could involve the potential exchange of complexes containing HDAC 
function with those containing HAT activity.  
 
Biochemical and cloning techniques have uncovered a large number of factors that 
interact with nuclear receptors in either a ligand-dependent or ligand-independent approach. 
Many of these factors have been shown to increase the activity of nuclear receptor activity 
in transient transfection assays, suggesting that they are used by nuclear receptors as 
coactivators of transcription. Many of these proteins function as components of large, 
multiprotein complexes but as the number of potential regulators exceeds by far the 
capacity to directly interact with a single receptor, it is logical to suggest that transcriptional 
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activation of nuclear receptors involves multiple factors that act in both a sequential and 
combinatorial manner to reorganize chromatin templates, modify and recruit basal factors 
and RNA polymerase II (Pollard and Peterson, 1998). HATs and HDACs include distinct 
families in which members are considered as regulators of transcription (Kouzarides, 2000; 
Caron et al., 2003; Yang, 2004; Sterner and Berger, 2000; Glozak et al., 2005) (Figure 15). 
 
 
 
 
Figure 15 Mechanism of receptor activation through a change of coregulatory
complexes in the presence of estrogen. 
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6.1 Coactivators 
Coactivators are a specific group of chromatin-remodeling complexes that change 
the organization of nucleosomes in the vicinity of promoters, making the core elements of 
promoters accessible for binding to general transcription factors (Figure 15) (Naar et al., 
2001; Lemon and Tjian, 2000; Taatjes et al., 2004). Several coactivators are able to bind to 
nuclear receptors however this section will focus on the more popular coactivators having a 
role on ERs transcriptional activity. Steroid receptor coactivator-1 (SRC-1), amplified in 
breast cancer1 (AIB1/ACTR/SRC-2), glucocorticoid receptor interacting protein 
1/transcriptional intermediary factor 2/SRC-3 (GRIP1/TIF-2/SRC-3), p300/CBP and 
p300/CBP-associated factor (p/CAF) (Fu et al., 2002; Fu et al., 2003; Xu et al., 1999) are 
but a few members of coactivators known to regulate the activity of ERα and ERβ. 
  
6.1.1 SRC-family 
The SRC family of coactivators contains not only LXXLL motifs that allow for ER 
binding but also contain C-terminal activation domains (AD1 and AD2) and N-terminal 
basic-helix-loop-helix/PAS (bHLH/PAS) domains, which associate with factors involved 
in chromatin remodeling. Specifically, AD1 recruits the histone acetyltransferases p300 
and Creb Binding Protein (CBP), while the AD2 interacts with protein arginine 
methyltranferases (PRMTs) such as coactivator-associated arginine methyltransferase 1 
(CARM1) and PRMT1. The existence of these secondary complexes allows for 
amplification of ER responses: SRC-1 together with CBP and GRIP1 together with 
PRMTs were shown to function in a synergistic manner to potentiate the transcriptional 
activity of ER (Stallcup et al., 2000).  
 
Both ERα and ERβ have a strong affinity preference for particular coactivators, 
which may be mediated through subtype specific utilization of different LXXLL motifs for 
their interaction with the SRC family of proteins (Li et al., 2003b; Wong et al., 2001). 
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Furthermore, GF stimulation enhances phosphorylation of the murine ERβ AF-1 and 
promotes SRC-1 binding and transcriptional activation (Tremblay et al., 1999b). SRC-1, 
GRIP1, and AIB1 are phosphorylated by MAPK, which enhances their activities (Smith 
and O'Malley, 2004). More elaborate control of coregulator function was demonstrated 
with the identification of six phosphorylation sites in AIB1 and different combinations of 
phosphorylation sites on AIB1 are required for mediating the activation of NF-κB 
compared to phosphorylation patterns on AIB1 required for oncogenic transformation of 
MEFs (Wu et al., 2004). High levels of SRC-1 in breast and uterus enhance the agonistic 
activity of tamoxifen (Shang and Brown, 2002). SRC-1 can also interact with CBP to 
activate ERβ-mediated transcription in a ligand-independent manner (Tremblay and 
Giguere, 2001). In tamoxifen treated women with breast cancer, high AIB1 expression, 
activated by ErbB2 signaling pathway counteracted the antagonistic effects of tamoxifen 
on ERs and was associated with a poor prognosis indicating the development of a 
tamoxifen resistant phenotype (Osborne et al., 2003). In fact, compared to SRC-1 and 
GRIP1, AIB1 is restricted to a few tissues including the uterus, mammary glands and the 
testis (Suen et al., 1998). Despite its restricted expression pattern, its disruption in mice 
severely affects growth and reproduction of mammary gland development (Xu et al., 
2000). Crosstalk between ERα and ErbB2 has been shown to result in phosphorylation of 
SRC-3 thereby enhancing its coactivating capacity (Font de Mora and Brown, 2000).  
 
6.1.2 CBP and p300 
The coactivator p300 and its related ortholog CBP are transcriptional integrators 
regulating NR function. The relative abundance of both is considered rate-limiting in 
diverse signaling pathways involved in metabolism and cellular differentiation (Goodman 
and Smolik, 2000). The coordination of these activities involves a scaffold function of the 
protein to tether transcription factors to the basal transcription apparatus and both possess 
an intrinsic HAT activity which not only modifies local chromatin to alter the access of 
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transcription factors to their cognate DNA binding site but are able to directly acetylate 
transcription factors and thereby alter their function (Kalkhoven, 2004; Fu et al., 2004). 
 
6.1.2.1  CBP and p300- Two of the same? 
While CBP was isolated as a coactivator of the transcription factor CREB (Chrivia 
et al., 1993) and p300 was discovered as a protein interacting with the transforming 
adenoviral E1A protein (Eckner et al., 1994), both were shown to have similar functions 
(Arany et al., 1995; Lee et al., 1996). The recognition that both CBP and p300 acted as 
coactivators for CREB, AP-1 (Bannister and Kouzarides, 1995) as well as nuclear hormone 
receptors (Kamei et al., 1996; Chakravarti et al., 1996) initiated a large number of studies 
revealing CBP and p300 as essential coactivators for several other transcription factors (Vo 
and Goodman, 2001; Goodman and Smolik, 2000). Transient overexpression of both 
proteins resulted in interchangeable functions, however using hammerhead ribozymes to 
lower the expression of CBP or p300 indicated that although both proteins are necessary for 
apoptosis and G1 arrest of F9 embryocarcinoma cells, differentiation was dependent upon 
p300. Interestingly, Kawasaki et al. further observed that p300 specifically regulated the 
expression of the cell cycle inhibitor p21Cip1, however expression of p27Kip1 was regulated 
by CBP (Kawasaki et al., 1998) revealing how treatment of F9 cells with retinoic acid 
(RA), which normally decreases the rate of proliferation, did not significantly reduce 
proliferation when p300 or CBP-directed ribozymes were expressed. Similar methods also 
demonstrated that p300 was necessary for the cellular response following ionizing radiation 
in MCF-7 cells, not CBP (Yuan et al., 1999a; Yuan et al., 1999b), and CBP and p300 were 
unable to mutually complement each other during the differentiation of 3T3-L1 
preadipocytes into mature adipocytes (Takahashi et al., 2002).   
 
One of the major paradoxes in CBP and p300 activity is that these two proteins are 
able to contribute to completely different cellular processes. Their importance was 
elucidated by the group of Yao (Kung et al., 2000) who after performing null mutations in 
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one allele of CBP in mice, rodents developed a variety of hematological abnormalities, 
including extramedullary myelopoiesis and erythropoiesis, lymph node hyperplasia and 
splenomegaly which are conditions associated with bone marrow failure. As mice grew 
older they developed a high incidence of hematological malignancies which include 
histiocytic sarcomas, monomyelocytic leukemia and lymphocytic leukemia. In addition, 
patients who suffer from Rubinstein-Taybi syndrome (RTS), due to CBP heterozygosity, 
also have increased incidence of malignancy (Miller and Rubinstein, 1995). Surprisingly, 
the hematological defects and cancer predisposition were not observed in mice that 
contained the identical mutation in one p300 allele although its role as a tumour-suppressor 
cannot be dismissed as reports have shown that p300 missense mutations is associated with 
loss of heterozygosity in tumours of patients suffering from colorectal and gastric 
carcinomas (Gayther et al., 2000; Muraoka et al., 1996).  
 
6.1.2.2  Functional domains 
CBP is an evolutionarily highly conserved protein. The human CBP cDNA shares 
89% homology at the DNA level with its murine homolog, while sharing 95% homology at 
the protein level (Giles et al., 1997). CBP shares 63% identity at the amino-acid level with 
p300 (Figure 16). Greater similarity is observed in specific regions such as the CREB 
binding site (KIX), the E1A binding site (C/H3) and the bromodomain (Arany et al., 1995). 
Because they have very similar cellular functions, the literature has often referred to these 
two proteins as CBP/p300. The modular structure of p300 and CBP facilitates these diverse 
functions through distinct domains. 
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The bromo domain regulates protein-protein interactions and facilitates association 
with chromatin. Three cysteine histidine rich domains (CH) serve as docking modules for 
transcription factors and the glutamine rich carboxyl terminus interacts with the NR 
coactivators, including the steroid receptor coactivators. Located between the amino acids 
1004 and 1044, just before the bromo domain (figure 16), is a region referred to as the CRD 
(cell cycle regulatory domain). This domain was named due to the fact that it was a target 
of p21CIP1 activity. Recent studies identified the CRD1 domain as the key site of p300 
sumoylation (Girdwood et al., 2003) which dampens its coactivating potential. 
  
Figure 16 CBP and p300 functional domains. The different domains and the factors 
known to associate with CBP and p300 are labeled above CBP. aa: amino acids. 
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6.1.2.3 CBP/p300- impact on ER activity 
ERα interacts functionally with p300 and CBP (Shibata et al., 1997) which are 
‘cointegrators’ as they form complexes with TBP and a variety of activator proteins 
(McKenna et al., 1999). CBP can stimulate unliganded ERα and ERβ transcription on ERE 
promoters. The finding that CBP enhanced estrogen-induced ERα transcription only from 
some EREs is consistent with experiments showing that CBP shows weaker interaction 
with the ERα LBD than SRC-1 in vitro (Heery et al., 2001). In contrast to ERα findings, 
CBP enhanced estrogen-induced ERβ transcription from pS2 and the distal PR (1148) 
EREs. Therefore, CBP interacts differently with ERα and ERβ depending on the ERE 
sequence as well as the cell type (Jaber et al., 2006). Acetylation of ERα within its hinge 
region was first described to occur in the presence of p300 which decreased its estrogen-
dependent activity (Wang et al., 2001). However, in the absence of estrogen, a previous 
study did demonstrate that p300 cooperated with unliganded ERα to stimulate the 
transcription of the pS2 promoter (Kraus and Kadonaga, 1998; Kobayashi et al., 2000a). In 
addition, only CBP and not the p160 family of coactivators was able to interact with ERα 
even in the presence of the pure receptor antagonist ICI 182,780 however transcriptional 
activation of target genes was not achieved (Jaber et al., 2006). 
 
Most proteins involved in the control of cell growth are regulated by 
phosphorylation and CBP and p300 are not an exception to this modification. MAPK 
phosphorylates CBP (Janknecht and Nordheim, 1996; Liu et al., 1999) to maximize its 
intrinsic HAT activity (Ait-Si-Ali et al., 1999). Similarly cyclinE/cdk2 and the PI3-K/Akt 
pathway were able to phosphorylate CBP/p300 to also enhance its activity in order to 
encourage transcription of certain substrates and promote cell cycle progression (Sanchez et 
al., 2007; Ait-Si-Ali et al., 1998; Huang and Chen, 2005).  
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6.2 Corepressors 
  The fact that all known natural ligands of ERs are agonists suggests that the cellular 
role of NRs is to elevate transcription from target gene promoters; hence, the existence of 
coactivator proteins that amplify these responses is reasonable. Physiologically, however, 
there are fluctuating levels of circulating estrogens, and in tissues such as ovary, 
chronically high levels of estrogen could provide for sustained ER activation and 
overstimulation of ER biological pathways. Thus, as coactivators enhance ER activity, 
there has to exist pathways in which the activation is controlled by decreasing the 
transcriptional activity of nuclear receptors (Figure 15).  
 
Corepressor proteins have been identified because they reduce the agonist effects of 
estrogens. A recently described corepressor of ERα and ERβ, termed repressor of estrogen 
receptor activity (REA), decreases ER activity by interfering with SRC-1 access to the 
receptor (Martini et al., 2000). RIP140, an LXXLL-motif containing protein, associates 
with the estrogen-bound ERs through the AF-2 domain, occluding access of AF-2 
coactivators, such as SRC and CBP. In addition, RIP140 can decrease basal ER target gene 
expression by associating with histone deacetylase (HDAC) complexes, which repress 
transcription by catalyzing the condensation of chromatin (Smith and O'Malley, 2004). 
Interestingly, there is a direct repressive effect of RIP140 on ERβ activity which appeared 
to be stronger than on ERα. ERβ interacts with RIP140 more efficiently than ERα 
suggesting that RIP140 can differentially affect ERα and ERβ transactivation. Thus, the 
existence of corepressors that moderate the agonist activities of ERs provides an additional 
mechanism for fine-tuning the expression of ER target genes. 
 
Corepressors function with unliganded nuclear receptors to silence gene expression. 
These corepressors include nuclear receptor corepressor (N-CoR), silencing mediator of 
retinoid and thyroid hormone receptor (SMRT), HDACs and BRCA1 (Fu et al., 2003; Xu 
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et al., 1999). It is also apparent that cell signaling pathways can facilitate coactivator-
corepressor exchange, as cAMP stimulation of mammalian cells promotes dissociation of 
NCoR and SMRT from antagonist-bound PR, allowing for coactivator access (Wagner et 
al., 1998). Similarly, we found that SMRT inhibited basal transcription by ERα or ERβ, but 
SMRT inhibited estrogen-induced transcription for both ERα and ERβ, although the effect 
was more pronounced for ERα than ERβ. Notably, NCoR enhanced the anti-estrogen 4-
hydroxytamoxifen inhibition of ERα activity, but not ERβ activity whereas SMRT 
increased 4-hydroxytamoxifen inhibition of ERβ, not ERα (Keeton and Brown, 2005). 
 
Thus, estrogen and extracellular signaling pathways may enhance ERs action by 
coordinately enhancing the recruitment and activity of coactivators while decreasing the 
association and functionality of corepressors. Overall, posttranslational modification of 
cofactors appears to provide a mechanism to integrate extracellular signaling pathways, 
regulate assembly and dissociation of coregulators, and enhance or decrease the 
transcriptional efficacy of ER-cofactor complexes. 
 
7 Other Estrogen Receptor modifications 
In addition to phosphorylation and acetylation, other post-translational 
modifications have been identified influencing receptor function. Methylation of CBP by 
CARM1 is important for strong CBP coactivation of ER and GRIP1 complexes, and 
SUMOylation of SRC-1 or GRIP1 enhances coactivation functions by retaining these 
cofactors in the nucleus (Smith and O'Malley, 2004; McKenna and O'Malley, 2002). 
Acetylation and ubiquitination can decrease the half-life of not only ERs but cofactors 
involved in ERs transcriptional complexes by catalyzing their dissociation or degradation. 
The regulation of protein synthesis and degradation is a critical and highly regulated 
process.  
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7.1 The Ubiquitin-Proteasome pathway 
Protein degradation is an important step in many cellular functions. Not only are 
misfolded and damaged proteins destroyed to avoid toxicity but concentrations of 
regulatory proteins are adjusted by degradation at the appropriate time. In eukaryotic cells, 
an ATP-dependent protease known as the proteasome is responsible for a big part of protein 
targeted degradation. Different proteasomal complexes exist in the cell (Finley, 2009); 
however the type that will be focused on is the 26S proteasome. This form is composed of a 
20S core particle capped at one or both ends by a 19S regulatory particle (Groll et al., 1997; 
Tanaka, 2009). The 19S regulatory particle, containing ATPase subunits, guards the 
entrance to the degradation channel and plays a role in substrate recognition, unfolding and 
translocation onto the 20S particle (Tanaka, 2009; Finley, 2009).  
 
In order to be targeted towards degradation, proteins must be attached covalently to 
a tag that consists of several copies of the small protein ubiquitin (Figure 17) (Thrower et 
al., 2000; Weissman, 2001). Ubiquitin is attached to proteins by a series of three enzymatic 
activities. Subsequently, these substrates can either bind directly to the 19S subunit of the 
proteasome by interacting with the non-ATPase Rpn10 (Deveraux et al., 1994) and Rpn13 
(Husnjak et al., 2008) and/or the ATPase regulatory particle Rpt5 (Lam et al., 2002) 
otherwise ubiquitinated substrates can be brought to the proteasome by adaptors that bind 
both the proteasome and the ubiquitin chain on the substrate to deliver it for degradation 
(Elsasser et al., 2004; Kim et al., 2004; Verma et al., 2004a) however the complete picture 
has yet to be put together (Elsasser and Finley, 2005). 
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Figure 17 Ubiquitin-Proteasome Pathway.  
Ubiquitin molecules are activated by ubiquitin activating enzymes (E1) using ATP and 
transferred to ubiquitin conjugating enzymes (E2). Subsequently, the ubiquitin is transferred 
to the substrate which is recognized by ubiquitin protein ligase enzymes (E3) (Weissman, 
2001). The modification reaction does not stop after the addition of a single ubiquitin but 
continues so that an additional ubiquitin moiety is attached to a lysine of the first ubiquitin 
and so forth, generating a long ubiquitin chain formed on the substrate. Occasionally, an 
additional enzyme, called E4, is involved in this reaction (Hoppe, 2005). 
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The ubiquitin-proteasome pathway is an essential process for estrogen-dependant 
transcriptional activity of ERα and ERβ (Nawaz and O'Malley, 2004; Lonard et al., 2000; 
Nawaz et al., 1999; Reid et al., 2003; Picard et al., 2008; Tateishi et al., 2006). Studies have 
demonstrated that the requirement of the 26S proteasomal regulation of ERα and ERβ to 
maintain a continuous receptor turnover is essential in order to sustain or limit a hormonal 
response. In fact a component from the 26S proteasome subunit SUG1/TRIP1 interacts 
with several nuclear receptors in a ligand-dependant manner, including ERs (Masuyama 
and Hiramatsu, 2004; Tateishi et al., 2006; Zhang et al., 2006). In the presence of estrogen, 
ERβ interacts with SUG1 and the overexpression of SUG1 promotes the degradation of 
ERβ (Masuyama and Hiramatsu, 2004). Furthermore, the F domain of ERβ seems to 
protect the receptor from proteolysis by abrogating the binding of ERβ to the proteasome 
26S through SUG1 (Tateishi et al., 2006). 
 
7.1.1 E3-Ubiquitin Ligases 
CHIP (Carboxyl Terminus of Hsc70-Interacting Protein) is a chaperone-dependent 
U-box E3 ubiquitin ligase (Figure 17) known to mediate the degradation of ERα and 
attenuates receptor-mediated gene transcription (Fan et al., 2005; Tateishi et al., 2004). 
Recently, CHIP was shown to interact with N-terminal region of ERβ (Tateishi et al., 
2006). Even after ligand withdrawal, CHIP selectively eliminates the active form of ERβ 
providing evidence that receptor degradation is involved in transcriptional attenuation. The 
recruitment of another E3-ubiquitin ligase, E6-AP (Li et al., 2006), to ERα was dependent 
upon the phosphorylation of Ser-118 (Valley et al., 2005). Furthermore, E6-AP has been 
shown to participate in the regulation of the cellular levels of ERβ by degrading the 
receptor through the 26S proteasome (Picard et al., 2008). The recruitment of E6-AP on 
ERβ is also triggered by phosphorylation of AF-1 domain Ser-94 and Ser-106 (Figure 13). 
During activation of ERβ by MAPK, the recruitment and the action of E6-AP was 
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estrogen-independent and regulated by MAPK demonstrating the importance of activation-
degradation cycling for the activity of the receptor.  
 
Absence of the BRCA1 tumour suppressor gene highly predisposes women to 
develop breast and ovarian cancer (Perou et al., 2000; Sorlie et al., 2001). BRCA1 is 
implicated in a broad spectrum of biological processes including cell proliferation, cell 
cycle progression and DNA repair/recombination (Starita and Parvin, 2003; Parvin, 2004). 
BRCA1, together with BARD1 (BRCA1-associated RING domain), act as a ring E3 
ubiquitin ligase (Hashizume et al., 2001; Wu et al., 2008). A recent study shows that this 
transcriptional regulation is processed by the non-classical pathway of ERs since BRCA1 
promoter lacks EREs (Hockings et al., 2008). ERβ may play an important role in its 
regulation, since BRCA1 associated tumours show significantly higher expression of ERβ 
compared to ERα (Litwiniuk et al., 2008).  
 
The human ubiquitin-conjugating enzyme 7 (UbcH7), which was found to play a 
role in nuclear receptor transactivation, is another interesting target for the regulation of 
ERβ by the proteasome pathway (Verma et al., 2004b). UbcH7 interacts with SRC-1 which 
is essential for the coactivation function of UbcH7. Furthermore, immunoprecipitation 
assay in MCF-7 and T-47D demonstrated a hormonal-dependant recruitment of UbcH7 on 
ERα promoter. Another estrogen-inducible RING E3 ligase is EFP (estrogen-responsive 
finger protein) (Chen et al., 2006). Upon estrogen treatment, EFP transcription is enhanced 
by both ERs and breast cancer cell lines positive for EFP protein simultaneously express 
either ERα or ERβ protein (Ikeda et al., 2004). In ovarian cancer tissues a strong 
correlation was found between EFP and ERβ.  
 
7.1.1.1 MDM2 
Mdm2 belongs to a large family of (really interesting gene) RING-finger-containing 
proteins, and as most of its members, Mdm2 functions an E3 ubiquitin ligase (Figure 17) 
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(Jackson et al., 2000) and targets various substrates for mono and/or poly ubiquitination 
affecting substrates compartment localization, and/or concentration levels by proteasome-
dependent degradation. Mdm2 was identified as an amplified gene on a Murine Double-
Minute chromosome, in a spontaneously transformed derivative of the BALB/c cell line 
3T3DM, tumourigenic in nude mice (Fakharzadeh et al., 1991). The human homolog, 
Hdm2 also contains an oncogenic potential. The importance placed on Mdm2 over the past 
years is mostly due to its function as the major inhibitor of the tumour suppressor p53. 
Their interdependence was proved by the complete rescue of lethality of embryos lacking 
mdm2 by elimination of p53 (Iwakuma and Lozano, 2003).  
 
Additional functions for Mdm2 have been identified in cell cycle control, 
differentiation, cell fate determination, DNA repair, basal transcription and other biological 
processes which can contribute to its oncogenic potential (Ganguli and Wasylyk, 2003). 
Studies show that increased expression of Mdm2 is due to gene amplification, increased 
transcription, or enhanced translation (Oliner et al., 1992; Watanabe et al., 1994)., in fact, 
Mdm2 amplification is seen in approximately 7% of all human tumours (Momand et al., 
2000) In general, overexpression of Mdm2 is linked to a worse prognosis and a more 
advance stage of the disease (Cordon-Cardo, 2004). On the other hand, elevated levels of 
Mdm2 expression in ERα-positive breast carcinoma (40%) (Quesnel et al., 1994; McCann 
et al., 1995) is associated with a favourable prognosis (Onel and Cordon-Cardo, 2004; 
Cordon-Cardo, 2004).  
 
Mdm2 is induced in response to growth and survival factors and mediates their 
signal into the nucleus. The expression of mdm2 is also induced by IGF-1 treatment 
activation of the PDGF-β receptor (Fambrough et al., 1999; Leri et al., 1999). The 
PI3K/Akt survival pathway is pivotal in the cellular response to serum and IGF-1. 
Activation of this pathway induces association between Akt and Mdm2 with subsequent 
phosphorylation of serines 166, 186 and 188 (Meek and Knippschild, 2003; Milne et al., 
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2004; Feng et al., 2004). Akt induces phosphorylation of Mdm2 which promotes its 
stabilization through the inhibition of its self-ubiquitination (Feng et al., 2004), which 
permits its association with p300 and lowering its interaction with p53 (Mayo and Donner, 
2001; Zhou et al., 2001). This provides a mechanism where Akt can counteract p53 induced 
apoptosis.  
 
Strict control of the steroid receptor superfamily signaling is paramount to the 
maintenance of regulated cell function. Susceptibility to Mdm2 is common to these 
receptors and represents a critical node of regulation (Sengupta and Wasylyk, 2004). From 
results generated on the pS2 promoter (Metivier et al., 2004), Mdm2 when recruited to 
unliganded ERα at the endogenous ERE pS2 promoter encourages a fruitless cycle with a 
fast turnover of about 20 min. The fate of the polyubiquitinated receptor is proteasomal 
destruction. However in the presence of estrogen, ERα binds the ERE which then interacts 
with RNA polymerase II followed by E6AP and then Rpt6. The turnover of ERα under 
these conditions is of 45 min which favours gene transcription. In addition, ERα also 
modulates the p53/Mdm2 regulatory loop. In the presence of ERα and p53, the ERα 
protects p53 from Mdm2 (Liu et al., 2000). In turn, the accumulated p53 inhibits the ERα 
directed transcription by preventing its binding to the ERE of its target genes (Liu et al., 
2000). Interestingly, estrogen-bound ERα can be recruited to the mdm2 promoter and 
enhance Mdm2 protein synthesis, suggesting that ERα can participate in the regulation of 
Mdm2 transcription (Kinyamu and Archer, 2003).  
 
Overall, Mdm2 performs a vital role in mediating the regulation of hormone 
receptors such as ER, by controlling its stability and activity in response to levels of its 
ligand, which shows that continuous elevated levels of Mdm2 in cells responding to steroid 
hormones can lead to oncogenic transformation.  
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7.2 SUMOylation 
Another post-translational modification is the attachment of Small Ubiquitin-like 
MOdifier (SUMO) proteins to target proteins. Although SUMO modification resembles 
that of ubiquitin, the consequences are distinct (Ulrich, 2005). SUMO proteins can alter the 
target localization, activity and stability mainly by modulating protein-protein interactions 
and DNA binding (Geiss-Friedlander and Melchior, 2007) and although this modification 
correlates mostly with the inhibition of transcription factors and/or their cofactors activity 
(Gill, 2005) it appears ERα is an exception (Sentis et al., 2005). Overexpression of SUMO-
1 stimulates the activity of ERα due to its sumoylation within its hinge region. In addition, 
SUMOylation of SRC-1 stimulates its activity promoting furthermore the activity of ERα. 
Although the present work focused on ERα, it will be of interest to observe how 
SUMOylation affects ERβ transcriptional activity as diverse coregulator complexes 
modulate ERβ activity and are, for the majority, regulated by SUMO as well (Karamouzis 
et al., 2008).  
 
7.3 Methylation 
Coactivator-associated arginine methyltransferase 1 (CARM1) is one of the most 
studied methyltransferases implicated in nuclear receptor transcriptional regulation. 
CARM1 was initially identified as a partner of p160 coactivators (Chen et al., 1999), 
CARM1 is considered a secondary coactivator to ER only being able to function in the 
presence of p160 coactivators. Its importance has been shown in CARM1 null fibroblasts 
and embryos exhibiting aberrant expression of estrogen-responsive genes (Yadav et al., 
2003). In addition CARM1 overexpression in breast cancer has been observed by the 
increase on cyclin E1 gene (El et al., 2006). In breast cancer cell lines MCF-7, addition of 
estrogen lead to the activation of ps2 and E2F through the recruitment of CARM1 which 
methylated histones at the gene promoter (Bauer et al., 2002; Frietze et al., 2008).  
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7.4 Glycosylation 
Another dynamic modification of nuclear and cytosolic proteins is Ser(Thr)-O-β-
GlcNAcylation. O-GlcNAc and phosphorylation have similar cycling rates and generally 
occur on the same proteins. Several site mapping studies have also shown that O-GlcNAc 
and phosphorylation can be alternatively attached to the same serine or threonine residue 
within a protein (Zachara and Hart, 2006). The reciprocal site leads to different functional 
properties or activities of proteins, including the c-myc oncogene, RNA polymerase II, and 
ERβ (Cheng and Hart, 2001; Zachara and Hart, 2006).  
 
The competitive interplay between these two modifications is important in 
nutrient/stress sensing, transcription, and signaling, and the balance between them on 
signaling proteins is key to normal cellular metabolism and functions. Prior work 
established that ERβ is alternately O-GlcNAcylated or phosphorylated at Ser-16 within the 
N-terminal of the protein (Cheng and Hart, 2001). O-GlcNAcylated renders ERβ less active 
in stimulating target gene expression, yet is more stable within the cell. Phosphorylation of 
Ser-16 renders ERβ more active in stimulating target gene expression, but paradoxically is 
rapidly degraded.  
 
Overall, posttranslational modifications appear to provide a mechanism to integrate 
extracellular signaling pathways, regulate assembly and dissociation of complexes to 
enhance or decrease the transcriptional efficacy of ER-cofactor complexes. 
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7.5 Non-Genomic actions of ER 
  
7.5.1 ERs at the membrane 
The initial school of thought was that ERs were nuclear transcription factors which 
required the interaction with DNA in order to exert their effects. Nonetheless recent 
evidence shows that not only ERs but other nuclear receptors, such as AR and PR are able 
to exert extranuclear/non-genomic activity (Madak-Erdogan et al., 2008). The non-genomic 
actions of ERs are characterized by rapid responses that do not require DNA interaction by 
the receptors themselves, but are mainly regulated by ER-dependent activation or 
repression of intracellular signaling kinases (Figure 18) (Ordonez-Moran and Munoz, 
2009). Extranuclear signaling of ERs has been shown to activate important signaling 
pathways including s-Src, PI3-Kinase/Akt and MAPK pathways which result in Ca2+  
mobilization from the endoplasmic reticulum, induction of nitric oxide production, 
rearrangement of the cytoskeleton and proliferation all of which are dependent on cell-type 
specificity.  
 
ERs do not contain a transmembrane domain nor an intrinsic kinase domain, 
therefore post-translational modifications such as myristoylation (Rai et al., 2005), 
palmitoylation (Galluzzo et al., 2007; Acconcia et al., 2005) and protein-protein interaction, 
are probably involved to recruit ERα and ERβ to the plasma membrane. Studies 
demonstrated the presence of ERα in lipid rafts through its interaction with calveolin-1 and 
palmitoylation on cysteine (C447) of ERα (Acconcia et al., 2005). Shc and IGF-IR were 
shown to play a role in the recruitment of ERα to the membrane observed by siRNA 
knockdown (Song et al., 2004) which was inducible by tamoxifen but inhibited through the 
treatment of fulvestrant (ICI) (Huynh and Pollak, 1993) or inhibitors of MAPK (Kahlert et 
al., 2000). In addition, ERα can also interact with ErbB2 directly protecting breast cancer 
cells from tamoxifen-induced apoptosis (Chung et al., 2002). 
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ERs can interact with several other signaling molecules such as c-Src (Wong et al., 
2002), Shc (Song et al., 2002), and the p85α subunit of PI3K (Sun et al., 2001) leading to 
the activation of secondary signaling messengers and downstream kinase pathways, such as 
MAPK and Akt. These events have been well documented in the cardiovascular system 
where estrogen exerts rapid modulation of the vascular endothelium through nitric oxide 
production (Schlegel et al., 2001; Schlegel et al., 1999). Also, MCF-7 cells exhibit E2-
dependent activation of MAPK through the association of ERα with Shc, Src and Ras 
resulting in cell cycle progression (Migliaccio et al., 1996). Furthermore these kinases are 
then capable of activating nuclear ERs and coregulatory proteins thus promoting ER-
dependent transcription. This bidirectional crosstalk between ERs and growth factors 
enhances the survival potential of breast cancer cells which can potentially create a greater 
resistance to single forms of molecular therapy. 
Figure 18 Non-genomic effects of ERs.  
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7.5.2 GPR30 
It wasn’t until recently that another receptor responsive to estrogen, in the absence 
of ERα and ERβ (Filardo et al., 2000) led to the identification of a new member of the 
estrogen receptor family. Unlike its transcription factor counterparts, GPR30, also known 
as G protein-coupled estrogen receptor 1 (GPER1) is a seven transmembrane-domain G 
protein-coupled receptor (GPCR) considered until recently an orphan receptor. In 2005 two 
groups (Revankar et al., 2005; Thomas et al., 2005) showed that GPER1 could bind E2 and 
activate intracellular signaling by coupling with Gs proteins, stimulating cAMP production 
and transactivate EGFR by cleaving heparin-bound EGF. Although a receptor agonist (G-1) 
has been developed for GPER1 which discriminates its actions from the classical ERs, 
several studies report that E2 acts independently of GPER1, leaving its action as an ER not 
entirely accepted (Pedram et al., 2006) (Madak-Erdogan et al., 2008) (Otto et al., 2008; 
Ahola et al., 2002).  
 
The cellular localization of GPER1 is ambiguous as reports place it within the 
endoplasmic reticulum (Revankar et al., 2005) and at the plasma membrane (Filardo et al., 
2007; Funakoshi et al., 2006). The receptor is expressed in the uterus (Otto et al., 2009), 
ovaries (Owman et al., 1996) and mammary glands (Otto et al., 2009), specifically the 
theca and granulose cells (Wang et al., 2007). However GPER1 deficient mice did not 
exhibit any abnormalities in uterine function, reproduction or mammary gland (Otto et al., 
2009) (Wang et al., 2008; Martensson et al., 2009; Isensee et al., 2009; Windahl et al., 
2009) which in contrast to ERα and ERβ knockouts, demonstrate that GPER1 is not 
required for reproduction or for normal female reproductive organ physiology. Considering 
however the available biological and pharmacological data, E2 is likely a physiological 
ligand but maybe not the main ligand and the establishment of a broader pharmacological 
spectrum may reveal other ligands as it also appears to be a target for estrogenic endocrine 
disruptors (Pandey et al., 2009).    
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8 Implications of ER action 
 
8.1 ER subtypes in tumour progression 
ER signaling is required for normal functioning and maturation of the mammary 
gland by promoting DNA synthesis, however aberrant signaling can lead to abnormal 
cellular proliferation, promoting the progression of breast cancer. ERα is the dominant 
isoform and correlates with most of the prognostic factors in breast cancer (Fuqua et al., 
2003). Several studies report an increase ERα/ERβ ratio in breast cancer compared to 
benign tumors and normal tissues (Roger et al., 2001; Shaw et al., 2002), suggesting that 
ERα aberrant signaling is most likely involved in tumour development and progression 
while ERβ is likely to act as a tumour suppressor as proposed by studies reporting that 
overexpression of ERβ can inhibit ERα-positive breast cancer (Strom et al., 2004; Speirs et 
al., 2002; Paruthiyil et al., 2004; Williams et al., 2008; Speirs, 2002). However it would be 
unique among tumour suppressors to be expressed in over 75% of lesions (Shaw et al., 
2002).   
 
8.2  ERβ; Friend or foe 
8.2.1 ERβ, potential oncogene? 
Differential signaling between ERα and ERβ has been demonstrated with estradiol 
and tamoxifen at the AP-1 response element in ER target genes (Paech et al., 1997) and 
reviewed in chapter 5.5, suggesting that the ratio of ERα/ERβ may result in alternate gene 
regulation and could consequently be important in determining the response to ER 
modulators.  
Estrogen metabolism drastically changes with menopause, with a marked decrease 
of serum estrogens resulting in a relative increase of androgens. In postmenopausal women, 
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estrogen-metabolizing enzymes aromatase, steroid sulfatase and 17β-HSD play important 
roles in the pathobiology of breast cancer (Honma et al., 2006; Vermeulen et al., 1986). 
Androstenediol, one of the major sex steroid hormones present in postmenopausal breast 
tissue (Szymczak et al., 1998; Vermeulen et al., 1986) exhibiting estrogenic function, is 
known to preferentially bind to ERβ over ERα (Kuiper et al., 1998). This suggests a 
relatively more important role for ERβ in the pathobiology of breast cancer in 
postmenopausal than premenopausal women. Early reports on ERβ mRNA expression in 
breast cancer described significant associations with the rate of tumour recurrence while on 
endocrine therapy (Speirs et al., 1999b; Speirs et al., 1999a); suggesting ERβ is a poor 
prognostic indicator. In addition, ERα negative/ERβ positive tumours have revealed a 
proliferative role for ERβ (Skliris et al., 2006) due to its correlation with proliferation 
markers Ki-67 and CK5/6, although these tumours represent 10-20% of diagnosed tumours 
of the breast (Murphy et al., 2003). 
Two studies have examined the clinical importance of ERβ in tamoxifen-treated 
patients with breast cancer using the same monoclonal antibody (Nakopoulou et al., 2004; 
O'Neill et al., 2004). One of the studies reported better survival in women with ERβ-
expressing tumours (Nakopoulou et al., 2004) compared to the second study which used a 
much higher concentration of ERβ antibody and a different cutoff value, revealing opposite 
results (O'Neill et al., 2004). Such reports have left the role of ERβ in tumour progression 
controversial. Few large studies have been performed analyzing ERβ protein expression in 
normal breast, early lesions and invasive cancers. Antibodies directed against the N-
terminal domain of ERβ, detecting both full-length ERβ and various C-terminal truncated 
isoforms, (Fleming et al., 2004) found no correlation between ERβ expression and tumour 
grade, proliferation, S-phase fraction or DNA ploidy, while others found ERβ status to be a 
significant predictor of response to endocrine therapy (Myers et al., 2004; Mann et al., 
2001).  
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8.2.2 Tumour-suppressor activity? 
Although not all reports agree on how ERβ impacts cancer development, more 
studies are leaning towards the possibility that ERβ may function as a tumour suppressor, 
and that loss of ERβ could promote tumourigenesis. The balance between ERα and ERβ 
plays a role in the development of hormone-dependent cancers in various organs such as 
the ovary (Pujol et al., 1998), colon (Konstantinopoulos et al., 2003), and prostate (Horvath 
et al., 2001). Indeed reduction in ERβ protein expression and up-regulation of ERα (Bardin 
et al., 2004) have been associated with the development of invasive phenotype (Skliris et 
al., 2003). In the study by Skliris et al. antibodies directed against the C-terminal were used 
and examined the expression of ERβ in relation to established clinical parameters of breast 
cancer. Results demonstrated a positive association between ERβ protein expression and 
disease-free survival (DFS), which was further supported by a significant inverse 
relationship between ERβ and the proto-oncogene ErbB2 (chapter 5.2).  
The finding of a positive influence of ERβ expression on the outcome of breast 
cancer patients treated with tamoxifen is supported by several reports where ERβ was 
detected by mRNA or IHC staining (Esslimani-Sahla et al., 2004; Gruvberger-Saal et al., 
2007; Folgiero et al., 2008). Positive ERβ protein staining was invariably almost always 
associated with a favorable response to anti-estrogen treatment, consistent with its potential 
anti-proliferative and anti-invasive properties, also observed in ERβ-expressing cell lines 
(Lazennec et al., 2001). When only the studies examining ERβ protein expression are 
considered, there is a surprisingly high degree of similarity in terms of assigning frequency 
of expression (Skliris et al., 2008). Though there are different conclusions with respect to 
the correlations between ERβ and prognostic markers, two types of prognostic studies have 
been performed to date, those evaluating the levels of ERβ mRNA levels and studies that 
examined protein expression. The studies defining ERβ as a poor prognostic marker have 
examined its RNA level by quantitative or semi-quantitative PCR, however primers used 
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may amplify alternative spliced RNA variants, potentially increasing the false-positive rate 
or skewing the results towards a higher expression rate. Protein analyses however, appear 
to be less contradictory suggesting that ERβ protein expression is a favorable prognostic 
indicator although cut-off values to determine ERβ-positivity vary (Jensen et al., 2001; 
Miyoshi et al., 2001; Mann et al., 2001; Omoto et al., 2002; Omoto et al., 2001), thus a 
more uniformly adopted classification of ERβ expression is required to help clarify the 
potential role of ERβ in cancer progression. The use of ERβ protein expression levels as a 
tissue biomarker, in addition to protein expression levels of ERα, has the potential of more 
successful indication of therapeutic responses and the development of the disease in ER-
positive tumours. 
 
8.3 Tackling ER-dependent cancers  
The initial therapeutic strategies of using selective estrogen receptor modulators 
(SERMs) such as tamoxifen, which inhibit the action of ERs, has proven to reduce the 
prevalence in early breast cancer and improve patient outcomes. Nonetheless resistance to 
all forms of endocrine therapy remains a major obstacle. Continuous work into ERs biology 
and the present progress of the field to understand resistance mechanisms, including 
molecular cross-talk between ERs and the various GF signaling pathways, and the 
coregulatory complexes involved, are generating greater options to offer better and specific 
treatments in order to target resistance and improve breast cancer outcome. Endocrine 
therapies can exert pressure on breast cancer cells pushing them to adapt to a new 
environment reflecting their distinctive plasticity. Under these circumstances, patients may 
have the misfortune of developing a resistance to anti-estrogen therapy, as observed with 
tamoxifen, due to developing hypersensitivity to the estrogenic properties of tamoxifen. In 
addition, upregulation of growth factor pathways involving ErbB2, IGF-IR and ErbB3 play 
an important part in the progression of this process (McMahon et al., 2005). Blockade of 
the downstream effects of the IGF-IR, ErbB3 and ErbB2 pathways would also be beneficial 
and allow continuing responsiveness to anti-estrogen treatments.  
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8.3.1 ER interacting compounds 
 
8.3.1.1 Selective ERs modulators (SERMs) 
Tamoxifen, raloxifene and toremifene are estrogen-like compounds harbouring 
agonistic and antagonistic properties known as selective estrogen receptor modifiers 
(SERM). SERMs compete for the same AF-2 binding site within the c-terminal domain as 
E2 of both ERs. Binding of tamoxifen will lead to dimerization but will affect the 
positioning of helix 12 partially occluding the coactivator-binding sites as a mean to 
dampen the transcriptional activity of ERs and instead promote corepressors binding 
(Brzozowski et al., 1997; Shiau et al., 1998; Privalsky, 2004; Nettles and Greene, 2005). 
The agonistic properties of SERMs are carried out by the AF-1 domain of ERs (Smith et 
al., 1997; McDonnell, 1999). These effects are tissue-dependent relying on the cellular 
availability of coregulatory complexes (Smith and O'Malley, 2004; Jordan and O'Malley, 
2007). Tamoxifen showed agonistic activity in endometrial cell lines where SRC-1 is 
highly expressed, but is antagonistic in mammary cell lines where the expression of SRC-1 
is much lower (Shang and Brown, 2002). In addition on AP-1 and sp-1 regulated genes, 
where E2 is an agonist to ERα and antagonist to ERβ, tamoxifen acts as an agonist for both 
receptor isoforms (Kushner et al., 2000; Paech et al., 1997; Webb et al., 1995; Saville et al., 
2000; Zou et al., 1999).  
 
In addition, elevated levels of ERβ are not involved in tamoxifen-stimulated growth 
of tamoxifen resistant tumours (Chen et al., 2005). The ratio of ERβ/ERα can alter the 
estrogen like properties of tamoxifen. In the absence of BRCA1, genistein (phytoestrogen) 
decreases the expression of ERα and increases ERβ, shifting the ratio in favour of ERβ, 
promoting tamoxifen's antagonistic activity. In cells with functional BRCA1, genistein 
increases the expression of ERβ, but does not change ERα level. Here again ERβ/ERα ratio 
increases making the cells more sensitive to tamoxifen. So genistein may render cells 
sensitive to antiestrogen tamoxifen irrespective of BRCA1 status (Thasni et al., 2008). 
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8.3.1.2 Selective ER down-regulators (SERDs) 
Much like E2 and SERMs, SERDs such as fulvestrant (ICI 182780) bind the LBD 
of ERs but acts as a pure antagonist by inhibiting dimerization and DNA binding 
(Wakeling et al., 1991; Bowler et al., 1989; Pike et al., 2001; Fawell et al., 1990). In 
addition, fulvestrant affects ER localization and triggers ERα, not ERβ, degradation by the 
26S proteasome by interacting with cytokeratins drawing the receptor close to nuclear-
matrix associated proteasomes (Carlson, 2005) (Long and Nephew, 2006; Peekhaus et al., 
2004).   
 
8.3.1.3 Estrogen agonist-like compounds 
Understanding how activated ERs elicit organ-specific effects is crucial in order to 
design pharmacological agents reproducing estrogenic effects in specific target tissues. As 
the endogenous agonist 17β-estradiol binds to both ER subtypes in tissues (Shughrue et al., 
2002) two approaches have been envisioned to accomplish selective modulation of ER 
activity: SERMs and selective ligands capable of binding with higher affinity for either ER 
subtype. Since the discovery of ERβ in 1996, a major effort was undertaken to develop 
compounds acting specifically on either ER subtype.  
 
Although several agonists exist for both types of ER subtypes, few have been 
studied in vivo. Selectivity of ER-specific agonists has been measured in in vitro screens 
with the use of transcriptional assays and competitive radioligand binding assays. The 
beauty of selective agonists is the fact that they represent a tool to assess the respective 
functions of ERα and ERβ. Comparative data on the selectivity for both types of ER-
selective compounds on classic estrogenic signaling are, to date, consistent. However there 
are few studies on the ERβ agonist in vivo positive effects. Both academic and industrial 
groups have developed ERβ ligands and have been quite successful in generating high 
affinity selective templates due to its differential tissue distribution and selective 
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estrogenicity supported by the diverse and often opposing functional roles of ERβ 
compared to ERα, described in earlier chapters. Designing ER-specific compounds was 
achievable once the crystal structure of the LBD ERβ bound to genistein was first obtained. 
In combination with the earlier structure of ERα LBD, it was discovered that the polar 
interactions of both ERs were identical. Crucially their binding pockets vary by two amino 
acids M336/L384 and I373/MM421 producing topological and pocket size differences that 
must be the basis for subtype selectivity. In search for selective agonists, several non-
steroidal families of compounds have been developed, inspired by the structure of 
genistein. 
 
The first ERβ-selective agonist diarylpropionitril (DPN) was reported in 2001 
(Meyers et al., 2001). It is a potent ERβ agonist with 30 to 70- fold selectivity over ERα 
(Mewshaw et al., 2005). On the other hand, Propylpyrazole (PPT) is approximately 400-
fold more potent on ERα than on ERβ (Hillisch et al., 2004) (refer to Table 1). These 
synthetic ER agonists induce specific ER conformations exposing interaction surfaces for 
coregulator recruitment, which can differ from estrogen (Shughrue et al., 1998). Following 
the elaboration of DPN, the next synthetic peptides to appear were ER-041, WAY-202041, 
WAY-200070 and 8β-VE2 in 2004 (Malamas et al., 2004) followed by WAY-202196 in 
2005, (Mewshaw et al., 2005) (Table 1). Since 2007, phytoestrogenic compounds have also 
been added to the list including MF101, an extract from 22 different herbs (Cvoro et al., 
2007) and liquiritigenin (LIQ) (Mersereau et al., 2008) isolated from individual plants that 
constitute the MF101 extract. These agonists have been well characterized in vitro however 
their biological activities have not been equally tested in vivo. Although DPN is the most 
commonly used agonist in rodent studies, comparative studies have shown that each 
compound produces distinct biological actions in vivo. DPN, ERβ-041, WAY-202196, 
WAY-20070 and MF101 alongside LIQ (Cvoro et al., 2007; Mersereau et al., 2008) do not 
increase significantly uterine weight at comparable doses, however 8β-E2 increases uterine 
weight at a dose 100-fold lower than the other agonists (Harris, 2007). Other examples 
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include vasomotor instability (hot flashes) in rats, which can be regulated by DPN but not 
ERβ041 (Malamas et al., 2004). In addition, a randomized-placebo-controlled study in 
2009 published that MF101 was able to also reduce hot flashes in postmenopausal women 
(Grady et al., 2009).  
 
Table 1. Affinity Selectivity of ER-subtype agonists. 
 
 
These results suggest that ERβ selective agonists use different mechanisms to 
regulate gene expression. Additional studies have demonstrated that even though agonists 
could regulate a common subset of genes, each agonist could also uniquely regulated other 
genes, indicating that these uniquely activated genes might contribute to the differing 
biological effects observed in vivo. When three different cell lines were studied, Caco-2, 
Ishikawa and HeLa, all engineered to express ERβ, there was very little overlap in the 
genes regulated by MF101 and LIQ in each cell line, demonstrating remarkable cell-type 
specificity in the gene expression response. This strongly suggests that more comparative 
studies will be indispensable to evaluate these agonists for potential therapeutic use in 
RBA* Fold Selectivity
ERα selective hERα ERα
PPT 49 410
16α-LE2 57 250
ERβ selective hERβ ERβ
DPN 18 72
8β-VE2 83 180
ERβ-041 72 225
WAY-202196 180 78
WAY-200070 133 68
*RBA: Relative Binding Affinity
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addition to the variety of molecular mechanisms used by ERβ to regulate transcription 
(Paruthiyil et al., 2009).  
 
The treatment of menopausal symptoms and osteoporosis in postmenopausal 
women has largely relied on estrogens, however the Women’s health Initiative (WHI) trial 
(Chlebowski et al., 2003; Manson et al., 2003; Rossouw et al., 2002; Shumaker et al., 2003; 
Wassertheil-Smoller et al., 2003) discovered that the risks outweighed the benefits of 
hormone therapy (HT). Therefore the discovery of estrogens-like compounds that can 
selectively regulate ERα and ERβ would be most beneficial. From what we currently know 
of ER subtype activity, selective estrogen towards ERβ could be more advantageous for HT 
as ERβ is generally thought to counteract ERα-dependent cell proliferation and tumour 
formation (Lazennec et al., 2001; Paruthiyil et al., 2004; Strom et al., 2004). The lack of 
proliferative effects of ERβ was demonstrated with ERβ041, which did not exhibit any 
proliferative effects on the mammary glands and uterus of rats (Harris et al., 2003a). In 
addition MF101 and LIQ were not able to stimulate uterine growth or breast cancer tumour 
formation in xenograft models (Cvoro et al., 2007; Mersereau et al., 2008). 
 
Studies performed on cell lines revealed that ERβ-selective agonists activated genes 
that were not normally induced by estrogen (Paruthiyil et al., 2009). In addition the ligands 
would not always activate the same genes in different cell-types, which leads to believe that 
availability and differential recruitment of coactivators could explain the variations and also 
it is possible that the drugs are not metabolized equally in the different cell types. If the 
metabolites are active, this might account for the differences in the regulated genes.  
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8.3.2 Targeting alternative pathways to control ER 
8.3.2.1 Aromatase Inhibitors (AI) 
Blocking aromatase has the benefit of decreasing the levels of circulating estrogen, 
which is more relevant in post-menopausal women producing estrogen by peripheral 
aromatization of androgens. Two classes of AI are presently in use for women diagnosed 
with ER-positive breast cancer, a steroidal-based inhibitor, exemestane, which binds 
aromatase irreversibly, and non-steroidal-based inhibitor which block reversibly aromatase 
(Smith and Dowsett, 2003). Clinical trials with these inhibitors investigated three different 
treatment strategies; substitution of tamoxifen with AI; sequential treatment with tamoxifen 
followed and AI during the first five years after surgery; and extended adjuvant treatment 
using AI after five years of tamoxifen. Results from these studied showed that AIs were 
more effective than tamoxifen in preventing the recurrence of a tumour when used in 
substitution or sequential strategies (Howell et al., 2005; Baum et al., 2003; Baum et al., 
2002; Jakesz et al., 2005; Thurlimann et al., 2005; Coombes et al., 2004). In addition, the 
tolerability of AIs is similar to tamoxifen, although adverse events with AI are more 
manageable as they prevent estrogen biosynthesis, and do act as inhibitors to estrogen 
receptors as opposed to tamoxifen which competes with estrogen for binding at the receptor 
acting as an inhibitor or an activator.   
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8.3.2.2 Signal transduction inhibitors (STIs) 
These inhibitors can act at two levels; they delay significantly the development of 
anti-estrogen resistance and/or affect hormone-resistant cancers. In ER-positive breast 
cancer, the combination of tamoxifen or AI with farnesyltransferase inhibitors (FTI) was 
able to inhibit cell growth and promote apoptosis (Ellis et al., 2003). Monoclonal antibodies 
raised against the ErbB family work by either preventing ligand binding to the receptor or 
interfering with ligand-independent receptor signaling. Amplification of EGFR, although 
only observed in 0.8-6% of breast cancer cases (Bhargava et al., 2005) is blocked by 
gefitinib (anti-EGFR) which given together with tamoxifen or fulvestrant, the anti-
proliferative effect and the trigger of apoptosis was greater in combination compared to 
either drug alone (Gee et al., 2003). ErbB2 is amplified in 20-30% of breast cancers and 
correlates with increased proliferation, higher metastatic potential and poor prognosis, as 
such several antibodies have been raised in order to inhibit its signaling potential (Ross and 
Fletcher, 1998; Slamon et al., 1987). The antibody lapatinib, a dual EGFR/HER2 inhibitor 
Figure 19 Mechanisms of action of therapeutic agents presently used to treat hormone-
dependent cancers- Adapted from (Ali and Coombes, 2002). 
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collaborates with tamoxifen to reduce levels of cyclin D1, inhibit cyclin E-cdk2 and 
increase p27 kinase inhibitor in order to disrupt cell proliferation (Chu et al., 2005). 
Furthermore, ER-positive breast cancer xenograph models overexpressing ErbB2 treated 
with trastuzumab, pertuzumab (both anti-ErbB2) and gefitinib, in order to completely block 
all ErbB pairs, with tamoxifen, responded better than treating with a single antibody 
demonstrating the outstanding plasticity of cancer cells (Arpino et al., 2007). 
 
8.3.2.3 Small-molecule HAT inhibitors  
 As mentioned previously, HATs can acetylate histones and non-histone proteins 
affecting enzymatic activity and protein-protein interactions. Bisubstrate inhibitors, 
described for PCAF and p300, are remarkably selective and bind to the enzymatic region of 
these two HAT proteins inhibiting their enzymatic activity (Lau et al., 2000). In addition, 
there is a selection of natural compounds; curcumin inhibits the acetylation of histone H3 
and H4 specifically by p300/CBP since no effect was observed by PCAF, which also 
contains the functional HAT domain (Balasubramanyam et al., 2004). Indeed, curcumin 
addition to tumour cells promoted apoptosis. The natural product garcinol inhibits PCAF by 
also promoting apoptosis (Mantelingu et al., 2007). Anarcadic acid, which can inhibit both 
PCAF and p300 activity, targets the NF-κB activation pathway. Although the idea of 
targeting HATs that play a role in cancer progression could potentially be a promising 
strategy in combination with other therapies, considering the fact that HATs are part of 
large multiprotein complexes creates a challenge when trying to validate HATs as drug 
targets.  
 
8.3.2.4 The proteasome as a drug target   
Inhibitors of the 26S proteasome as drug candidates came from studies done in 
different leukemia and lymphoma derived cells, where apoptosis was induced (Imajoh-
Ohmi et al., 1995; Orlowski et al., 1998). Most synthetic inhibitors are short peptides that 
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mimic substrates. One method utilized by proteasome inhibitors is to activate JNK-
mediated apoptosis. Activation of JNK leads to the phosphorylation of 14-3-3 proteins, 
translocation of bax into the mitochondria and release of cytochrome c initiating the 
cascade leading to apoptosis (Lopes et al., 1997). Another inhibitor targets NEDD8-
activating enzyme, which controls the activity of RING ubiquitin ligases that regulate the 
cell cycle and signal transduction pathways. Initial experiments have demonstrated that the 
inhibitor induces apoptotic cell death in different human tumour models (Soucy et al., 
2009).  
 
Knowing the specific molecular mechanisms or resistance adopted by hormone-
dependent tumors is vital in order to define the optimal timing and sequence of treatment. 
The molecular characterization of the complex signaling networks active in hormone 
resistant cells will allow to further develop pharmaceutical compounds targeted at the 
various components of these pathways to hopefully overcome or delay the onset of 
resistance to endocrine therapy in breast cancer. Our current knowledge, although growing, 
is still insufficient to identify groups of patients that will benefit from the different 
endocrine agents, because by profiling individual tumors, we could predict the most 
appropriate endocrine therapy for each patient. 
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9 Hypothesis and Objectives 
 
ERα and ERβ are important for the development, growth, and maintenance of the 
female and male reproductive systems yet aberrant regulation of these receptors is 
implicated in the initiation and progression of cancers. Similarly deregulated signaling by 
ErbBs has been associated with a strong mitogenic potential and correlation between ErbBs 
and ERα status has served as a predicting factor in the response to endocrine treatment. 
Nonetheless the response of ERβ to ErbBs signaling remains undefined.  
 
The studies accomplished during the progression of my doctoral degree were 
developed in order to improve our comprehension of the mechanisms regulating hormone-
independent activation of ERs, in particular ERβ, which its function (ERβ) as a definitive 
marker for either a tumour–suppressor or an oncogene remains unconvincing. Thereupon it 
was deemed crucial to investigate how the activity of ERα and ERβ was influenced 
following the activation of ErbB2/ErbB3 heterodimer and the consequent outcome on 
cellular proliferation.  
 
The objectives of my doctoral studies were: 
I) To determine the impact of ErbB2/ErbB3 activation on the transcriptional activity of 
ERs (1st article) by: 
a) Evaluating the effect of ErbB2/ErbB3 activation upon the transcriptional activity of 
ERβ in comparison to ERα. 
b) Establishing which regulatory pathways are elicited following the activation of 
ErbB2/ErbB3 and how they affect ERs.  
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c) Examining the implication of ERβ regulation of target genes following 
ErbB2/ErbB3. 
II) To understand the mechanisms implicated in the transcriptional regulation of ERβ as a 
result of ErbB2/ErbB3 signaling (2nd article) by: 
a) Determining the events which lead to transcriptional inhibition of ERβ. 
b) Studying the implications of Ser-255 phosphorylation in the degradation of ERβ. 
c) Evaluating the importance of CBP in the degradation of ERβ. 
d) Examining the impact of ERβ degradation on the proliferation of breast cancer cell 
lines.
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Foreword 
The development of a hormone-independent status in reproductive cancers as 
observed for the breast has been generally attributed to a deregulated function of ErbB2 
and ErbB3 receptor tyrosine kinases. In addition these tumors often express high levels 
of ERα for which its activity has been extensively studied. ErbB2/ErbB3 signaling has 
been shown to activate ERα by triggering pathways which promote its phosphorylation. 
Phosphorylation of ERα activates several pathways leading to cell proliferation and 
tumour progression. Despite the fact that ERβ is also expressed in several breast tumors, 
very few studies have examined the involvement of ERβ during the development of a 
hormone-independency by breast tumors. Phosphorylation of ERβ, by intracellular 
signaling pathways has been observed to increase its activity (Tremblay et al., 1999a). 
However recent evidence shows that ERβ is inhibited following the activation of 
ErbB2/ErbB3 by the activation of the MAPK p38 signaling pathway (St Laurent et al., 
2005b). From these results, the following publication was developed in order to improve 
our knowledge of the mechanisms leading to the down-regulation of ERβ transcriptional 
activity. We discovered that the activation of the PI3K/Akt pathway lead to the 
downregulation of ERβ even in the presence of estrogen and the coactivator CBP. The 
repression was due to the phosphorylation of an Akt-consensus site within the hinge 
domain of ERβ, Ser-255. These results are shared by other nuclear receptors tested 
harboring an Akt consensus site within their hinge region, similar to ERβ. Unlike ERβ, 
ERα was activated under these conditions demonstrating a molecular mechanism by 
which the activation of the PI3K/Akt pathway can discriminate the activity of ERβ from 
other nuclear receptors.  
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ABSTRACT 
The hormonal response of estrogen 
receptors ERα and ERβ is controlled by a 
number of cofactors including the general 
transcriptional coactivator CREB-binding 
protein (CBP). Growing evidence suggests 
that specific kinase signaling events also 
modulate the formation and activity of the 
ER coactivation complex. Here we show 
that ERβ activity and target gene 
expression are decreased upon activation 
of ErbB2/ErbB3 receptors despite the 
presence of CBP. This inhibition of ERβ 
involved activation of the PI3K/Akt 
pathway, abrogating the potential of CBP 
to facilitate ERβ response to estrogen. 
Such reduced activity was associated with 
an impaired ability of ERβ to recruit CBP 
upon activation of Akt. Mutation of serine-
255, an Akt consensus site contained in the 
hinge region of ERβ, prevented the release 
of CBP and rendered ERβ transcriptionally 
more responsive to CBP coactivation, 
suggesting that Ser-255 may serve as a 
regulatory site to restrain ERβ activity in 
Akt-activated cells. In contrast, we found 
that CBP intrinsic activity was increased 
by Akt through threonine-1872, a 
consensus site for Akt in the C/H3 domain 
of CBP, indicating that such enhanced 
transcriptional potential of CBP did not 
serve to activate ERβ. Interestingly, 
nuclear receptors sharing a conserved Akt 
consensus site with ERβ also exhibit a 
reduced ability to be coactivated by CBP, 
while others missing that site were able to 
benefit from the activation of CBP by Akt. 
These results therefore outline a regulatory 
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mechanism by which the PI3K/Akt 
pathway may discriminate nuclear receptor 
response through coactivator 
transcriptional competence.  
 INTRODUCTION-  
Estrogen mediates many aspects in 
growth, development and reproduction, 
through its interaction with estrogen 
receptors ERα and ERβ1. While encoded 
by unique genes, the two ERs share the 
functional domains characteristic of the 
nuclear hormone receptor family (1). 
These consist of a N-terminal region (also 
termed AB region) which confers ligand-
independent activation of ERs through its 
activation function AF-1, a highly 
conserved DNA-binding domain (C) that 
allows specific binding to genomic 
response elements, a flexible hinge region 
(D) that includes signals for nuclear 
localization and the binding of heat shock 
proteins, and finally a C-terminal region 
(EF) that contains the ligand binding 
domain, and the AF-2 function which 
mediates hormone-dependent activation.  
Increasing evidence suggests that, 
beside hormonal activation, ER function 
can be modulated by phosphorylation-
dependent mechanisms, involving a wide 
variety of protein kinases that mostly target 
the AF-1 domain (2,3). In particular, direct 
phosphorylation of ERα AF-1 by 
MAPK/Erk in response to EGF was shown 
to induce ERα transactivation in absence 
of ligand (4,5). Similarly, phosphorylation 
of Ser-167 by pp90RSK1 was described to 
promote ERα AF-1 activity (6). Activation 
of phosphatidylinositol 3-Kinase (PI3K) 
and Akt/PKB (protein kinase B) also 
contributed to phosphorylate ERα and 
mediate its ligand-independent activation, 
an effect shown to oppose the tamoxifen-
induced apoptosis in breast cancer cells (7). 
Although, phosphorylation of ERβ has not 
been examined in detail, ERβ has been 
proposed as a potential target for 
intracellular kinases that modulate its 
transactivation properties. It was found that 
the ability of EGF and oncogene ras to 
activate ERβ resulted from the MAPK-
directed phosphorylation of Ser-106 and 
Ser-124 within the AF-1 domain leading to 
favored recruitment of coactivators SRC-1 
and CBP (8,9). Furthermore, the ligand-
dependent activation of ERβ by proto-
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oncogen Brx was shown to involve 
phosphorylation of ERβ in a p38 dependent 
manner, although the exact site(s) were not 
described (10). More recently, we reported 
that activation of ErbB2 and ErbB3, which 
belong to the EGFR/ErbB receptor tyrosine 
kinase family, by growth factor heregulin 
resulted in a decrease in the estrogen-
dependent cell growth and activity of ERα 
and ERβ in breast cancer cells (11). 
However, unlike ERα, this transcriptional 
repression of liganded ERβ by heregulin 
was dependent upon ERβ AF-1 function, 
thereby supporting a repressive role for 
kinase-mediated pathways in regulating 
ERβ AF-1 and AF-2 functions. Taken 
together, the regulation of estrogen 
receptor activity by phosphorylation is 
intricate and could dictate receptor 
function, whether it involves activation or 
repression. 
Recent evidence has emerged that 
nuclear receptor coactivators may also 
serve as points of convergence between ER 
and growth factor signaling pathways. 
Phosphorylation of SRC coactivators has 
been described to modulate their intrinsic 
activities in mediating nuclear receptor 
transcription (12). Coregulatory proteins 
are often present in limiting concentrations 
in the nucleus so that modifications of their 
level of expression as well as their activity 
can lead to alterations in nuclear receptor 
signaling. The transcriptional coactivators 
CREB binding protein (CBP) and p300 are 
evolutionary highly conserved proteins and 
genetic evidence supports their availability 
to be critical. In humans, loss of one 
functional copy of cbp leads to Rubenstein-
Taybi syndrome, a haploinsufficiency 
disorder resulting in mental retardation 
(13). Through their extremely versatile 
ability in bridging numerous transcription 
factors, including most nuclear receptors, 
with the basal transcription machinery, 
recruitment of CBP/p300 is important to 
maintain appropriate transcriptional events 
(14). One of the likely mechanism 
responsible for CBP/p300 recruitment 
involves phosphorylation. It was reported 
that phosphorylation of CBP promotes its 
interaction with several transcription 
factors, including CREB, Smad3, NFκB 
p65 subunit, and p53 (15,16). We have 
recently shown that MAPK-dependent 
phosphorylation of ERβ also facilitates the 
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recruitment of CBP to potentiate the 
ligand-independent activation of ERβ in 
response to growth factors (9). Given such 
diversity in the signaling pathways 
integrated by CBP, it is believed that 
phosphorylation-mediated events may 
compete at various levels for the limited 
availability of CBP. 
Here we describe a molecular 
mechanism by which ErbB2/ErbB3 and 
PI3K/Akt signaling impairs the activity of 
ERβ by reducing its ability to recruit and 
use CBP as a coactivator. The repression 
by Akt was also found for other nuclear 
receptors, for which a conserved Akt site 
may also participate in a manner similar to 
ERβ. In contrast, nuclear receptors that do 
not share such homology yielded increased 
responsiveness to CBP and benefit from 
the enhanced intrinsic activity of CBP by 
Akt. 
 
 EXPERIMENTAL PROCEDURES 
Plasmid Constructs - Expression pCMX 
plasmids coding for ERα, ERβ, CBP, 
ErbB2, its constitutive variant V659E and 
ErbB3 receptors, and luciferase reporter 
constructs vitA2-EREtkLuc and 
UAStkLuc have been described 
previously (8,9,11). ERβ fragments 
corresponding to the AB (aa1-167) and 
DEF (aa234-549) regions were obtained 
by PCR amplification and fused in-frame 
with the Gal4 DNA binding domain. The 
ERβ serine-255 to alanine and the CBP 
threonine-1872 to alanine mutants were 
generated by PCR mutagenesis using pfu 
polymerase (Stratagene). All constructs 
were verified by automated sequencing. 
The expression plasmid coding for 
constitutively active PI3K p110α catalytic 
subunit was a kind gift from J. 
Downward, and plasmids expressing Akt 
and K179M kinase dead Akt were 
generously provided by T. Chan and P. 
Tsichlis. 
 
Cell Culture, DNA Transfection and 
Luciferase Assay - Human embryonic 
kidney 293T cells were cultured in 
Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 5% fetal 
bovine serum (FBS). The cells were 
maintained at 37°C in a humidified 
atmosphere with 5% CO2. For transient 
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transfection, cells were seeded in phenol 
red-free DMEM supplemented with 5% 
charcoal dextran-treated FBS, and 
plasmid constructs were introduced into 
cells using the calcium phosphate 
precipitation method as described (11). 
Typically, 50-60% confluent cells were 
transfected with 2μg of DNA per well 
which include 500ng of reporter plasmid, 
100ng receptor expression vector, 250ng 
CMX-βgal, 100ng each of PI3K and Akt 
expression vector, and 30ng CBP plasmid 
when indicated. After 5-8h, medium was 
changed and cells were stimulated with 
10nM estradiol (E2; Sigma) and/or 
50ng/ml heregulin-β (R&D Systems) for 
16-20h or left untreated. For luciferase 
assay, cells were lysed in potassium 
phosphate buffer containing 1% Triton X-
100, and light emission was measured 
using a luminometer (Wallac) after the 
addition of luciferin. Luciferase assays are 
performed in duplicates from at least three 
independent experiments, and values are 
expressed as relative light units (RLU) 
normalized to the β-galactosidase activity 
of each sample.  
 
Western Analysis and 
Immunoprecipitation Assay - Western 
analysis for the determination of 
phosphorylated and total Akt was 
performed as described with minor 
modifications (11). Briefly, transfected 
293T cells were treated with 50ng/ml 
heregulin-β for 20min, washed in ice cold 
PBS, and lysed in PBS containing 0.5% 
sodium deoxycholate, 0.1% SDS, 1% 
Triton-X100, 1mM sodium 
orthovanadate, 1mM sodium fluoride, 
1mM phenylmethanesulfonylfluoride and 
protease inhibitors (Roche). Cell lysates 
were then subjected to SDS-PAGE and 
proteins transferred to nitrocellulose for 
immunoblotting. Membranes were 
incubated at 4°C with blocking reagent 
(Roche) in TBS, probed with either a 
rabbit polyclonal antibody against 
phosphorylated Akt (Santa Cruz) or a 
mouse anti-Akt monoclonal antibody 
(Cell Signaling Technology), and signals 
revealed by ECL using appropriate HRP-
conjuguated secondary antibodies. The 
same procedure was used to determine the 
levels of ERβ, except that cells were 
transfected with HA-tagged ERβ (wt or 
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S255A) and analyzed by Western using an 
anti-HA antibody (12CA5). For 
immunoprecipitation assay, transfected 
cells were washed in ice cold PBS and 
lysed as described above. Cell lysates 
were precleared before incubation with an 
anti-CBP antibody (Santa Cruz) and 
protein A-Sepharose beads at 4°C. 
Immunoprecipitates were then washed in 
lysis buffer, resolved by SDS-PAGE, and 
analysed by western blotting using an 
anti-HA antibody. Membranes were also 
probed with an anti-CBP antibody for 
standardization of CBP levels in each 
well.  
 
Generation of Hs-ER stable clones and 
RT-PCR – ER-negative Hs578t breast 
cancer cells were maintained in DMEM 
containg 10% FBS, and transfected with 
expression vectors for ERα and ERβ as 
previously described (11), and resistant 
clones were isolated in the presence of 
G418 (0.6 mg/ml; Invitrogen) to generate 
respectively Hs-ERα and Hs-ERβ cell 
lines. Stable clones were functionally 
validated for their respective expression 
of ERα or ERβ by Western analysis and 
for their estrogenic response by luciferase 
assay, compared to mock-transfected Hs-
578t cells. Total RNA was isolated from 
cells using TRIzol reagent (Invitrogen) 
and RT-PCR analysis was performed as 
described (17). The relative signal 
intensity was analyzed (Alpha Innotech, 
San Leandro, CA) from three separate 
experiments. 
  
In Vitro Phosphorylation Assay - 
Bacterially expressed and purified GST 
fusions of wild type and S255A mutated 
ERβ were prepared as described (18). For 
in vitro phosphorylation assay, GST-ERβ 
fusions immobilized on glutathione-
Sepharose 4B beads were resuspended in 
kinase buffer containing [γ-32P]ATP 
(Amersham Biosciences) and active Akt1 
(Cell Signaling), and incubated at 30°C 
for 30 min according to the manufacturer 
instructions. Beads were then washed 
twice in kinase buffer and twice in PBS, 
and 32P incorporation was determined 
following SDS-PAGE and 
autoradiography. Gels were stained with 
Coomassie blue to monitor for equal 
loading.  
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Fluorescence Microscopy - Cells were 
seeded on coverslips in a six-well plate 
overnight prior to transfection in phenol 
red-free DMEM supplemented with 5% 
charcoal dextran-treated FBS. Transient 
transfections were carried as above using 
the expression plasmids YFP-CBP and 
CFP-ERβ. 20h after transfection, cells 
were washed twice with cold PBS and 
fixed in 4% formaldehyde. The coverslips 
were mounted on microscope slides and 
examined in fluorescence with 
excitation/emission filters of 435/470 nm 
(for CFP), and 480/535 nm (for YFP), 
using a Nikon TE-2000 inverted 
microscope. 
 
 RESULTS 
 
ErbB2/ErbB3 receptor dimer activation 
impairs the hormonal response and 
coactivation of ERβ by CBP - Activation 
of the epidermal growth factor receptor 
EGFR/ErbB1, a member of the ErbB 
receptor tyrosine kinase family, is well 
recognized to promote ERα and ERβ 
transcriptional activation (4,8). However, 
we have recently reported that activation 
of the ErbB2/ErbB3 heterodimer 
combination lead to a decreased 
transcriptional activity of ERβ (11). Given 
the ability of CBP to associate and 
promote the activation of ERβ by growth 
factor such as EGF (9), we addressed how 
CBP could modulate ERβ activity in 
response to ErbB2/ErbB3 activation. ER-
negative human embryonic kidney 293T 
cells were transfected with an EREtkLuc 
reporter and an ERβ plasmid. 
Cotransfection with CBP conferred a 2-
fold increase in ERβ basal activity, and a 
7-fold increase in the presence of 
hormone (Fig.1A). As previously reported 
(11), the activation of the ErbB2/ErbB3 
heterodimer by growth factor heregulin-β, 
which binds ErbB3, resulted in a reduced 
activation of ERβ by estrogen. Such 
impaired response was also mimicked 
using a constitutive variant of human 
ErbB2 (V659E), which corresponds to the 
natural mutation found in the rat Neu 
oncogene (19). However, while CBP 
strongly transactivates ERβ in control 
cells, it is unable to prevent the inhibition 
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of the hormonal response of ERβ when 
the ErbB2/ErbB3 heterodimer is not only 
expressed but also stimulated by 
heregulin-β (Fig.1A). Despite the 
presence of CBP, the transcriptional 
activity of ERβ was decreased in both a 
hormone-independent and dependent 
manner. This inhibition was even more 
pronounced in cells expressing the 
constitutive ErbB2 V659E mutant. 
Signaling of the EGFR/ErbB family 
members involves the activation of a 
variety of kinase pathways. More 
specifically, activation of the 
ErbB2/ErbB3 heterodimer has been 
shown to efficiently couple with the 
PI3K/Akt pathway, mainly through the 
intrinsic ability of numerous SH2 binding 
motifs within ErbB3 that recognize the 
p85 regulatory subunit of PI3K (20,21). In 
order to evaluate the impact of 
ErbB2/ErbB3 activation on the Akt 
pathway, the activity of endogenous Akt 
was determined by Western analysis using 
a phospho-specific antibody against Ser-
473. While treatment of mock-transfected 
293T cells with heregulin-β did not lead 
to activation of Akt, indicating that 
endogenous expression of ErbB3 is 
negligible, if not absent, an increase in 
phosphorylated Akt was observed in cells 
expressing ErbB2/ErbB3 and treated with 
heregulin-β (Fig.1B). Similarly, cells 
expressing the ErbB2 V659E variant in 
presence of ErbB3 also showed increased 
levels of phosphorylated Akt. 
  
 Activation of the PI3K/Akt 
pathway mimics the inhibition of ERβ 
response to hormone in the presence of 
CBP through the C-terminal region of 
ERβ - The possibility that ErbB2/ErbB3 
activation by heregulin-β decreases ERβ 
activity and its coactivation by CBP by 
enhancing the activity of Akt was further 
tested by transient expression of a 
membrane bound and constitutively active 
p110α subunit (CAAX) of PI3K. 
Expression of the p110α mutant was 
sufficient to activate endogenous Akt in 
293T cells, which was further enhanced 
when cells were cotransfected with a 
plasmid for wt Akt, as determined by 
Western blot analysis (22, data not 
shown). Under these conditions, we found 
that the estrogen-dependent activation of 
90 
 
 
ERβ in the presence of CBP, which 
reached almost 12-fold compared to 
untreated cells, was strongly impaired 
dropping to a 3-fold response in Akt-
activated cells (Fig.2A). A previously 
observed in ErbB2 V659E-expressing 
cells in response to Akt activation 
(Fig.1A), addition of CBP reduces further 
the response of ERβ to estrogen when 
compared to cells without exogenous 
CBP. These results suggest that ectopic 
expression of CBP could not relieve the 
inhibition of ERβ by the PI3K/Akt 
pathway, therefore mimicking the results 
in ErbB2/ErbB3-expressing cells. The 
repression of ERβ by activated Akt in the 
presence of CBP was partially relieved in 
cells expressing a dominant negative form 
of Akt (K179M), suggesting that the 
effects of activated PI3K on ERβ mainly 
transit through Akt (Fig.2A). We next 
performed Western analysis to ascertain 
whether the modulation of ERβ activity 
was not a direct effect of its protein 
concentration under the conditions used. 
As shown in Fig.2B, activation of the Akt 
pathway lead to an accumulation of ERβ 
in untreated cells. A similar increase was 
also observed in the presence of estrogen, 
although the levels of ERβ were slightly 
lower compared to untreated cells, 
probably reflecting an increase in ER 
turnover in response to hormone as 
previously reported (23). These results 
suggest that the inhibition in ERβ activity 
to Akt activation is not related to a 
decrease in ERβ protein levels. 
CBP is known to transactivate estrogen 
receptors through both its AF-1 and AF-2 
activities (9,24). In an attempt to identify 
the functional domain within ERβ 
responsible for its impaired ability to be 
coactivated by CBP in response to Akt, 
we used Gal4 fusions of truncated forms 
of ERβ for which each respective AF-
containing domain has been removed. Fig. 
2C shows that in Akt-activated cells, the 
activation of a Gal4-ABβ (corresponding 
to ERβ aa1-167) on a UAStkLuc reporter 
was further enhanced by CBP, reaching a 
near 5-fold increase compared to control 
cells. The N-terminal domain of ERβ is 
known to contain several serine residues 
which are conserved within recognition 
motifs for Ser/Thr kinases of the MAPK 
family, and phosphorylation of specific 
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residues was shown to allow for 
coactivators such as CBP to be recruited 
and potentiate ERβ AF-1 activity (8,9). 
However, none of the potential 
phosphorylation sites within ERβ AB 
region belongs to a consensus Akt site, 
suggesting that the enhanced activity of 
ERβ AF-1 by CBP in response to Akt 
might possibly result from other kinase 
pathways activated by Akt or direct 
effects on CBP itself. We next tested the 
role of the C-terminal region of ERβ in 
the same conditions. Cells transfected 
with a Gal4-DEFβ (aa234-549) showed a 
reduced hormone-dependent activity to 
Akt activation in the presence of CBP, 
mimicking the response observed with 
full length ERβ (Fig. 2C, right panel). 
These results indicate that the repressive 
effect of activated Akt on CBP-mediated 
transactivation of ERβ is mediated 
through a region contained in the C-
terminal portion of ERβ, which in the 
context of the full length receptor, seems 
to counteract the positive effect on the 
AF-1 activity.  
 
Serine-255 in the hinge region mediates 
ERβ inhibition to ErbB2/ErbB3 signaling - 
Our examination of the C-terminal 
sequence of mouse ERβ revealed a 
consensus sequence RQRSAS255 in the 
hinge region of ERβ that corresponds to 
the recognition motif RxRxx(S/T) for the 
kinase Akt (Fig. 3A). To determine 
whether Ser-255 is a direct target for Akt-
mediated phosphorylation, we used site-
directed mutagenesis to convert the serine 
at position 255 into an alanine, and 
performed an in vitro kinase assay. Fig. 3B 
shows that disruption of Ser-255 strongly 
abolished the phosphorylation of ERβ by 
Akt compared to wild type, indicating that 
Ser-255 can be efficiently phosphorylated 
by Akt. We then tested whether Ser-255 
was involved in the inhibition of ERβ 
activity to ErbB2/ErbB3 activation as 
observed in Fig.1A. Using the S255A 
mutant in luciferase assay, we found that 
the inhibition observed for wt ERβ by 
either ErbB2/ErbB3 dimer expression or its 
activation with heregulin-β, was 
completely abrogated by disruption of Ser-
255 (compare Figs.1A and 3C). 
Noticeably, the hormonal response of 
92 
 
 
S255A was enhanced upon ErbB2/ErbB3 
activation, and further potentiated by CBP. 
This enhanced response to hormone by the 
S255A mutant was also observed in 
response to Akt activation using the 
constitutively active p110α PI3K construct 
in transfection (Fig. 3C). Therefore, the 
results indicate the hinge region of ERβ 
contains a specific site that not only can be 
targeted by Akt but also dictates 
responsiveness of ERβ to CBP coactivation 
in response to Akt signaling pathway. In 
order to determine whether Ser-255 is 
involved in the regulation of ERβ in terms 
of protein levels, we next performed 
Western analysis on cells expressing the 
ERβ S255A mutant. As compared to wild 
type ERβ (Fig. 2B), the disruption of Ser-
255 completely abrogated the accumulation 
of ERβ in response to Akt activation (Fig. 
3D), indicating that Ser-255 is a critical site 
in the regulation of ERβ levels by the 
PI3K/Akt pathway.  
 
ERβ modulates the intranuclear behaviour 
of CBP in an Akt-dependent manner 
through Serine 255 - Studies using 
fluorescent tagged proteins have 
demonstrated that expression of estrogen 
receptor, in particular ERα, affects the 
intranuclear organization of coactivators of 
the SRC/p160 family in response to 
hormone or antiestrogens (25-27). Based 
on our results on the transcriptional 
response of ERβ to CBP in Akt activated 
cells, we investigated whether ERβ could 
modulate the intranuclear behaviour of 
CBP in response to Akt activation. 
Expression plasmids encoding a YFP-
tagged full length CBP and a CFP-fused 
ERβ were generated and functionally 
validated in luciferase coactivation assay 
(data not shown). We first determined the 
intranuclear distribution of CBP by 
transfecting cells with YFP-CBP in 
absence of ERβ. In these conditions, CBP 
mainly localized into discrete clustered 
nuclear regions or foci, with a 
subpopulation showing a more diffuse 
pattern throughout the nucleus (Fig.4A). 
This particular behaviour of CBP has been 
observed in different cell types under basal 
or non activated conditions, and although 
not fully characterized, such pattern was 
associated to poorly transcribing or 
transcriptional inactive compartments 
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devoid of nascent mRNA transcription and 
active RNA polymerase II (28-30). Given 
our results on the effects of CBP on ERβ 
activity, we tested whether ERβ could 
modulate the intranuclear distribution of 
CBP by cotransfecting cells with YFP-CBP 
and CFP-ERβ. Both proteins were shown 
to colocalize to the nucleus but the ectopic 
expression of ERβ strongly diminished the 
formation of CBP-related speckles, 
resulting in a more dispersed distribution of 
CBP throughout the nucleus (Fig.4A). 
Interestingly, when the Akt pathway was 
activated in cells expressing both YFP-
CBP and CFP-ERβ, CBP appeared to 
readopt the formation into speckles, while 
the dispersion of ERβ remained unaffected, 
indicating that Akt can induce a 
relocalization of CBP within the nucleus in 
the presence of ERβ (Fig.4A). Given the 
role of ERβ Ser-255 to impair CBP-
mediated coactivation of ERβ in response 
to Akt, we next tested a CFP-ERβ S255A 
construct on CBP intranuclear distribution. 
We observed that as opposed to wt ERβ, 
expression of the S255A mutant did not 
favor CBP to fully reform into speckles, 
but instead CBP remained in a more 
diffuse pattern (Fig.4A). This distinct 
behaviour of CBP in response to wt vs 
S255A ERβ expression was also observed 
in the presence of hormone (data not 
shown), indicating that both unliganded 
and liganded receptor affect in a similar 
manner CBP nuclear distribution to Akt 
activation. These results suggest that CBP 
relocalizes into the nucleus in response to 
Akt activation and that this behaviour 
depends on the presence of ERβ in a 
manner specific of Ser-255. 
 
Cellular activation of Akt releases CBP 
from ERβ through Serine-255 - The 
observation that CBP could relocalize 
within the nucleus in a manner dependent 
of ERβ, and that Ser-255 seems to 
modulate that behaviour in response to Akt 
activation, prompted us to determine the 
effect of activation of the PI3K/Akt 
pathway on the interaction of ERβ with 
coactivator CBP. We found that under 
basal conditions CBP potently 
coimmunoprecipitated with ERβ and that 
this interaction was further stabilized in the 
presence of estradiol (Fig.4B), thus 
correlating with the enhanced activation of 
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ERβ by hormone and CBP (Figs.1A and 
2A). However, such interaction was 
strongly disrupted in Akt-activated cells 
independently on the presence of hormone 
(Fig.4B). We then tested the S255A mutant 
using similar conditions and found that, as 
opposed to wt ERβ, CBP could efficiently 
immunoprecipitate the mutant ERβ in 
absence or in presence of estradiol despite 
activation of Akt in cells (Fig.4B). These 
results therefore provide a role for ERβ 
Ser-255 to induce a release of CBP from 
ERβ in response to Akt activation. 
 
Akt promotes the intrinsic transcriptional 
activity of CBP through Thr-1872 - CBP 
has been described as being targeted by 
several kinase signaling pathways, of 
which for example cyclin dependent kinase 
or MAPK/Erk-directed phosphorylation of 
CBP lead to upregulate its histone 
acetyltransferase activity, and therefore its 
intrinsic potential to activate transcription 
(31). In order to determine how CBP could 
affect transcription by ERβ in response to 
Akt, we generated a Gal4 fusion of full 
length CBP which, by interacting onto a 
UAStkLuc reporter, allows to monitor 
directly CBP transcriptional activity in a 
luciferase assay. Cells transfected with 
Gal4-CBP showed a 4-fold activation in 
luciferase activity compared to cells 
expressing an empty Gal4 plasmid 
(Fig.5A), indicating that CBP was able to 
promote transcription under these 
conditions. A further increase in CBP 
activity, reaching 8-fold activation 
compared to control, was observed upon 
expression of constitutive p110α PI3K and 
Akt in cells, suggesting that CBP intrinsic 
ability to promote transcription can be 
enhanced by Akt. By looking at the 
sequence of CBP, only one putative site 
(Thr-1872) is contained within the 
consensus motif for Akt. Interestingly, this 
site is homolog to Ser-1834 of p300 which 
was recently described as a target of Akt 
that promotes p300 activity (32). We 
therefore substituted Thr-1872 by an 
alanine residue and tested a Gal4-CBP 
T1872A mutant for its activity. We found 
that not only was the response to Akt 
activation completely abrogated by the 
mutation, but the basal activity was also 
severely impaired (Fig.5A), indicating that 
Thr-1872 is a crucial regulatory site for 
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CBP activity. The T1872A mutation did 
not significantly affect the steady state 
levels of CBP expressed in cells and Akt 
activation did not modulate wild type or 
mutated CBP levels as shown by Western 
analysis (Fig.5B). Given the ability of CBP 
to respond to Akt through Thr-1872, we 
next tested whether this site was involved 
in the response of ERβ and of ERα to Akt. 
We found that, although the CBP T1872A 
mutant was less efficient in promoting ERβ 
response to estrogen, it behaves similarly 
as wt CBP in the inhibition of ERβ by Akt, 
indicating that these effects were 
independent of CBP Thr-1872 (Fig.5C). 
However, the activation of ERβ S255A by 
Akt in the presence of wt CBP was lost 
when CBP T1872A mutant was expressed 
in cells. Similar results were obtained with 
ERα (Fig.5C), suggesting that in contrast 
to ERβ, ERα seems to benefit from the 
enhanced activity of CBP to Akt in a 
manner dependent of Thr-1872. 
 
Estrogen-responsive genes are regulated 
differently by heregulin in ER-expressing 
stable clones – Based on our results on the 
apparent difference between ERα and ERβ 
response to CBP when Akt is activated and 
to delineate each ER contribution, we 
generated ERα and ERβ-expressing stable 
clones using ER-negative Hs578t breast 
cancer cells. Hs578t cells are an 
appropriate model to study the effect of 
Akt since they exhibit high basal Akt 
activity through ErbB receptor signaling 
and mutated active ras (33,34). In addition, 
Akt can be further activated by heregulin-β 
in each Hs-ER stable clone in a time-
dependent fashion (Fig.6A), indicating that 
these cells maintain the ability to respond 
to heregulin-β (35). Stable expression of 
ERα or ERβ also confers enhanced 
estrogen-dependent activation of Akt 
compared to negative cells (Fig.6A). Using 
RT-PCR analysis on Cathepsin D1 (CatD1) 
and progesterone receptor (PR), two 
recognized estrogen-responsive genes, we 
found their expression were enhanced by 
estradiol in both ER stable clones, 
compared to negative control cells 
(Fig.6B). However, these increases were 
severely impaired by the addition of 
heregulin-β to Hs-ERβ cells, therefore 
correlating with results obtained in 
luciferase assays. In contrast, treatment of 
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Hs-ERα cells with heregulin-β further 
potentiated the estrogen-stimulated 
expression of both genes (Fig.6B). This 
suggests that the regulation of CatD1 and 
PR expression by ERβ was more 
dependent on the effect of heregulin-β than 
the one through ERα (Fig.6B). Under these 
conditions, the CBP steady-state levels 
were not significantly modified in Hs-ERα 
and Hs-ERβ cells (Fig.6C). 
 
A conserved Akt site can predict the 
transcriptional response of nuclear 
receptors to CBP - Based on our results on 
the critical role of Ser-255 in regulating the 
response of mouse ERβ to Akt and CBP 
coactivation, we checked whether the Akt 
motif containing Ser-255 was conserved 
within the nuclear receptor family. It 
should be noted that Ser-255 is located 
within the hinge region of ERβ which is 
generally more conserved between ERs 
and orphan estrogen-related ERR 
receptors, than with other nuclear 
receptors. As such, the sequence alignment 
in Fig. 7A showed that while ERα and all 
three isoforms of ERR contain the 
necessary arginine residue at position –3, 
and the less stringent arginine/lysine 
residues at position –5 of the canonical site 
for Akt (36) in their respective hinge 
regions, only ERRβ possesses the expected 
phosphorylated serine (Fig.7A). It is 
interesting to note that as opposed to the 
mouse and rat isoforms, human ERβ does 
not contain a serine at the corresponding 
position, but rather has a negatively-
charged aspartic acid residue. In addition, 
human, mouse and rat forms of ERα do not 
share the conserved serine residue, having 
a glycine or leucine when aligned with 
ERβ Ser-255 (mERα is shown in Fig.7A). 
Although no perfect consensus site for Akt 
could be found in glucocorticoid (GR) and 
progesterone receptors (PR), a putative Akt 
site conserved in mouse and human GR 
was found with the required arginine 
residue at position –3 and was aligned with 
ERβ. In order to address how other nuclear 
receptors responded to Akt and CBP-
mediated coactivation and to find a 
possible correlation in respect to their 
sequence homology with ERβ Ser-255, we 
tested various nuclear receptors in 
luciferase assay. Using an ERE-driven 
luciferase reporter known to bind and 
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respond to ERRs as dimers (37), we found 
that coexpression of CBP increased the 
activity of the three ERR isoforms by 2- to 
3-fold in 293 cells (Fig.7B). Interestingly, 
when Akt activation was induced with 
p110α PI3K expression, CBP only failed to 
further transactivate ERRβ, whereas ERRα 
and ERRγ reached respectively 3- and 5-
fold activation compared to controls. Under 
these conditions, the response of ERRβ to 
Akt activation and the inability of CBP to 
potentiate transactivation strongly 
correlates with what we observed with 
ERβ, and therefore points to a shared role 
for the putative Ser-191 Akt site of ERRβ 
that overlaps with Ser-255 of ERβ. This 
observation also applies to GR for which 
CBP-mediated coactivation was severely 
abrogated in response to Akt. Conversely, 
among the receptors tested that do not 
share homology with ERβ Ser-255, we 
found that ERα, PR and peroxisome 
proliferator-activated receptor PPARγ were 
all further activated by CBP in Akt-
activated cells in the presence of their 
respective ligand (Fig.7B). CBP, which has 
originally been described to directly 
interact with cAMP responsive binding 
protein CREB, also potentiated CREB 
activation to Akt. Hence, the impaired 
ability of CBP to transactivate ERβ in 
response to Akt can be transposed to other 
receptors that share an apparent homology 
with ERβ Ser-255 containing motif. 
Accordingly, at least for those receptors 
tested that do not fit into that category, they 
seem to benefit from the enhanced intrinsic 
activity of CBP in response to activation of 
the PI3K/Akt pathway. 
 
DISCUSSION 
 Increasing evidence suggests that 
besides ligand activation, nuclear receptors 
are responsive to kinase signaling 
mechanisms, and for estrogen-responsive 
tissues in particular, this may represent a 
mean to regulate the different ER-mediated 
transcriptional pathways (2,3). More 
recently the idea that signaling pathways 
can also mediate transcriptional repression 
of estrogen receptors has lead to further 
investigate how these pathways are tightly 
controlled (11,38). Here we show that 
activation of ErbB2/ErbB3 receptors and 
the PI3K/Akt pathway can impair the 
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transcriptional response of ERβ to estrogen 
and its coactivation by CBP. The 
mechanism underlying ERβ inhibition 
involves Ser-255 which upon its 
phosphorylation by Akt prevents CBP to 
interact with ERβ, therefore abrogating 
ERβ activity. 
Dimerization of ErbB3 with its 
preferred partner ErbB2 is considered the 
most potent combination of ErbB receptors 
in terms of cellular growth and 
transformation (39). Deregulated signaling 
by ErbB2/ErbB3 has been associated with 
detrimental mitogenic potential in a 
number of reproductive cancers and the 
correlation of ErbB2 with ERα status has 
served as a predictive factor in endocrine-
based therapy (40,41). However, the 
response of ERβ to ErbB2/ErbB3 
activation is not clearly defined and the 
exact role of ERβ in tumorigenesis remains 
uncertain. We found that the transcriptional 
response of ERβ to estrogen was 
diminished upon activation of 
ErbB2/ErbB3 with ErbB3 ligand heregulin 
or the constitutive ErbB2 variant V659E 
derived from the Neu oncogene. These 
results have been transposed to ERβ-
expressing stable breast cancer cells, 
therefore altering endogenous ER-
responsive genes, as observed with the 
downregulation of CatD1 and PR. Both 
conditions were associated to increased 
cellular activation of Akt. Intriguingly, 
while coactivator CBP potently contributes 
to enhance basal and estrogen-dependent 
response of ERβ, it became inefficient to 
render optimal activation of ERβ in Akt 
activated cells. These effects seem to be 
specific to CBP since we showed that 
coactivator SRC-1 was able to relieve ERβ 
inhibition to heregulin signaling (11). 
Based on our observations that SRC-1 and 
CBP can trigger ERβ response to growth 
factors in an AF-1 dependent manner (8,9), 
it was predicted that both coactivators 
would behave similarly. In an attempt to 
delineate the role of the AF-1 domain, we 
found using an N-terminal form of ERβ 
that CBP promoted ERβ activation to Akt, 
suggesting a positive effect of the Akt 
pathway that obviously did not correlate 
with the response of the full length 
receptor. Although the N-terminal region 
of ERβ contains phosphorylation sites 
described to be directly phosphorylated by 
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MAPK conferring AF-1 activity of the 
receptor in response to EGF or ras (8,18), it 
does not have consensus site for Akt, and 
therefore upregulation in AF-1 activity by 
Akt might relate to possible indirect 
effects, including activation of CBP itself, 
as predicted in Fig.5A. Removal of the AF-
1 region demonstrated a similar inhibitory 
pattern as observed with the full length 
ERβ, and further identifies Ser-255 as a 
functional site responsible for the 
inhibition of ERβ to ErbB2/ErbB3 and Akt 
signaling. Together, these findings clearly 
demonstrate that many signaling events 
converge to ERβ to regulate cofactor 
assembly and transcriptional activity either 
in a positive or negative manner.  
Our observation that ERβ cellular 
levels were augmented by the PI3K/Akt 
pathway in the presence or absence of 
estrogen raised the possibility that ERβ 
turnover is regulated by Akt. Interestingly 
and consistent with this idea is the apparent 
opposite regulation of the S255A mutant in 
the same conditions, suggesting that Ser-
255 is a determinant involved in ER 
recycling in response to Akt signaling. 
Studies using ERα have integrated the 
response to estrogen with the cellular 
degradation of the receptor, thus supporting 
a means by which target cells can sustain 
or limit a hormonal response through a 
continuous receptor turnover. ERα has 
been shown to be degraded through the 
proteasome pathway in a ligand-dependent 
manner (23,42), and blocking proteasome 
activity impaired the ability of ERα to 
mediate a transcriptional response to 
hormone (43-45), suggesting that ER 
turnover is necessary for receptor activity. 
Similarly, activation of the PI3K/Akt 
through PDGF stimulation of smooth 
muscle cells was shown to target CREB for 
degradation in a phosphorylation-
dependent manner (46). 
 Recent studies derived from 
fluorescent-based approaches have 
revealed the dynamic nature of ERα 
within the nucleus and its behaviour with 
transcriptional coactivators in response to 
hormonal stimuli (26,44,47,48). Under 
basal conditions and in the absence of 
ERβ, CBP adopted a speckled pattern 
with a subpopulation being more diffuse 
within the nucleus. The reason for such 
behaviour is unclear, but the ability of 
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CBP to form speckles has been observed 
in different cell types under non activated 
conditions, and was associated to poorly 
transcribing or transcriptionally inactive 
compartments devoid of nascent mRNA 
transcription and active RNA polymerase 
II (28-30). The speckled clustering of 
CBP has also been shown to not segregate 
with regions of histone hyperacetylation, 
suggesting a decreased activity of CBP 
(49). However, such compartmentalized 
pattern of CBP was not always related to 
transcriptional inactivity, as the 
promyelocytic protein PML was identified 
as a nuclear receptor coactivator that 
segregates CBP into nuclear bodies (50). 
Interestingly, the expression of ERβ 
resulted in a marked decrease in speckle 
formation and a more diffuse pattern of 
CBP thoughout the nucleus which 
overlapped with the distribution of ERβ. 
This colocalization of ERβ and CBP 
occured in absence or presence of 
estrogen, therefore correlating with the 
enhanced activation of ERβ by CBP in 
luciferase assays. However, the activation 
of the PI3K/Akt pathway has the distinct 
effect of driving CBP to readopt a 
speckled pattern while ERβ remained 
diffused, coinciding with a reduced ERβ 
activity. Although these studies did not 
allow assessing directly the interaction 
between CBP and ERβ, it is interesting to 
note that while the S255A mutant was 
tested, the formation of CBP-related foci 
was greatly reduced in Akt activated cells. 
The expression of ERβ therefore allows 
for a redistribution of CBP in the nucleus 
which implicates Ser-255 as a determinant 
in the response to Akt. Consistent with 
these observations, activation of Akt led 
to a release of CBP from ERβ even in the 
presence of estrogen as determined in 
coimmunoprecipitation assay, whereas 
disruption of Ser-255 was found to 
stabilize such interaction. These 
observations emphasize the role of Ser-
255 in mediating CBP release from ERβ 
in a phosphorylation-dependent process. 
While phosphorylation provides an 
important mechanism by which steroid 
hormone receptors can be activated (3), 
increasing evidence suggests that 
phosphorylation also mediates nuclear 
receptor inhibition or repression involving 
various mechanisms and different kinase 
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pathways. Phosphorylation of serine 236 
by PKA was reported to impair ERα 
dimerization and hence transcriptional 
activity (51). Phosphorylation of AF-1 
Ser-112 by MAPK reduced the ligand 
binding affinity and activity of PPARγ 
(52). In the case of the androgen receptor, 
Ser-210 and Ser-790 were identified as 
phosphorylation sites for Akt which 
inhibited the association of AR with 
coactivator ARA70 (53). Our results 
therefore provide a mechanism by which 
ErbB2/ErbB3 and Akt signaling impairs 
ERβ activity through a phosphorylation-
dependent release of coactivator CBP. 
CBP/p300 are general signal 
integrators common to many transcription 
factors and evidence suggests that part of 
the mechanism that regulates their 
function involves direct phosphorylation 
(14). Interestingly, phosphorylation of 
Ser-1834 by Akt was shown to promote 
p300 histone acetyltransferase activity and 
its transcriptional potential (32). By 
mutating the corresponding site within 
CBP, we observed that Thr-1872 is 
essential to promote CBP enhanced 
transcriptional capacity in response to Akt 
activation. However ERβ was not able to 
benefit from this improved activity as 
opposed to the S255A mutant, suggesting 
that phosphorylation of ERβ at Ser-255 
may prevail in the response of ERβ to 
Akt. Indeed, phosphorylation of Ser-255 
impaired CBP recruitment to ERβ and did 
not allow for proper CBP-mediated 
coactivation, therefore preventing any 
potential of CBP to activate ERβ. A 
similar mechanism was described in the 
inhibition of C/EBPβ-targeted gene 
expression by insulin, except that the 
phosphorylation of Ser-1834 in the C/H3 
domain of p300 by Akt prevented p300 to 
interact with C/EBPβ (54). CBP Thr-1872 
is also contained in the C/H3 domain, 
which is described to mediate the 
recruitment of many transcription factors 
to CBP/p300 (14). However, our results 
suggest that Thr-1872 of CBP does not 
regulate the transcriptional response of 
ERβ to Akt. A recent report has described 
the interaction of ERα with CBP C/H3 
domain in the presence of an antiestrogen, 
as opposed to the previously recognized 
N-terminal interaction domain of CBP for 
agonist-bound nuclear receptors, but 
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whether phosphorylation of CBP was 
involved has not been determined (55).  
 Genetic studies have established 
that the cellular availability of CBP is 
critical for normal physiologic functions 
and as a coactivator that integrates the 
effects of several transcription factors, this 
may represent a mean by which CBP can 
discriminate between various regulatory 
pathways (16,56). As such, while testing 
other members of the nuclear receptor 
family, we found that unlike ERβ, the 
activation of ERα by Akt was potentiated 
in the presence of CBP and further 
contributed to enhance the expression of 
known ER target genes such as CatD1 and 
PR, in stably ERα-expressing breast 
cancer cells. ERα does not contain the 
corresponding Ser-255 found in ERβ, but 
an Akt site within ERα AF-1 domain, 
which is absent in ERβ, has been 
described to functionally activate ERα 
(7,57). Such isoform-selective 
coactivation of ERs by CBP may 
represent a mechanism by which CBP can 
discriminate between ERα and ERβ 
regulated pathways in response to Akt 
signaling. This mechanism can become 
important in pathologic conditions such as 
early breast cancer, in which activation of 
Akt is extremely frequent as a 
consequence of ErbB2 amplification (58). 
Clinically, Akt activation strongly 
correlates with ERα in breast tumours, 
while the prognostic value of ERβ is not 
established (40,59). It seems therefore 
interesting to propose that the negatively-
charged aspartic residue that corresponds 
to mouse Ser-255 could predict for a 
reduced response of human ERβ to CBP 
coactivation. Clearly, further studies are 
needed to unravel these distinctions.  
 The ER isoform-specific effect of 
CBP by the PI3K/Akt pathway has also 
been observed between ERR members. As 
opposed to ERRα and ERRγ, ERRβ 
contains a consensus for Akt found within 
the same region as ERβ, and was found 
negatively regulated by Akt in the 
presence of CBP. Although structurally 
closely related to the ERs, the ERRs do 
not exhibit estrogen binding and are still 
considered orphan receptors without a 
known endogenous ligand. However, our 
results predict that ERRs can be 
selectively regulated by kinase signaling 
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pathways such as PI3K/Akt, and with the 
emerging role of ERR isoforms in 
modulating ER functions and target gene 
expression (37,60), it will be of interest to 
investigate whether such regulation might 
influence these aspects.  
The present findings demonstrate a 
molecular mechanism by which the 
PI3K/Akt pathway may dictate the 
activity of ERβ and other nuclear 
receptors, through their selective ability to 
use CBP as a coactivator. With the impact 
of ErbB2 signaling and/or Akt activation 
pathways to also affect CBP intrinsic 
coactivation properties, elucidation of the 
various regulatory signals that dictate 
nuclear receptor-coactivator functions 
might provide insights into their 
integrative function. 
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 FIGURE LEGENDS 
Fig. 1. ErbB2/ErbB3 signaling impairs the hormonal response and coactivation of 
ERβ by CBP. 
A, 293-T cells were transfected with an ERβ plasmid and an EREtkLuc reporter, and 
expression vectors encoding ErbB2 and ErbB3, or a constitutively active ErbB2 (V659E) 
mutant in the presence or absence of CBP. Cells were then treated with 10nM estradiol 
(E2) and/or 10ng/ml heregulin (Hrg-β) for 20h and harvested for transcriptional activity. 
Luciferase values were normalized to β-galactosidase activity and expressed as fold 
activation compared to untreated cells set at 1.0. B, 293-T cells were transfected with 
ErbB plasmids and treated with 10ng/ml heregulin for 20 min as indicated. Total cell 
extracts were analyzed by electrophoresis, and endogeneous Akt phosphorylation was 
monitored by Western blotting using a specific anti-phospho Akt. Cell lysates were also 
analyzed for Akt content using an anti-Akt antibody. 
Fig. 2. The effect of Akt activation on ERβ response to CBP coactivation is 
mediated by the C-terminal region of ERβ.  
A, 293T cells were transfected with the EREtkLuc reporter and expression plasmid for 
ERβ in the presence or absence of CBP. Cells were also transfected with plasmids for Akt 
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or its kinase dead K179M mutant form, in the presence of the constitutively active p110α 
subunit of PI3K, as indicated. Cells were then treated with 10nM E2 for 20h and 
harvested for transcriptional activity. Luciferase values were normalized to β-
galactosidase activity and expressed as fold activation compared to untreated cells set at 
1.0. B, Western analysis of ERβ in response to Akt activation. 293T cells were 
transfected with ERβ in absence or presence of p110α PI3K and Akt plasmids to trigger 
the Akt pathway. Cells were then treated with 10nM E2 or left untreated for 20h, and 
harvested for Western analysis using an anti-ERβ antibody. Loading was monitored with 
β-actin for each sample. C, Cells were transfected with a UAStkLuc reporter and 
truncated forms of ERβ corresponding to the N-terminal or AB region (left), or the C-
terminal or DEF region (right) fused to the Gal-4 DNA binding domain. Cells were also 
transfected with p110α and Akt plasmids, and treated with 10nM E2 for 20h prior to 
luciferase assay. Luciferase values are expressed an in (A).  
Fig. 3. Serine-255 in the hinge region of ERβ is a target for Akt phosphorylation and 
mediates the inhibition of ERβ activity to ErbB2/ErbB3 signaling. 
A. Schematic representation of serine-255 that resides within a consensus recognition 
motif for Akt in the hinge region of ERβ. B, In vitro phosphorylation assay of partially 
purified wt and S255A GST fusions of ERβ using activated Akt. 32P-labeled proteins 
were analyzed by autoradiography (upper panel). Proteins were stained with Coomassie 
to ensure equal loading (lower panel). C, 293T cells were transfected with an EREtkLuc 
reporter and an expression vector encoding ERβ S255A mutant. Transcriptional activity 
was assessed in cells expressing either ErbB2/ErbB3 receptors activated by heregulin-β, 
or p110α/Akt, in presence or absence of CBP. Treatments were 10nM E2 and/or 10ng/ml 
heregulin-β for 20h. Normalized luciferase values are expressed as fold activation 
compared to untreated cells set at 1.0. D, Western analysis of ERβ S255A mutant in 
response to Akt activation. Cells transfected with S255A mutant with or without 
p110α/Akt plasmids, were treated or not with 10nM E2 and then harvested for Western 
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analysis using an anti-ERβ antibody. Loading was monitored with β-actin for each 
sample.  
Fig. 4. Serine-255 of ERβ modulates the intranuclear behaviour of CBP and its 
release from ERβ in response to Akt activation. 
A, Subnuclear localization of CBP and ERβ by fluorescence microscopy. 293T cells were 
transfected with YFP-CBP in absence or presence of CFP-ERβ or CFP-ERβ S255A 
plasmids. Akt was activated by cotransfecting cells with p110α and Akt plasmids. 
Fluorescence signals were visualized using filters for YFP and CFP shown alone and 
merged. Cell nuclei were also stained with DAPI. B, CBP is released from ERβ through 
Ser-255 in Akt-activated cells. Cells were cotransfected with HA-tagged wt or S255A 
ERβ in the presence of CBP, and then treated or not with 10nM E2 for 20h. To activate 
the Akt pathway, cells were also transfected with PI3K p110α and Akt plasmids. 
Immunoprecipitation was carried out with an anti-CBP antibody, and ERβ was analyzed 
by Western. CBP was also monitored in each sample by Western analysis. 
Fig. 5. Akt promotes the intrinsic transcriptional activity of CBP through Thr-1872. 
A, The intrinsic ability of CBP to activate transcription was assessed by transfecting cells 
with a UAStkLuc reporter in the presence or absence of Gal4 fusions of CBP or CBP 
T1872A mutant, and p110α/Akt plasmids. Cells were harvested 20h after transfection 
and analysed for luciferase activity. B, Western analysis of CBP and T1872A mutant in 
response to Akt activation. Loading was monitored with β-actin for each sample. C, Thr-
1872 of CBP is not involved in the response of ERβ to Akt. 293T cells were transfected 
with a EREtkLuc reporter and expression vectors encoding ERβ, ERβ S255A mutant, or 
ERα in the presence of CBP or CBP T1872A plasmid. The p110α/Akt plasmids were 
used to trigger Akt in cells. After transfections, cells were treated with 10nM E2 for 20h 
or vehicle and transcriptional activity was measured. Normalized luciferase values are 
expressed as fold activation compared to control cells set at 1.0.  
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Fig. 6. Estrogen-responsive genes are regulated differently by ERα and ERβ in 
response to heregulin-β. 
A- Activation of Akt in stable Hs-ERα and Hs-ERβ clones in response to heregulin-β and 
estrogen. ERα and ERβ-expressing stable clones have been generated using ER-negative 
Hs578t cells (control) and were treated with 10ng/ml heregulin-β for the indicated time or 
10nM E2 for 60min. Endogeneous Akt phosphorylation was monitored by Western 
blotting using a specific anti-phospho Akt. Cell lysates were also analyzed for Akt 
content using an anti-Akt antibody. B- RT-PCR analysis of ER responsive genes from 
Hs-ER clones and Hs control cells treated with 10ng/ml heregulin-β and/or 10nM E2 for 
20h prior to RNA isolation. Representative images are shown from at least three separate 
experiments. GAPDH expression was used to normalize samples. C- Western analysis of 
CBP in Hs-ER stable clones and Hs control cells treated as above. Samples were 
normalized for protein loading with β-actin. 
Fig. 7. A conserved Akt site dictates the transcriptional response of nuclear 
receptors to CBP. 
A- Sequence alignment for predicted Akt phosphorylation site of nuclear 
receptors. Shown are the predicted phosphorylated serine (arrow) with the obligatory 
arginine residue (R) at position –3, and the less stringent arginine/lysine (K) at position –
5 of receptor sequences aligned with mouse ERβ. The predicted Akt site is conserved in 
human and mouse ERRβ and GR. B, Response of nuclear receptors to Akt and CBP 
coactivation. 293T cells were transfected with expression plasmids for the indicated 
nuclear receptors with their respective luciferase reporter as follows : EREtkLuc for 
ERα and the estrogen-related receptor ERR isoforms; GREtkLuc for glucocorticoid 
(GR) and progesterone receptor (PR); PPREtkLuc for peroxisome proliferator-activated 
receptor (PPARγ); and CREtkLuc for cAMP responsive binding protein CREB. Cells 
were also transfected with CBP and/or p110α/Akt plasmids, and treated with ligands as 
follows : 10nM E2 (ERα), 10nM dexamethasone (GR), 10nM progesterone (PR), or 
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1μM troglitazone (PPARγ) for 20h prior to determination of luciferase activity. 
Normalized luciferase values are expressed as fold activation compared to untreated 
cells set at 1.0 for each receptor. 
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Foreword 
 
The information available on the role of ERβ remains quite limited. Its regulation 
and its role in tissues are presently ambiguous. Some groups have considered ERβ to 
promote cellular proliferation and could be a good target as a prognostic marker in the 
establishment of hormone-dependent tumors (such as in the breast), while others support 
the concept that ERβ is a tumor-suppressor. Here we investigate how the activity of ERβ 
unlike that of ERα is inhibited following the activation of ErbB2/ErbB3 heterodimer. In our 
first study we identified the region within ERβ that was necessary for the inhibition. In 
addition, the presence of CBP was required in order to observe an inhibition of ERβ. 
Therefore the role played by CBP was also investigated. In this manuscript we have 
established a mechanism by which the activation of the PI3K/Akt pathway downregulates 
ERβ due to an increased degradation of ERβ that requires the 26S ubiquitin-Proteasome 
system. Furthermore we found that CBP was necessary to trigger ERβ degradation, a 
mechanism that is subtype specific as ERα degradation was not detected. We observed in 
breast cancer cell line MCF-7, which expresses both subtypes, a decrease in its proliferation 
when ERβ is present. These results strongly suggest that during ErbB2/ErbB3 deregulation, 
there is a targeted degradation of ERβ dependent on CBP which provides these cells with a 
stronger proliferation potential. Therefore the ratio of ERα/ERβ, under these conditions, is 
relevant in order to predict the fate of cell growth. 
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Abstract 
Estrogen-regulated target gene expression is mediated through direct interaction 
with ERα and ERβ. Yet, alternative signaling events contribute to the activity of ERs. We 
show that heregulin-β stimulated ErbB2/ErbB3 activates the PI3-K/Akt pathway 
prompting ERβ degradation by the 26S proteasome, a mechanism involving the 
coactivator CBP. We found that CBP promoted ERβ degradation following Akt 
activation, which was relieved by the Akt-consensus site mutant ERβS255A supporting a 
role for a negatively charged hinge region in regulating ERβ turnover. Active Akt induced 
a stable interaction between ERβ and Mdm2 which was promoted by CBP leading to poly-
ubiquitination of ERβ. Akt sites mutants CBPT1872A or Mdm2S186/188A resulted in a 
dissociation of the ERβ-CBP-Mdm2 complex and reduced ERβ ubiquitination. Heregulin-
β promoted of MCF-7 breast cancer cells proliferation with a decrease in ERβ levels, 
while ERα remained unchanged. Knockdown of Mdm2 restored endogenous levels of 
ERβ resulting in a reduced growth of MCF-7 cells. These studies identify an Akt-
regulated phosphorylation switch involving CBP, dictating ERβ activity and turnover to 
growth factor signaling pathways through Mdm2-mediated ubiquitination.  
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Introduction 
Estrogen regulates many aspects of reproductive physiology, development, and 
metabolism, but is also mitogenic in hormone-regulated cancers, such as breast and 
endometrial cancers. Its effects are mediated by the actions of estrogen receptors ERα 
and ERβ, which are homologous members of the nuclear receptor family of ligand-
inducible transcription factors. Although encoded by unique genes, both isoforms 
recognize palindromic estrogen-responsive elements in target gene promoter/enhancer 
regions, share similar estradiol binding affinity, and undergo post-translational 
modifications in response to hormone and to various cellular kinase pathways [1–3]. 
Whereas an increased expression of ERα strongly correlates with the development and 
proliferation of breast carcinomas, therefore providing a basis for endocrine adjuvant 
therapy, the clinical value of ERβ remains uncertain.  
Both ER isoforms are composed of distinct functional regions; a conserved C-
terminal globular region harboring the ligand-binding domain (LBD) and the 
transcriptional coactivator interaction function AF-2, a centrally-located highly 
conserved DNA binding domain (DBD), a hinge region which links the DBD and LBD, 
and a poorly conserved N-terminal domain containing an autonomous transactivation 
function (AF-1) which exhibits ligand-independent activity and strong phosphorylation 
capacity. Much of the studies performed on the ligand-independent activation of both 
ERα and ERβ have revealed a diversity of potential mechanisms. Among these, 
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members of the EGFR/ErbB family were identified to regulate ERα and ERβ 
transcriptional activity through transduced kinase signaling pathways that conduct ER 
phosphorylation [3,4]. However, the outcome of ER phosphorylation by ErbB receptors 
not only differs according to the identity of the activator and the selectivity of targeted 
site(s), but also differently impacts the transcription potential of ERs. For example, 
phosphorylation of the AF-1 by MAPK/Erk in response to EGF was shown to induce 
ERα activity [5,6]. Likewise, activation of EGFR/ErbB1 resulted in ERβ AF-1 
phosphorylation, recruitment of steroid receptor coactivator SRC-1 and CREB-binding 
protein (CBP), and subsequent receptor activation [7,8]. On the other hand, activation of 
the ErbB2/ErbB3 heterodimer by growth factor heregulin-β was able to repress ERβ 
response to estrogen in breast cancer cells, an effect relieved by promoting constitutive 
activation of the AF-1 [9] or by mutating an Akt site located within the hinge region of 
ERβ [10], indicating that phosphorylation of ERβ through the PI3-K/Akt pathway was 
involved in such response. 
Several coactivators have been described to enhance the transcriptional activity 
of ERs, notably CBP and its heterologue p300, which mediate histone acetylation to 
remodel chromatin and facilitate transcription [11]. CBP/p300 have also been described 
to acetylate other transcriptional regulators, such as ERα [12], androgen receptor [13], 
and SRC-3/ACTR [14], as a mean to control transcriptional activity. The versatile role of 
CBP/p300 in transcription allows it to act as an integrative factor for diverse 
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transcription factors to bridge with components of the basal transcriptional machinery, 
allowing CBP/p300 to act as a scaffold for the formation of multi-component complexes 
[15]. The array of transcription factors, many of which have been implicated in cancer, 
that can interact with CBP/p300 suggests that competition for the limited intracellular 
pool of CBP/p300 must be achieved in a very dynamic process and through preferred 
recruiting signals. Elucidation of these mechanisms will certainly contribute to 
understand CBP/p300 specific activity and plasticity.  
Studies on ERα have integrated the transcriptional response to estrogen with the 
26S proteasome-directed degradation of the receptor [16,17], thus supporting a mean by 
which target cells can sustain or limit a hormonal response through a continuous 
receptor turnover. As such, components of the ubiquitin-proteasome system, including 
the 19S proteasome regulatory subunit Trip1/SUG1 [18], the E3 ubiquitin ligases E6-AP 
[16] and CHIP [19], and the estrogen-responsive finger protein EFP [20] were shown to 
enhance the hormonal response of ERα, suggesting that degradation of the receptor is 
closely related to its transcriptional competence. Given the potent ability of ERβ to 
respond to kinase signaling pathways, we recently reported that ERβ was ubiquitinated 
in response to the Mek1/Erk pathway [21], thereby providing evidence that mechanisms 
other than estrogen binding may dictate ER ubiquitination. Activation of Erk resulted in 
specific AF-1 phosphorylation, which regulates ERβ ubiquitination and activity through 
the recruitment of E6-AP [21], suggesting that phosphorylation-dependent mechanisms 
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determine the activation-degradation process of ERβ in order to integrate its response to 
changes in kinase-activated pathways.   
In this study, we describe how ErbB2/ErbB3 receptor activation selectively 
commits ERβ towards degradation through the activation of the PI-3K/Akt pathway. We 
identified the E3 ubiquitin ligase Mdm2 as being phosphorylated and recruited to ERβ in 
a hormone-independent manner in order to mediate ERβ ubiquitination and turnover. 
This process requires a negatively charged hinge region of ERβ and an Akt-mediated 
phosphorylation of CBP, illustrating the capacity of CBP to couple ERβ activity and 
proteasomal degradation by integrating phosphorylation-directed kinase signaling 
pathways in breast cancer cells.  
 
Results 
Activation of the PI3-K/Akt pathway by heregulin-β directs ERβ degradation  
We previously reported that activation of ErbB2/ErbB3 receptor heterodimer by 
heregulin-β was capable of decreasing the transcriptional response of ERβ to CBP 
coactivation [10]. In order to elucidate the possible mechanisms involved, we observed 
that, whereas the steady-state levels of ERβ increased following activation of 
ErbB2/ErbB3 by Heregulin-β or by expressing CBP in 293T cells, a significant decrease 
in the amount of ERβ was found when both conditions were combined (Fig. 1A). The 
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decrease in ERβ was dependent upon the 26S proteasome system as shown with the use 
of MG-132 inhibitor. Given the potent ability of ErbB2/ErbB3 to activate the PI3-K/Akt 
pathway [22], we observed that inhibition of Akt by transfecting cells with a dominant 
negative p85 regulatory subunit restored the levels of ERβ to those seen with CBP (Fig. 
1A). The role of the PI3-K/Akt pathway was further established using a constitutively 
p110α active form of PI3-K which led to a decrease in ERβ content in the presence of 
CBP (Fig. 1B). A similar reduction in ERβ levels was observed in the presence of 
estrogen (Fig. 1C), indicating that these effects occur independently of the presence or 
absence of hormone.  
Consistent with our previous observations that ERα responded differently from 
ERβ to Akt activation [10], no significant changes were observed in ERα levels in 
response to CBP expression and ErbB2/ErbB3 activation (Fig. 1D), indicating that this 
mechanism implicates ERβ. To determine whether the decrease in ERβ steady-state 
levels was consequent of its degradation, we performed cycloheximide chase 
experiments which showed that the half life of ERβ was increased from 5 to 8 h in the 
presence of CBP, confirming that CBP is able to stabilize ERβ (Fig. 1E). However, 
activation of Akt greatly reduced the turnover rate of ERβ (t½= 2 h) in these conditions. 
These findings further demonstrate that induction of the Akt pathway through 
ErbB2/ErbB3 receptors induces the targeted degradation of ERβ by the 26S proteasome. 
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Ser-255 regulates the proteasomal degradation of mouse ERβ  
Based on our previous findings that phosphorylation of Ser-255 located within 
the hinge region of ERβ was required in the repression of the receptor by the 
ErbB2/ErbB3 pathway [10], we next tested the role of Ser-255 on ERβ degradation. As 
opposed to wild-type receptor, the levels of ERβ S255A mutant were elevated in the 
presence of CBP and under ErbB2/ErbB3 activation (Fig. 2A). Such requirement of Ser-
255 to mediate ERβ degradation was dependent on CBP, since accumulation of the 
S255A mutant to ErbB2/ErbB3 activation in the absence of CBP (Fig. 2A) was 
comparable to wild-type receptor (Fig. 1A). Similarly, S255A mutation prevented ERβ 
downregulation by constitutive p110α and CBP (Fig. 2B). In cycloheximide chase 
analysis, whereas basal turnover rates remained mostly unchanged between wt and 
S255A ERβ (t½= ~5 h), the S255A mutation protected ERβ from degradation under Akt 
activation (Fig. 2C). To determine whether these effects were restricted to nuclear ERβ, 
we performed Western analysis on fractionated cell compartments (Fig. 2D). Nuclear 
ERβ levels were found markedly decreased by CBP and Akt activation (Fig. 2E), 
correlating with results obtained using whole cell extracts. It is interesting to note that 
cytoplasmic ERβ levels were mostly unregulated, except when both CBP and Akt were 
added which reduced its content. Again, Ser-255 mutation largely prevented the 
response of ERβ (Fig. 2E). These results identify Ser-255 as an important regulatory site 
that governs ERβ degradation by the PI3-K/Akt pathway. 
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The E3 ubiquitin-ligase Mdm2 regulates ERβ levels and activity in an Akt-
dependent manner 
Degradation through the 26S proteasome implicates the action of a family of E3 
ubiquitin ligases, which covalently attach small ubiquitin moieties at specific lysine 
residues of target proteins. Interestingly, the E3 ligase Mdm2, which plays a key role in 
tumor suppressor p53 degradation, is tightly controlled by phosphorylation [23]. In 
particular, activation of Akt has been shown to enhance the ability of Mdm2 to poly-
ubiquitinate p53 [24,25]. We therefore investigated the role of Mdm2 in mediating ERβ 
degradation in response to Akt activation. We found that the steady-state levels of ERβ 
were reduced upon expression of Mdm2 in 293T cells, an effect that was dependent on 
the E3 ligase activity of Mdm2 as the inactive C462A mutant was inefficient (Fig. 3A). 
Under these conditions, the ability of Mdm2 to reduce ERβ levels was not completely 
dependent on Ser-255, as levels of the S255A mutant were also affected by Mdm2 (Fig. 
3B). 
We next determined whether Mdm2 affected ERβ transcriptional activity. 
Luciferase assays using an estrogen-responsive EREtkLuc reporter revealed that 
expression of Mdm2 abolished the ligand-independent activation of ERβ by CBP (Fig. 
3C), suggesting a repressive function of Mdm2. Also, Mdm2 impaired part of the 
activation of ERβ by estrogen in absence or presence of CBP. When Akt was activated, 
the expected decrease in ERβ response to CBP, as we previously reported [10], remained 
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unaffected upon Mdm2 expression. These effects were reliable upon the integrity of 
Mdm2 E3 ligase activity, as the use of a C462A ligase dead mutant did not result in ERβ 
repression, but rather increased ERβ response to Akt and CBP, thereby relieving their 
potential to inhibit ERβ (Fig. 3C). This effect suggests a role for endogenous Mdm2 in 
mediating the decrease in ERβ transcriptional potential in Akt-activated cells. The 
repressive effect of Mdm2 on ERβ activity was although not observed with the S255A 
mutant (data not shown), indicating that Ser-255 plays a role in ERβ transcriptional 
repression.  
A cluster of Akt phosphorylation sites, which consist of Ser-166, 186 and 188, 
has been shown to activate Mdm2 in response to mitogenic/survival signals, resulting in 
enhanced p53 ubiquitination and degradation [24,25]. We thus set out to first determine 
whether activation of ErbB2/ErbB3 resulted in Mdm2 phosphorylation. We detected a 
strong increase in Mdm2 phosphorylation in 293T cells in response to ErbB2/ErbB3 
activation with heregulin-β, which was significantly reduced upon PI3-K inhibition 
using LY-294,002 or dominant negative p85α subunit (Fig. 3D). Mdm2 phosphorylation 
was also induced with the constitutive p110α form of PI3-K. We next analyzed the 
contribution of Mdm2 phosphorylation on ERβ protein levels by generating serine to 
alanine mutations at position 166 (A1), and 186 and 188 (A2) of Mdm2. Western 
analysis showed that, whereas the A1 mutation still permitted Mdm2 to decrease ERβ 
levels in response to Akt activation, the A2 mutation abolished such effect (Fig. 3E), 
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suggesting that Mdm2 Ser-186 and -188 mediate ERβ downregulation by Akt. These 
effects were mostly reproduced using the S255A mutant, indicating that Ser-255 in these 
conditions plays a minor role.  
 
Mdm2 interacts with and promotes ERβ ubiquitination 
As Mdm2 was able to promote ERβ downregulation and transcriptional 
repression, we tested the interesting possibility that it could interact with ERβ in cells. 
Indeed, Mdm2 was able to coimmunoprecipitate with ERβ under basal conditions, and 
the interaction was enhanced by the presence of CBP or the activation of the PI3-K/Akt 
pathway (Fig. 4A). Interestingly, a stronger signal was further achieved when both CBP 
and constitutive p110α were added, suggesting that CBP and Akt contribute to stabilize 
the ERβ/Mdm2 complex.  Consistent with these results, disruption of the Akt responsive 
Thr-1872 of CBP using a T1872A mutant strongly impaired the ERβ/Mdm2 interaction 
(Fig. 4A). These results demonstrate that Thr-1872, which was reported to direct CBP 
activation to Akt [10], is required to facilitate the interaction between Mdm2 and ERβ in 
Akt-activated cells. The interaction between Mdm2 and ERβ was partly dependent on 
Mdm2 ligase activity, as the C462A mutant exhibits a reduced ability to interact with 
ERβ (Fig. 4A). ERβ Ser-255 is also involved in the interaction with Mdm2, as the 
S255A showed an impaired recruitment of Mdm2 (Fig. 4A), and the additive effect of 
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Akt and CBP in inducing such recruitment was absent (Supplementary Fig. S1), as 
opposed to wild-type ERβ (Fig. 4A).  
The formation of the ERβ/Mdm2 complex was mainly dependent upon the 
integrity of Ser-186/188 of Mdm2 (Fig. 4B), correlating with their role on ERβ 
degradation (Fig. 3E). It was reported that the cytoplasmic-nuclear shuttling of Mdm2 
was induced by Akt, and that Ser-166 and -186 were involved [24]. In order to determine 
whether impairment of the A2 mutant to interact with ERβ was dependent on its cellular 
localization, we performed nuclear coimmunoprecipitation assays on isolated nuclei. 
Results show that wild type and mutated A1 and A2 forms of Mdm2 were still able to 
maintain an interaction with ERβ, although to a lesser extent with the A2 mutant (Fig. 
4C). In fluorescent microscopy, we found that disruption of Ser-186/188 was more 
efficient in sequestering Mdm2 into the cytoplasmic compartment, as compared to Ser-
166 (Supplementary Fig. S2). These results suggest that the activation of Akt not only 
targets ERβ to complex with Mdm2, but facilitates the entry of Mdm2 into the nucleus 
to enhance its interaction with ERβ.  
 Following on its role in reducing ERβ levels, we next determined whether Mdm2 
was able to promote ERβ ubiquitination. We found that activation of Akt induced the 
ubiquitination of ERβ, an effect potentiated by the presence of CBP (Fig. 4D). Both 
CBP knockdown using a lentiviral-based shRNA, and expression of the Akt-defective 
T1872A CBP mutant led to a decrease in ERβ ubiquitination, supporting an important 
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role for CBP in promoting ERβ ubiquitination by Akt. Interestingly, knockdown of 
Mdm2 markedly impaired ERβ ubiquitination induced by Akt and CBP, establishing 
ERβ as a suitable target of Mdm2 in these conditions (Fig. 4D). Again, Ser-255 appears 
to be important but not essential in signaling ERβ ubiquitination by Mdm2 (Fig. 4E), 
which is consistent with the reduced capacity of S255A to be degraded in a CBP and 
Akt-dependent manner (Fig. 2).  
 
CBP promotes the degradation of ERβ by Mdm2  
Our results highlight an essential role of CBP in promoting ERβ ubiquitination 
and degradation by Mdm2. Consequently, we addressed the importance of CBP and 
whether it can recruit Mdm2 in conditions in which ERβ ubiquitination is favored. 
Using a one-hybrid reporter assay with a Gal4-Mdm2 fusion construct, we found that 
activating Akt enhanced by 1.5 fold the reporter activity, suggesting that 
phosphorylation of Mdm2 by Akt promoted a transcriptional response (Fig. 5A). 
However, addition of CBP increased by near 4-fold such response, whereas the T1872A 
mutant was less efficient, indicating that Akt activation promotes the recruitment of CBP 
to Mdm2 in a manner dependent on Thr-1872 (Fig. 5A). The critical role of CBP Thr-
1872 was further demonstrated in Western analysis and cycloheximide chase 
experiments, showing that CBP T1872A mutant prevented ERβ degradation in Akt-
activated cells (Fig. 5B and Supplementary Fig. S3). We next determined which region 
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of CBP was involved in recruiting Mdm2 using a two-hybrid assay. With the prominent 
role of CH3 Thr-1872 in the regulation of ERβ degradation, it was surprising to observe 
that the CH3 domain did not contribute significantly to Mdm2 recruitment (Fig. 5C). 
However, of the other domains tested, the KIX showed the strongest interaction with 
Mdm2 in response to Akt activation. Interestingly, CBP KIX domain has been described 
to interact with phosphorylated CREB through a direct contact with KIX Tyr-658 [26]. 
We found that disruption of Tyr-658 in the KIX domain abrogated the Akt-dependent 
interaction with Mdm2 (Fig. 5C), pointing toward a recruiting role of CBP Tyr-658 to 
mediate the interaction with phosphorylated Mdm2. We also found that the recruitment 
of Mdm2 to CBP was dependent on Ser-186/188, possibly reflecting again the 
importance of these sites in Mdm2 nuclear shuttling (Fig. 5D). In addition, of the other 
nuclear receptor coactivators tested for their possible implication to promote ERβ 
downregulation in response to Akt activation, none were able to mimic the effect of 
CBP, even its ortholog p300 and coactivators such as SRC-1, p/CIP and PCAF, known 
to share to different degree HAT enzymatic activity and co-interaction with ERβ 
(Supplementary Fig. S4).  
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A negatively charged hinge region dictates human ERβ degradation to the Akt 
pathway 
When aligned with human ERβ, Ser-255 of mouse ERβ corresponds to Asp-236 
in their respective hinge region, suggesting the interesting possibility that the negative 
charge provided by the aspartic residue in hERβ could mimic a phosphorylated state 
such as in the mouse isoform. Furthermore, the conserved glutamic residue at position 
237 can also contribute to provide a negatively charged environment in the hinge region 
of human ERβ. We thus tested whether human ERβ was able to behave in a similar 
fashion as to the mouse isoform under conditions of Akt activation. Indeed, hERβ levels 
were decreased in response to ErbB2/ErbB3 activation and CBP expression in a manner 
dependent on the Akt pathway and the 26S proteasome (Fig. 6A). Ubiquitination of 
hERβ was also strongly induced by CBP and activation of Akt, an effect dependent upon 
Mdm2 ligase activity and CBP Thr-1872 phosphorylation (Fig. 6B), indicating that 
hERβ is a target of Mdm2. To ascertain these effects to the two negative sites in hERβ 
hinge region, we observed that mutating either Asp-236 (D/A) or in combination with 
Glu-237 (DE/AA) to alanine residues prevented the downregulation of ERβ by CBP and 
Akt, with a stronger effect using the double mutant (Fig. 6C). These results identify Asp-
236 and Glu-237 as important sites in the regulation of human ERβ turnover by the Akt 
pathway, and support a role for a negatively charged hinge region in that process.  
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Mdm2 supports an anti proliferative role of ERβ in breast cancer cells 
The role of Mdm2 was monitored on growth of human MCF-7 breast cancer 
cells in response to heregulin-β. Maintaining cells in the presence of 50ng/ml heregulin-
β markedly increased their proliferation over a period of 5 days without the prior need of 
estrogen (Fig. 6D). However, Mdm2 knockdown in MCF-7 cells significantly reduced 
the effect of heregulin-β as compared to shLuc control, suggesting an important 
contribution of Mdm2 in the proliferative potential of MCF-7 cells to heregulin-β. Under 
the same conditions, there was a decrease in the content of ERβ during treatment with 
heregulin-β, which was restored upon Mdm2 knockdown (Fig. 6E). Meanwhile, the 
levels of ERα were not as much affected following heregulin-β treatment and Mdm2 
knockdown. These results demonstrate that an enhanced MCF-7 proliferative state 
correlates with a decrease in ERβ content, and that increasing ERβ by interfering with 
Mdm2 activity results in MCF-7 growth retardation despite the presence of heregulin-β.  
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Discussion 
In this study, we demonstrate that activation of cell-surface tyrosine kinase 
ErbB2/ErbB3 receptors by growth factor heregulin-β triggers the phosphorylation of E3 
ligase Mdm2 and coactivator CBP by the PI3-K/Akt pathway, resulting in a concerted 
effort in promoting the ubiquitination and degradation of ERβ by the 26S proteasome. In 
addition, this mechanism is regulated by a negatively-charged cluster within the hinge 
region of ERβ, thus adding to the propensity of ERβ to be down-regulated by such 
incoming survival signals that can sustain breast cancer cell growth.  
ERβ activity is tightly controlled by phosphorylation and several sites, residing 
mostly within the AF-1 region, were identified to mediate ERβ response to estrogen and 
growth factors [3]. This study further identified mouse Ser-255 and corresponding 
human Asp-236 to play a crucial role along with human Glu-237 in regulating ERβ 
turnover to Akt activation. Both these sites are located within in the hinge region of ERβ 
and confer a negatively charged nature to this region (once phosphorylated for mERβ), 
which seems essential in mediating receptor degradation. Interestingly, these sites are 
part of an Arg-X-X-Ser/Asp-Glu hinge motif of ERβ, which is conserved in higher 
vertebrates, including cervidae, birds and primates, suggesting a shared mechanism in 
ERβ regulation. However, such motif is not present in ERα, which might explain that 
unlike ERβ, ERα was not subjected to the downregulation by CBP in the same 
conditions, although other mechanisms such as lysine modifications have implied the 
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hinge region in ERα degradation [27–30]. Among the other nuclear receptors that share 
the motif with ERβ, the estrogen-related receptor ERRβ also exhibits a conserved Arg-
X-X-Ser-Glu sequence in the hinge region and similar to ERβ, its activity was also 
inhibited by CBP and Akt [10]. Interestingly, with the emerging role of ERR isoforms in 
breast cancer progression, the clinical status of ERRβ has been shown to correlate with 
that of ERβ in human primary breast tumors [31], raising the possibility that ERRβ 
might serve as a phosphorylation target of Akt and be regulated in a similar fashion as 
ERβ by CBP and Mdm2. 
We previously reported that activation of ErbB2/ErbB3 receptors was able to 
weaken the transcriptional activity of ERβ and that CBP was involved in such repression 
[10]. Here, we demonstrate that the inhibitory response of ERβ by ErbB2/ErbB3 is 
closely associated to its degradation, implicating CBP as an important determinant in 
ERβ turnover. This is in contrast with the ability of CBP to act as a transcriptional 
activator of ERβ, as it was shown in response to EGF and Erk activation for example [7]. 
In such case, the phosphorylation of ERβ by EGF signaling occurred within the AF-1 
domain, which then triggered CBP recruitment and transcriptional activation without the 
prior need of hormone [7,8]. However, the repression of ERβ by ErbB2/ErbB3 signaling 
was observed in the presence of CBP and implicated phosphorylation of the hinge region 
of mouse ERβ [10]. This illustrates the capacity of CBP to integrate in a dynamic 
fashion various signaling pathways through a preferred use of interacting sites on ERβ in 
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order to translate a transcriptional response. In this case, by regulating ERβ response to 
the Akt pathway, and by being itself subjected to phosphorylation at Thr-1872 in that 
process, we show that CBP acts as a scaffold protein not only restricted to transcriptional 
regulation but that also favors ERβ polyubiquitination through the recruitment of Mdm2, 
thereby providing an important role of CBP in ERβ turnover. Such dual effect has been 
reported for other nuclear receptor coactivators in situation of agonist-induced 
transcription. Notably, AIB1 was reported to mediate the activation and degradation of 
ERα by estrogen [32], both processes being closely associated with each other through 
the 26S proteasome pathway [16,17]. The E3 ligase E6-AP was also shown to exhibit 
dual activity toward ERα by inducing both its activity and degradation in response to 
hormone [33]. Here we show that CBP is directly involved in promoting ERβ 
polyubiquitination to non-hormonal cellular signals. In that respect, our findings are in 
agreement with the reported role of p300 to participate in tumor suppressor p53 
ubiquitination and on its apparent ability to serve as an E4 polyubiquitin ligase [34,35]. 
In the case of ERβ, the reason why p300 remained inefficient is unclear, but the 
attractive idea that CBP may behave as an E4 ligase of ERβ, promoting its 
polyubiquitination under cellular anti-apoptotic signals, warrants further investigation to 
explain how CBP exhibits such an intrinsic versatility to regulate transcription in 
seemingly opposite ways. 
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The role of Akt in ERβ degradation by ErbB2/ErbB3 signaling was primarily 
established with the use of selective inhibitors and expression of dominant negative 
components of the PI3-K/Akt pathway. Such implication led us to identify the E3 ligase 
Mdm2 in mediating ERβ ubiquitination and degradation, establishing ERβ as a novel 
target of Mdm2. Mdm2 is well recognized to perform ubiquitination of tumor suppressor 
p53, a critical event that maintains homeostatic levels of p53 in normal unstressed cells 
but primarily leads to p53 suppression and cell overgrowth in several Mdm2-
overexpressed or amplified types of cancers. Our identification of ERβ as a novel target 
of Mdm2 is in line with the emerging concept that Mdm2 contributes to tumor 
development through additional p53-independent mechanisms. As such, other Mdm2 
substrates such as Rb, E2F1, FoxO3a and androgen receptor, have recently been 
described and associated to cell proliferation and tumorigenesis [36]. Mdm2 ligase 
activity is regulated by multisite phosphorylation of which Ser-166, 186 and 188 are 
included in a cluster that is responsive to growth factor/mitogenic signals [23]. We show 
that whereas Ser-166 seems dispensable, Ser-186 and 188 are essential in mediating the 
recruitment of Mdm2 to ERβ in response to Akt activation, mostly by inducing a 
relocalization of Mdm2 towards the nucleus. Such Akt-dependent nuclear shuttling of 
Mdm2 has been reported to involve Ser-166 and 186 in order to regulate p53 function 
[24]. This illustrates a common mechanism for Mdm2 availability shared by p53 and 
ERβ, and possibly other substrates, although some site selectivity seems to be required. 
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The increased interaction between ERβ and Mdm2 by the PI3-K/Akt pathway was 
potentiated by CBP, revealing a stabilizing effect of CBP on ERβ/Mdm2 complex 
formation. In addition to ERβ Ser-255 which participates in this interaction, the 
phosphorylation of CBP at Thr-1872 was essential to incite the interaction between ERβ 
and Mdm2, and also promote its own recruitment of Mdm2, providing a prominent role 
of Thr-1872 for ERβ/CBP/Mdm2 complex assembly. However, we found that Tyr-658 
of the KIX domain, as opposed to Thr-1872 containing CH3 domain of CBP, was 
directly implicated in contacting Mdm2 in these conditions, suggesting that an 
interdomain communication triggered by Akt is needed to confer a proper conformation 
of CBP to recruit phosphorylated Mdm2. Structural studies of CBP KIX domain have 
revealed a shallow hydrophobic groove stabilized by Tyr-658 which mediates 
interaction with phosphorylated CREB [26]. Whether such mechanism can also be 
envisioned for the recruitment of phosphorylated Mdm2 remains to be determined, but 
our data remain consistent with the reported recruitment of Mdm2 to p300 in p53 
degradation, although the structural determinants may differ [37]. With our recent 
findings that Thr-1872 was identified as an Akt targeted site which dictates CBP 
intrinsic transcriptional activation potential in response to the PI3-K/Akt pathway [10], 
this study provides a functional relationship between the transcriptional activity of CBP 
and its ability to mediate protein degradation. The indispensable use of specific Akt sites 
of each component in order to maximize ERβ/CBP/Mdm2 assembly, leads us to propose 
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a mechanism by which an intersite phosphorylation switch regulates ERβ turnover in 
Akt-activated breast cancer cells. In this model presented in Fig. 7, ErbB2/ErbB3 
receptor activation by heregulin-β provides the incoming Akt signal that mediates, in a 
concerted manner, Mdm2 nuclear translocation and activation, CBP phosphorylation and 
recruitment of Mdm2, and their interaction with ERβ through its negatively charged 
hinge region. Such assembly then promotes ERβ ubiquitination and degradation by the 
26S proteasome pathway, resulting in a marked decrease in ERβ and enhanced 
proliferation of breast cancer cells.  
Whereas ERα is considered the dominant subtype and correlates with most of the 
prognostic factors in breast cancers, the role of ERβ remains unclear. Overexpression of 
ErbB receptors is a frequent event in breast cancer and downstream signaling events that 
crosstalk with the ER pathway are strongly associated to endocrine resistance [4,38–40], 
a major obstacle in breast cancer treatment. In that respect, we showed that 
phosphorylation of ERβ by MAPK/Erk signaling pathway impacts its hormone-
independent AF-1 transcriptional activity [7,8,21,41]. However, recent studies have 
added to the clinical value of ERβ in hormone-dependent cancers such as breast [42], 
ovarian [43] and prostate cancers [44], providing ERβ with antiproliferative functions. 
Our findings that increasing ERβ levels by Mdm2 knockdown resulted in MCF-7 
growth retardation in the presence of heregulin-β are consistent with such activity of 
ERβ under pro-apoptotic conditions and bring important implications for the 
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pathophysiological assessment of breast tumors. Indeed, as ERα levels were less 
affected compared to ERβ in such setting, this raises the interesting possibility that 
Mdm2 activity can modulate the ERα/ERβ ratio in positive breast cancer cells. Mdm2 
overexpression or amplification is a common event in breast cancer, and a higher 
ERα/ERβ ratio was reported in breast tumors compared to normal tissues, and was 
associated with an invasive phenotype [45–48]. Differential signaling between ERα and 
ERβ subtypes has also been demonstrated with estrogen and tamoxifen at the AP-1 
response element in ER target genes [41,49], indicating that the ratio of ERα/ERβ is 
important in determining the response to selective ER modulators. More recently, 
increasing ERβ expression induced adhesion protein expression resulting in a reduced 
migration potential of breast cancer cells [50] and ERβ knockdown increased the growth 
of MCF-7 cells [51]. Although still debated, these studies raise the possibility that ERβ 
may possess tumor suppressor-like activity, where loss of ERβ could encourage 
tumorigenesis, and illustrate an unmet medical need to develop novel therapeutic 
strategies and tools to define the role of ERβ in cancer cell biology. 
Our study identifies a novel mechanism that regulates ERβ function through an 
Akt-mediated phosphorylation switch involving CBP, which dictates ERβ activity and 
turnover to growth factor signaling pathways. The identification of ERβ as a novel target 
of Mdm2 also provides an opportunity of considering both as correlated biomarkers to 
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predict for a more successful indication of therapeutic responses and outcome of ER-
positive tumors.  
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Materials and Methods 
 
Plasmid Constructs—Expression of pCMX plasmids coding for ERα, ERβ, CBP, 
ErbB2, ErbB3, and luciferase reporter constructs vitA2-ERE-tkLuc and UAStkLuc have 
been described previously [10]. The mouse ERβ Ser-255, human ERβ Asp-236 and Glu-
237, and CBP Thr-1872 to alanine mutants were generated by PCR mutagenesis using 
Pfu polymerase (Stratagene) or Pwo DNA polymerase (Roche Diagnostics). All 
constructs were verified by automated sequencing. Expression plasmids coding for the 
constitutively active p110α catalytic subunit and the dominant negative p85α Δi-SH2-N 
subunit of PI3-K were a kind gift from J. Downward. The coding region of mouse 
Mdm2, generously provided by G. Ferbeyre, was inserted into respectively pCMX-HA 
and pCMX-Gal4 to produce N-terminal tagged constructs. The Mdm2 C462A ligase-
deficient mutant, and the S166A (A1) and S186, 188A (A2) mutants were generated by 
mutagenesis as above. The CBP functional subdomains were obtained by PCR 
amplification and fused in-frame with the VP16 activation domain.  
Cell Culture, DNA Transfection, and Luciferase Assay—Human embryonic kidney 293T 
cells and human breast cancer MCF-7 cells were maintained in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 5% and 10% fetal bovine serum (FBS) 
respectively. For transient transfection, cells were seeded in phenol red-free DMEM 
supplemented with 5% charcoal dextran-treated FBS and plasmid constructs were 
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introduced using the calcium phosphate precipitation method as described [10]. 
Typically, cells were transfected with 1.5 μg of DNA per well, containing 400 ng of 
reporter plasmid, 100 ng of receptor expression vector, 200 ng of CMX-βgal, 100 ng 
each of PI3-K, Akt and Mdm2 expression vectors, and 30 ng of CBP plasmid when 
indicated. After 5-8 h, the medium was changed and cells were treated with 10 nM 
estradiol (E2; Sigma) for 16-20 h or left untreated. Cells were then harvested and 
luciferase assays were performed in duplicate from at least three independent 
experiments, and values were expressed as relative light units normalized to the β-
galactosidase activity of each sample as previously described [10]. 
Western Analysis and Immunoprecipitation Assay— To determine ER protein levels, 
Western analysis was carried out in MCF-7 cells, or by transfecting 293T cells with HA-
tagged or untagged ERα or ERβ (wt or mutants). Cells were then treated with 50 ng/ml 
heregulin-β1 (R&D System), 10 μM E2 and/or 1 μM proteasome inhibitor MG-132 
(Enzo Life Sciences) for 16h and harvested as described [10]. Immunoblotting was 
performed using specific antibodies to ERα and ERβ (Santa Cruz Biotechnology) or 
anti-HA antibody (12CA5), and signals revealed by chemiluminescence using 
appropriate horseradish peroxidase-conjugated secondary antibodies. In each 
experiment, total protein content was normalized using an anti-β-actin antibody (Novus 
Biologicals). Western analysis of phosphorylated and total Mdm2 was performed using 
respectively a monoclonal antibody against phosphorylated Ser-166 of Mdm2 (Cell 
153 
 
 
Signaling Technology) and an anti-Mdm2 polyclonal antibody (Santa Cruz 
Biotechnology). To analyze ERβ/Mdm2 interaction, coimmunoprecipitation analysis 
was performed in cells transfected with wild type or mutated ERβ (myc-tagged) in the 
presence of HA-tagged Mdm2 (wild-type and mutant). Immunoprecipitation of ERβ was 
performed as described [21], except that NaCl concentration was raised to 0.7 M and no 
SDS was added in the lysis buffer. The anti-HA antibody (Roche Diagnostics) was used 
for immunoblotting.  
Ubiquitination of ERβ - To analyze the ubiquitinated forms of ERβ, 293T cells were 
transfected with human or mouse ERβ (wild type or mutated) in the presence or absence 
(negative control) of an HA-tagged ubiquitin encoding plasmid [21]. Plasmids for CBP 
(wt or T1872A), Mdm2 (wt or C462A), and PI3-K p110α were also added as indicated. 
Immunoprecipitation of ERβ and blotting with an anti-HA antibody were as described 
[21].  
Cycloheximide Chase- 293T cells were transiently transfected with plasmids expressing 
HA-tagged wild type or S255A ERβ in absence or presence of PI3-K p110α and/or CBP 
plasmids. At 12 h after transfection, cycloheximide (Sigma) was added at a 
concentration of 50 µM and cells were lysed for Western analysis at the indicated time 
points. Each signal intensity, derived from three separate experiments, was quantified 
using an image analyzer (Alpha Innotech, San Leandro, CA) and expressed relative to β-
actin levels.  
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Preparation of Nuclear and Cytoplasmic Extracts - Nuclear and cytoplasmic extracts 
were prepared by resuspending cells in hypotonic buffer as previously described [21]. 
The content of selective markers for nuclear (anti-nucleolin; Stressgen Bioreagents) and 
cytoplasmic (anti-β-actin; Novus Biologicals) compartments were tested by 
immunoblotting to ensure for the qualitative purity of the prepared fractions. 
Coimmunoprecipitation of ERβ and Mdm2 was achieved as described above using an 
anti-HA antibody (Roche Diagnostics) and an anti-myc (9E10) antibody. 
Cell proliferation assay - Cell proliferation was measured by using the [3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyl] tetrazolium bromide (MTT) assay essentially as 
described [9]. Briefly, MCF-7 cells were seeded at low density in phenol red-free 
DMEM supplemented with dextran charcoal-treated serum in 24-well plates. The 
following day (day 0), treatments with 50 ng/ml heregulin-β and/or 10nM E2 were 
started and added in fresh medium every subsequent day. For growth measurements, 
0.5 mg/ml MTT was added to cells during 1–2 h, followed by extraction with 0.04 M 
HCl in 2-propanol. Absorbance was determined by spectrophotometry at 570 nm. All 
samples were assayed in triplicate from three to four independent experiments. 
RNA Interference- Lentiviral knockdown of Mdm2 was performed essentially as 
described [41,52]. Small hairpin RNA duplexes targeting the sequence 
GGAATTTAGACAACCTGAA of human Mdm2 (shMdm2) were inserted in pLenti 
vector, a kind gift of C. Beauséjour. The shCBP encoding plasmid was kindly provided 
by C. Massaad. Viral particles were produced in 293T cells as described [41,52], and 
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used to infect MCF-7 cells. Mdm2 and CBP efficient knockdown were monitored by 
Western analysis (data not shown). A shRNA targeting luciferase (shLuc) was used as a 
negative control. 
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Figure legends  
Figure 1. ErbB2/ErbB3 receptors signal ERβ degradation by the 26S proteasome 
through the PI3-K/Akt pathway.  
(A) Human 293T cells were transiently transfected with mouse ERβ in the presence or 
absence of plasmids encoding ErbB2, ErbB3, CBP, and p85α dominant negative form of 
PI3-K. Cells were then treated with 50ng/ml heregulin-β or left untreated for 16 h and 
harvested for Western analysis using an anti-ERβ antibody. Increasing concentrations of 
26S proteasome inhibitor MG132 (1 and 10μM) were also used to treat cells. Loading 
was monitored with β-actin for each sample. (B) Similar as in (A) except that 
constitutive p110α PI3-K and Akt plasmids were used to trigger Akt activation. MG-132 
was used at 1μM. (C) Western analysis similar as in (B). Cells were treated or not with 
10 nM estradiol (E2) for 16 h. (D) 293T cells were transfected with an ERα expression 
plasmid in the same conditions as in (A), and harvested for Western analysis using an 
anti-ERα antibody. (E) Cycloheximide chase experiment in 293T cells expressing ERβ 
in absence or presence of CBP and p110α PI3-K plasmids. Cells were treated with 
50μM cycloheximide (CHX) and lysed at the indicated time points for Western analysis. 
Results are normalized to β-actin content and expressed as a percentage of change of 
time zero, which was set at 100%. 
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Figure 2. Serine 255 in the hinge region regulates ERβ proteasomal degradation by 
the PI3-K/Akt pathway.  
(A) Western analysis of 293T cells transfected with ERβ S255A mutant, in the presence 
or absence of ErbB2, ErbB3, CBP, and p85α PI3-K plasmids. Cells were treated with 
50ng/ml heregulin-β or left untreated for 16 h. β-actin was monitored for protein 
loading.  (B) Similar as in (A) except that a p110α PI3-K plasmid was used. (C) 
Cycloheximide chase experiment in cells expressing the ERβ S255A mutant in absence 
or presence of CBP and p110α PI3-K. Cells were treated with 50μM cycloheximide and 
lysed at the indicated time points for Western analysis. Results are normalized to β-actin 
content and expressed as a percentage of change of time zero, which was set at 100%. 
(D) Validation of cell fractionation into cytoplasmic (C), soluble nuclear (N) and nuclear 
matrix (M) protein extracts by Western analysis using antibodies against nucleolin and 
β-actin markers. (E) Western analysis of HA-tagged wild type and S255A mutated ERβ 
in fractionated cell compartments. Transfected 293 cells were fractionated into 
cytoplasmic, soluble nuclear and nuclear matrix preparations as in (D), and analyzed by 
Western using an anti-HA antibody. An Akt-unresponsive T1872 CBP mutant was also 
used in transfection.   
Figure 3. Activation of the E3 ubiquitin ligase Mdm2 by Akt promotes ERβ 
downregulation and transcriptional repression.  
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(A) 293T cells transfected with increasing concentrations of Mdm2 exhibit a decrease in 
ERβ levels as determined by Western analysis. The E3 ligase-deficient C462A mutant of 
Mdm2 was also tested. β-actin was monitored for control loading. (B) Similar as in (A) 
except that the S255A ERβ plasmid was used. (C) The transcriptional activity of wild 
type and S255A mutated ERβ was determined by luciferase reporter assay using an 
EREtkLuc reporter. 293 cells were transfected with or without the indicated plasmids 
and treated with vehicle or 10nM E2 for 16 h. Cells were then harvested for luciferase 
activity measurements, and values normalized to β-galactosidase activity and expressed 
as fold response compared with untreated cells set at 1.0. (D) The PI3-K/Akt induces 
endogenous Mdm2 phosphorylation in 293T cells. Cells were transfected with the 
respective plasmids for ErbB2/ErbB3, constitutive p110α and dominant negative p85α 
PI3-K as indicated, and then treated or not with 50ng/ml heregulin-β and increasing 
concentrations (5 and 10 nM) of the PI3-K inhibitor LY294,002 for 20 min. Mdm2 
phosphorylation was monitored using a specific anti-phospho Mdm2. (E) 
Downregulation of ERβ is dependent upon Ser186/188 of Mdm2. Western analysis of 
HA-tagged wild type and S255A mutated ERβ in response to expression of Mdm2 
mutants S166A (A1), and S186/188A (A2), compared to wild type. The p110α PI3-K 
was used to constitutively activate Akt. Samples were analyzed by Western blot with an 
anti-HA antibody and protein loading was monitored with β-actin. 
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Figure 4. Mdm2 interacts with ERβ and promotes its ubiquitination following Akt 
activation. 
(A) Mdm2 coimmunoprecipitates with ERβ. 293T cells were transfected with HA-
tagged ERβ in absence or presence of myc-tagged Mdm2, along with CBP and PI3-K 
constructs as indicated. Immunoprecipitation (IP) was carried out with an antibody 
specific to ERβ and Mdm2 was detected by immunoblotting analysis (IB) using an anti-
myc antibody. ERβ was monitored in each sample using an anti-HA antibody. An HA-
tagged S255A ERβ was also tested in the same conditions, as well as the ligase-deficient 
C462A Mdm2. (B) Ser186/188 of Mdm2 is required to mediate interaction with ERβ. 
Immunoprecipitation assay similar as in (A) to test the ability of Mdm2 S186/188A 
mutant compared to wild type in response to PI3-K/Akt activation. (C) Nuclear 
coimmunoprecipitation assay on isolated nuclei of cells expressing wild type, S166A 
(A1) and S186/188A (A2) Mdm2 in the presence of ERβ, CBP and p110α PI3-K. 
Immunoprecipitation was carried out using an Mdm2 antibody and immunoblot with an 
ERβ antibody. Mdm2 content was normalized in each nuclear fraction. (D) Mdm2 
mediates the ubiquitination of ERβ in response to Akt activation. 293T cells were 
transfected with myc-ERβ in the presence of HA-ubiquitin, and ubiquitination of ERβ 
was detected by immunoblotting using an HA antibody on immunoprecipitated ERβ 
extracts. CBP (wt and T1872A) and P110α PI3-K were added as indicated. Knockdown 
of specific targets was achieved by lentiviral infection using shCBP or shMdm2 RNAs, 
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with shLuc (luciferase) used as a negative control. ERβ content was normalized in each 
sample using a Myc antibody. (E) Ser-255 is needed to achieve maximal ERβ 
ubiquitination under Akt activation. Ubiquitination assay performed similarly as in (D) 
of wild type and S255A myc-tagged ERβ in response to CBP and PI3-K/Akt activation. 
Figure 5. The Thr-1872 Akt site of CBP is required to mediate Mdm2 recruitment 
and ERβ degradation. 
 (A) Mdm2 interacts with CBP in an Akt-dependent manner. One-hybrid assay using 
Gal4-Mdm2 fusion in 293T cells transfected with a UAStkLuc reporter. CBP (wt and 
T1872A) and PI3-K/Akt plasmids were added to measure their effect on luciferase 
reporter activity. Values are normalized to β-galactosidase activity and expressed as fold 
response compared with control cells set at 1.0. (B) CBP Thr-1872 is involved in ERβ 
degradation by the PI3-K/Akt pathway. Cycloheximide chase experiment in 293T cells 
expressing ERβ. The effect of wt and T1872A CBP were monitored on ERβ levels 
following treatment with 50μM cycloheximide. Cells were lysed at the indicated time 
points for Western analysis. Results are normalized to β-actin content and expressed as a 
percentage of change of time zero, which was set at 100%. (C) The interaction of CBP 
with Mdm2 requires Tyr-658 of the KIX domain. Two-hybrid assay of cells transfected 
with Gal4-Mdm2 and VP16-fused CBP subregions representing various functional 
domains (depicted on top). Luciferase activity was measured on a UAStkLuc reporter in 
response to activation of the PI3-K/Akt pathway. Results are normalized to β-
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galactosidase activity and expressed as fold response relative to empty VP16 construct 
set at 1.0. (D) Ser-186/188 of Mdm2 are required to coimmunoprecipitate CBP. 
Immunoprecipitation of CBP and CBP T1872 was carried out in 293T cells with an 
antibody specific to CBP and samples were immunoblotted for the presence of myc-
Mdm2 or -S186/188A (A2) mutant using a myc antibody. CBP content was normalized 
by Western analysis in each sample.   
Figure 6. The Akt-induced activation of Mdm2 by heregulin-β promotes human 
ERβ degradation and increases proliferation of breast cancer cells.  
(A) Human ERβ is degraded by CBP and the PI3-K/Akt pathway upon activation of 
ErbB2/ErbB3. Western analysis of ERβ in 293T cells transfected with ErbB2, ErbB3, 
CBP, and p85α PI3-K constructs as indicated. Cells were treated with vehicle or 
50ng/ml heregulin-β in presence or absence of increasing concentrations (1 and 10μM) 
MG-132. β-actin was used to monitor loading (B) CBP and the PI3-K/Akt pathway 
promotes human ERβ ubiquitination by Mdm2. 293T cells were transfected with myc-
ERβ in the presence of HA-ubiquitin, and ubiquitination of ERβ was detected by 
immunoblotting using an HA antibody on immunoprecipitated ERβ extracts. CBP (wt 
and T1872A) and P110α PI3-K were added as indicated. ERβ content was normalized in 
each sample using a Myc antibody. The ligase-defective C462A mutant of Mdm2 was 
also tested. (C) A negatively charged hinge region mediates human ERβ degradation to 
the PI3-K/Akt pathway. Western analysis of 293T cells expressing wild type, D236A 
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(D/A) or D236A/E237A (DE/AA) mutants of ERβ. CBP (wt or 1872A) and p110α PI3-
K plasmids were also added as indicated. β-actin was used to control loading. (D) Mdm2 
supports the growth of breast cancer cells by heregulin-β. MTT proliferation assay was 
done on human breast cancer MCF-7 cells treated or not with 50ng/ml heregulin-β 
starting at day 0 and maintained over a period of 4 days. Cells were harvested each day 
for MTT reduction colorimetric assay. Results are expressed as percent change from 
untreated cells set at 100% and represent mean values of triplicate measurements from 
three to four independent experiments. Lentiviral infections with shLuc or shMdm2 
were carried out 24 h prior to treatments (day -1). (E) Heregulin-β promotes ERβ 
degradation by Mdm2 in MCF-7 cells. Western analysis of ERα and ERβ in MCF-7 
cells treated or not with 50ng/ml heregulin-β was performed as in (D). Samples were 
collected at day 4 of treatments and analyzed with respectively an ERα or ERβ antibody. 
Total Mdm2 content was also monitored with an antibody against Mdm2. β-actin was 
used to control loading. Lentiviral infections or shLuc and shMdm2 constructs were 
carried out as in (D).    
Figure 7. A schematic model of ERβ degradation by the 26S proteasome involving 
an Akt-concerted intersite phosphorylation switch. 
Activation of ErbB2/ErbB3 receptors by heregulin-β signals the PI3-K/Akt pathway that 
induces a concerted effort of interacting partners to target ERβ to the 26S proteasome 
system of degradation. These include the E3 ligase Mdm2 which following Akt 
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activation translocates to the nucleus and interact with ERβ in a process involving Ser-
186 and -188 Akt sites and coactivator CBP. CBP acts as a scaffold protein to further 
enhance and stabilize the Mdm2/ERβ complex through phosphorylation of Thr-1872, an 
Akt-targeted site essential for CBP intrinsic response and recruiting ability toward ERβ 
and Mdm2. The phosphorylation of mouse ERβ Ser-255 by Akt provides a negatively 
charged environment within the hinge region which accordingly exists in human ERβ 
with corresponding Asp-236 and conserved Glu-237, and facilitates Mdm2 recruitment 
in Akt-activated cells. Such assembly then promotes ERβ ubiquitination and degradation 
by the 26S proteasome pathway, resulting in a marked decrease in ERβ and enhanced 
proliferation of breast cancer cells in response to mitogenic/survival signals. 
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CHAPTER 3: GENERAL DISCUSSION, 
PERSPECTIVES AND CONCLUSIONS 
 
1 ErbB2/ErbB3regulation of ERβ 
One of the major contributions of the work presented here is the unraveling of a 
previously unknown mechanism which differentially regulates ERα and ERβ and provides 
a greater comprehension of ER regulation during the activation of ErbB receptor signaling. 
ErbB2/ErbB3 partnering has been described to be the most powerful combination within 
the family of ErbBs observed in many poor-prognostic cancers (Karunagaran et al., 1996). 
In fact, studies have demonstrated that ErbB2/ErbB3 constitutive signaling correlates with 
the development of resistance to anti-hormone treatment in ER positive cell lines labeling 
them aggressive tumors. The mechanisms leading to the eventual loss of ERs hormone-
responsiveness following ErbB deregulation is still not clear, however the results exposed 
in this thesis suggest a potential mechanism by which a shift in ERα/ERβ ratio can affect 
ER-positive cell proliferation in the absence of estrogen and therefore possibly lead to a 
hormone-independent state of proliferation, a severe outcome of prolonged anti-estrogen 
treatment in hormone-dependent cancers. 
 
One of our main objectives was to examine the behavior of ER subtypes following 
the activation of ErbB2/ErbB3 by growth factors. The first article presented in this thesis 
reveals an event by which ERα and ERβ are selectively regulated due to the activation of 
certain kinase pathways and the presence of coregulatory complexes. We sought to 
investigate how the selectivity in responses was established between ERα and ERβ.  
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We found that subtype specificity relies on the amino acid sequence of nuclear 
receptors. Although the AF-1 was initially thought to be involved, our studies identify the 
hinge domain as a discriminatory region of nuclear receptor response to cellular events. On 
the premises of these results our next objective was to identify the mechanisms involved in 
the differential regulation of ERβ and ERα. We uncovered that ERβ unlike ERα was 
targeted towards the ubiquitin-proteasomal machinery following ErbB activation. Decrease 
in the levels of ERβ correlated with an increase in the proliferation of breast cancer cells 
treated with the ErbB3 ligand, HRG-β1, demonstrating that the ERα/ERβ ratio is an 
important parameter which can define the proliferation potential of breast cancer cell lines. 
 
1.1  Activation of ErbB2/ErbB3 in hormone-independent 
cancers 
Endocrine therapy is the predominant treatment option for women diagnosed with 
ER-positive breast cancer. Yet, high levels of ER-expressing tumors lead to endocrine 
therapy resistance. Overexpression of the ErbB family of growth factor receptors has been 
associated with resistance to endocrine therapy. In fact, overexpression of ErbB3 has been 
observed in 17% of breast tumors (Witton et al., 2003; Naidu et al., 1998) while ErbB2 is 
amplified in 20-30% of breast tumors and correlates with increased proliferation, higher 
metastatic potential, accelerated relapse and poor patient prognosis (Slamon et al., 1987; 
Ross and Fletcher, 1998). Although ErbB2 can dimerize with any of the three other ErbB 
members, it preferentially heterodimerizes with ErbB3 creating a powerful and prevalent 
signal transducer accounted in several breast cancers (Introduction section 5.3) 
(Karunagaran et al., 1996; Citri et al., 2003). Stimulation of ErbBs leads to the activation of 
particular signaling pathways determined by the ligand and receptor homo/hetero 
dimerization (Figure 20) (Introduction section 5.2).  
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Figure 20 Summary of signaling pathways described in the introductory chapters, 
unraveled by our studies regulating the transcriptional activity (classical and non-classical)
and the non-genomic activities of ERα and ERβ following membrane receptor activation,
with a particular emphasis on ErbB2 (dark pink)/ErbB3 (light pink) RTK activation.
Figure was adapted from (Sanchez et al., 2009). 
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1.1.1  Intracellular pathways regulating ERs activity 
The regulation of downstream factors (such as ERs) not only depends on cellular 
content but also which extracellular cues are translated to intracellular signaling pathways 
(Figure 20). Interaction of growth factors, such as Hrgβ1, with ErbB3 promotes 
heterodimerization with ErbB2 which has been associated with the activation of the 
PI3K/Akt pathway (Motoyama et al., 2002; Hutcheson et al., 2007). Similarly we observed 
that Hrgβ1 was able to activate ErbB2/ErbB3 in our model of transfected 293T cells which 
caused the activation of the PI3K/Akt pathway. It is however important to consider that 
ErbB2 can equally activate MAPK pathways and such activation has been shown to 
stimulate the transcriptional activity of ERα and ERβ by targeting specific sites within the 
N-terminal, AF-1 domain of both receptors (Figure 20). However results from our first 
study revealed a down-regulation of ERβ transcriptional activity that was ligand-dependent 
and independent, suggesting that estrogen cannot relieve the inhibitory effect of the 
PI3K/Akt pathway, following HRGβ1 treatment. Although both pathways can be activated, 
Akt and PI3K mutants (containing a dead kinase activity) and PI3K inhibitor LY23213 
completely abrogated the observed effects, strongly suggesting that the outcome observed 
for ERβ was primarily induced by the PI3K/Akt pathway.  
 
Nonetheless ERα was activated under these conditions, suggesting that Akt 
signaling could positively regulate this subtype. In addition we do not exclude the possible 
participation of the MAPK pathway which our laboratory observed (Sauvé et al., 2009; St 
Laurent et al., 2005a) to be activated by ErbB2/ErbB3, yet we stipulate that the PI3K/Akt 
pathway is the predominant activated pathway as inactivation of the MAPK pathway did 
not completely relieve the transcriptional repression by the activation of the ErbB2/ErbB3 
pathway (St Laurent et al., 2005a).  
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It would be interesting to examine if ErbB2 does indeed participate in the 
degradation of ERβ as previous results demonstrate that specifically blocking its signaling 
capacities does partially relieve the inhibition on ERβ (St Laurent et al., 2005a). This could 
imply that possibly other signaling pathways could participate with Akt to inhibit the 
activity of ERβ whilst still promote transcriptional activation through ERα.  
 
1.2  Downregulation of ERβ is intensified by CBP 
Downregulation of ERβ by the activation of Akt was further decreased in the 
presence of CBP. Activation of intracellular kinase signaling cascades leads to the 
phosphorylation of several cytoplasmic and nuclear targets which control cell fate. The 
decrease observed in the transcriptional activity of ERβ whether ligand-dependent and /or 
independent was more pronounced by the presence of CBP. CBP and its heterologue p300 
are functional integrators of multiple signal transduction pathways and diverse transcription 
factors compete with each other to interact with a limiting amount of CBP/p300 within the 
cell (Lemasson and Nyborg, 2001; McKay and Cidlowski, 2000). However CBP/p300 can 
regulate diametrically opposite processes, from cell proliferation to growth arrest. They are 
required for the transcription of oncogenic transcription factors contributing to cell growth, 
transformation and development (Goodman and Smolik, 2000). Yet they can act as tumour-
suppressors by increasing the expression of apoptotic genes such as the ones controlled by 
BRCA1 and p53 (Kung et al., 2000; Pao et al., 2000; Gu and Roeder, 1997). The ability of 
CBP/p300 to serve as mediators for cell proliferation of growth arrest has been proposed to 
be highly dependent on cellular environment (Goodman and Smolik, 2000).  
 
1.2.1 The power of switching on and off transcription by CBP 
CBP is recognized as a coactivator to transcription factors, however reports show 
that CBP or its homolog, p300, can negatively affect the activity of transcription factors by 
switching from one promoter to another. Competition between different transcription 
factors for CBP/p300 plays a role in the coordination of gene expression in response to 
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signaling (Kamei et al., 1996). Indeed phosphorylation of CBP/p300 by the IκB Kinase 
complex, IKKα, potentiates its coactivating function on the NF-κB promoter leading to the 
inhibition of p53 transcriptional regulation (Huang et al., 2007) as a result of a decrease in 
the association of CBP from p53 following IKKα phosphorylation. This also indicates that 
different signaling pathways can interfere with one another and modulate the availability of 
CBP for a particular transcriptional complex via posttranslational modifications (Chapter 
7). In agreement with this concept, it was shown that CBP methylation by CARM1 causes a 
transcriptional switch from CREB-regulated to nuclear hormone receptors regulated gene-
expression (Xu et al., 2001). In fact several posttranslational modifications of CBP have 
been reported to regulate its activity. SUMOylation of p300 by Ubc9 (Girdwood et al., 
2003) has the ability of inhibiting the coactivating activity of p300 by the recruitment of 
HDAC complexes. Phosphorylation of CBP/p300 within its C-terminal domain (figure 16) 
amplifies its HAT activity (Introduction, section 6.1.2) stimulating the transcriptional 
activity of substrates during neuronal differentiation (Ait-Si-Ali et al., 1999). In addition 
Akt was shown to target p300 phosphorylation at Ser-1384 which was capable of 
increasing its HAT activity, contributing to inflammatory gene expression by TNF-α 
(Huang and Chen, 2005).  
 
We observed that the presence of CBP was required to inhibit the activity of ERβ. 
Although we detected an increase in the activation of CBP’s coactivating potential (Chapter  
2, section 1, figure 5) there was a marked decrease in the transcriptional activation of ERβ, 
which initially lead us to believe that CBP was possibly recruited to other promoters 
resulting in a downregulation of the activity of ERβ. Coimmunoprecipitation assays 
reflected a decrease of the interaction between ERβ and CBP when the Akt pathway was 
activated. The treatment of estrogen was not capable of altering the interaction, 
substantiating our initial results that ligand-binding could not activate ERβ during Akt 
signaling. In order to support the hypothesis of a switch mechanism by CBP following Akt 
activation, we looked at the steady-state levels of both CBP and ERβ. CBP levels were not 
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affected by the activation of Akt following Hrβ1 treatment (chapter 2, section 1, Figure 
6C). Akt is effectively a positive regulator of CBP. It is able to interact with p300 within 
the C-terminal domain where the Akt consensus phosphorylation site is present (1459-1892 
aa) and maintain steady-state levels of the coactivator (Chen et al., 2004). However we 
observed a decrease in the levels of ERβ, which we discovered to be subtype specific, as 
ERα levels were not affected. Our experiments in chapter 2, section 2, demonstrate that in 
fact the decrease of the levels of ERβ is due to the targeted degradation of receptor.  
 
Therefore it seems apparent that CBP could play two distinct roles on each ER 
subtype. It could promote degradation of ERβ while simultaneously activate ERα. However 
considering the low expression levels of CBP and results demonstrating the requirement of 
CBP to degrade ERβ, in a context where both are expressed, we could speculate that 
possibly p300, which is equally targeted by Akt (Chen et al., 2004), could participate in the 
transcriptional activation of ERα. We looked at other coactivators, such as p300, to observe 
if they were also capable of regulating negatively ERβ. However not only did p300 not 
induce a downregulation of steady-state levels of ERβ but other coactivators of the SRC 
family did not decrease the levels of ERβ either, strongly pointing out a specific role for 
CBP in the downregulation of ERβ. However, it would be interesting to verify if both p300 
and CBP are recruited to ERα-bound promoters, by Chromatin Immunoprecipitation 
assays, giving us an indication of simultaneous behaviour of coactivators following Akt 
activation.     
 
1.2.2  ER regulation following post-translational regulation 
Since the results demonstrated the requirement of CBP in Akt-mediated 
downregulation of ERβ was not that of a coactivator, we investigated other possibilities for 
the role of CBP. The first case reporting a role for acetylation in the control of protein 
stability was observed by the HAT activity of the coactivator PCAF on the function of E2F-
1. PCAF-mediated acetylation of E2F-1 increased the stability of the protein (Ianari et al., 
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2004; Martinez-Balbas et al., 2000). Although the underlying mechanisms remain 
unknown, we also observed a stabilisation of ERβ in the presence of CBP but in the 
absence of Akt activation (chapter 2, section 2, Fig 1). Other observations point to 
acetylation as a signal for protein degradation. In fact, both phosphorylation and acetylation 
collaborate to target the degradation of substrates. Indeed, both posttranslational 
modifications have been observed to be implicated in the regulation of protein degradation 
via the ubiquitin/proteasome pathway of the haematopoietic transcription factor GATA-1 
(Kouzarides, 2000; Glickman and Ciechanover, 2002). Acetylation and MAPK 
phosphorylation were both required to trigger ubiquitin-proteasome targeted degradation of 
GATA-1 (Hernandez-Hernandez et al., 2006).  
 
As our results indicate, the presence of CBP followed by the activation of Akt led to 
the targeted degradation of ERβ by the 26S proteasome complex, which was corroborated 
following the treatment of the proteasome inhibitor, MG-132 (chapter 2, section 2, figure 
1A). In fact ERβ was strongly ubiquitinated following the activation of Akt in the presence 
of CBP. This HAT has previously been described to participate in the degradation of 
proteins such as E2F-1 following DNA-damage (Galbiati et al., 2005) and its HAT activity, 
although does not stimulate degradation, acetylates and inhibits the activity of STAT1 
through the recruitment of HDAC3 (Kramer et al., 2009). We did not look at the levels of 
acetylation of ERβ in order to detect if its acetylation was required for its ubiquitination to 
take place. Mutation of the HAT domain within CBP or verifying by the levels of ERβ 
acetylation we could obtain further information on the role of CBP in the degradation of 
ERβ. We did observe however that an Akt-unresponsive CBP, lead to the recuperation of 
the levels of ERβ even during Akt activity. Also, HAT containing proteins could promote 
the interaction of acetylated substrates with E3-ligases (Introduction, section 7). The 
degradation of HIF-1α occurs after its interaction with pVHL, an E3-ligase complex, which 
mediates its ubiquitination (Ke and Costa, 2006). The acetylation of HIF-1α promoted the 
interaction with pVHL and its subsequent ubiquitination and degradation (Bilton et al., 
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2006). A similar mechanism is observed with the SV40T antigen and the retinoblastoma 
tumour suppressor RB (Shimazu et al., 2006; Leduc et al., 2006).     
 
1.2.3  A Ubiquitin-ligase activity for CBP? 
New investigations are confirming the occurrence of enzymes harbouring both HAT 
and ubiquitination activities. Recent studies have shown that CBP/p300 can act as an E4-
ligase and itself ubiquitinate substrates, such as p53, which proceeds to its degradation (Shi 
et al., 2009). The N-terminal of p300 and CBP can catalyse the poly-ubiquitination of p53 
after the initial mono-ubiquitination performed by Mdm2. This E4 activity of p300 was 
also observed for another target of Mdm2, Tip60 (Col et al., 2005). Interestingly, although 
previous work demonstrated acetylation and ubiquitination relied upon one another, the E4 
activity of p300 did not require its HAT function. However, PCAF, which in addition 
contains within its N-terminal an E4-ubiquitin ligase activity, partly relies on its HAT 
activity (Linares et al., 2007). Our results on ERβ ubiquitination (chapter 2, section 2, 
Figure 4E) do not eliminate the participation of CBP as an E4-ubiquitin ligase. Though the 
selective knockdown of CBP affected the general level of poly-ubiquitination of ERβ, 
residual poly-ubiquitination of the nuclear receptor still remained (chapter 2, section 2, Fig. 
4E) the ubiquitination of ERβ in the presence of Akt-unresponsive CBP T1872A was 
almost entirely eliminated. Further investigations identifying CBP as an ERβ targeting-E4-
ligase would be of interest as very limited information of enzymatic function for HATs is 
available.  
 
In addition CBP/p300 has been observed to participate in the degradation of 
selective targets by recruiting the substrates directly to the proteasome. p53 turnover was 
found to be dependent on the E3-ligase activity of Mdm2 and the potential of CBP to 
interact with components of the 26S Proteasome complex (Zhu et al., 2001). In fact CBP 
can be a target of the proteasome (Brouillard and Cremisi, 2003; Poizat et al., 2000) and it 
has been observed to redistribute towards PML bodies for this function (St-Germain et al., 
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2008). PML bodies could represent sites were ubiquitinated proteins are processed prior to 
proteasomal degradation as they were observed to contain proteasome complex components 
(Lallemand-Breitenbach et al., 2001). In fact a subpopulation of coactivator GRIP1 is able 
to localize to discrete nuclear foci containing PML bodies, CBP and enriched in 
components of the 26S proteasome which led to a decrease in the levels of GRIP1 
(Baumann et al., 2001). In our first publication we observed that following Akt activation, 
CBP redistributed into nuclear foci, a hallmark of PML bodies. Although ERβ distribution 
did not adopt the identical distribution of CBP, its diffuse pattern does not refute this 
possibility either. By examining if ERβ effectively interacted with components of PML 
bodies following Akt activation we could conclude that CBP whether an E4-ligase or not, 
redistributes ERβ to sites of active degradation.  
 
1.3   Mdm2 and CBP regulate the level of ERβ 
Several studies have now established that optimal nuclear receptor transcriptional 
activity is achieved by a continuous receptor turnover. ERα and ERβ have been shown to 
be targets of the ubiquitin-proteasome pathway that can be estrogen-dependant and 
independent (Nawaz and O'Malley, 2004; Lonard et al., 2000; Nawaz et al., 1999; Reid et 
al., 2003; Picard et al., 2008; Tateishi et al., 2006). Ubiquitination of either ERα and/or 
ERβ can be carried out by several E3 ligases described in section 7.1. Activation of the 
PI3K/Akt pathway is known to stabilize and activate Mdm2. Phosphorylation of Mdm2 at 
Ser-166 and Ser-188 (considered the major site (Milne et al., 2004)) by Akt can decrease its 
ubiquitination and as a result is stabilized (Feng et al., 2004). Mdm2 stabilization has been 
shown to promote poly-ubiquitination and degradation of substrates such as p53 (Li et al., 
2003a). 
 
1.3.1  Mdm2 is activated by ErbB2/ErbB3 
 Akt activation by ErbBs targets the degradation of p53 by Mdm2 but this time 
targeting Ser-166 and Ser-186 (Zhou et al., 2001; Ogawara et al., 2002). Furthermore, 
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Ferreon et al. have described that CBP plays a role in the degradation of p53 in unstressed 
cells by functioning synergistically with Mdm2 (Ferreon et al., 2009). Several nuclear 
receptors are targets of Mdm2 induced degradation. GR activity is regulated by Mdm2 and 
is influenced by p53. In the presence of its ligand, GR is inhibited when Mdm2 is present 
during the cell’s response to stress. Inhibition of GR is due to its increased 
polyubiquitination by Mdm2 which requires the presence of p53 (Sengupta and Wasylyk, 
2001). Since the inhibition of GR is p53 dependent, this suggests that cells lacking p53, as 
it occurs in most cases during cancer development, Mdm2 might promote rather than 
suppress GR-mediated transcription, as observed for ER (Saji et al., 2001). The regulation 
of nuclear hormone receptors by Mdm2 has additional levels of complexity due to the 
cross-talk between the receptors. AR degradation is promoted through a sequential 
phosphorylation of AR by Akt and recruitment of Mdm2 into an AR-Akt-Mdm2 triplex, 
where AR ubiquitination is mediated through the E3-ubiquitn ligase activity of Mdm2 
(Deep et al., 2008; Lin et al., 2002). In addition the AR receptor is also targeted towards the 
26S proteasome complex in a mechanism that involves Mdm2 and HDAC1 (Gaughan et 
al., 2005). Therefore it appears that Akt signaling not only activates nuclear factors but it 
can also regulate their protein level within the cell.  
 
1.3.2  Role of Mdm2 on ERs 
Studies have shown that ERα is able to regulate the levels of Mdm2 (Suga et al., 
2007). Reciprocally, Mdm2 can promote the degradation of ERα in a ligand-dependent and 
independent manner (Duong et al., 2007) which associates with the observation of a 
negative correlation between these two factors in breast cancer (Turbin et al., 2006). 
However others have demonstrated that Mdm2 can activate ERα transcription (Saji et al., 
2001) therefore the cellular environment is crucial for the regulation of ERα. No studies so 
far have examined the potential regulation of ERβ by Mdm2. Mdm2 is an E3 ubiquitin-
ligase which targets p53 towards ubiquitination (Michael and Oren, 2003). Low levels of 
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Mdm2 activity can induce mono-ubiquitination and nuclear export of p53, whereas high 
levels promote ubiquitination and nuclear degradation of p53 (Li et al., 2003a). 
 
Results from our second manuscript show that Mdm2 can control the levels of ERβ. 
In fact, as observed in coimmunoprecipitation assays, mutation of Mdm2 at ser 186 and 
188, rendering Mdm2 unresponsive to Akt, affect its ability to interact with ERβ. Mutation 
of these two sites affected the relocalisation of Mdm2 towards the nucleus, however 
examining the nuclear fractions; we observed that the mutants who localized to the nucleus 
were not capable of interacting as strongly with ERβ compared to the wild-type, 
demonstrated in chapter 2, section 2 figure 3. Therefore these sites are not only important 
for the activation and the relocalisation of Mdm2 towards the nucleus but also participate in 
the interaction with ERβ which lead to a disruption of ERβ protein levels. 
 
1.3.2.1 Ser-166, a negative regulator of Mdm2 ? 
Curiously, we observed that the mutation of Ser 166 of Mdm2, known to respond to 
Akt phosphorylation, unexpectedly maintained its potential to decrease the levels of ERβ. 
The MAPK pathway can also target ser-166, even in the absence of Akt activation 
(Malmlof et al., 2007). Studies have shown that activation of PI3K signaling pathway is 
able to reduce the activity of Mdm2 (Stommel and Wahl, 2004) by phosphorylation 
although specific sites were not explored. This suggests that in our model phosphorylation 
of Ser-166 by Akt (or possible MAPK through ErbB2) moderates the E3-ligase activity of 
Mdm2.  
 
1.3.3  Mdm2 and CBP 
Activation of the PI3K/Akt did not to promote a greater interaction between ERβ 
and Mdm2 which was reflected in the levels of ubiquitination of ERβ. Interestingly a 
dramatic increase in the ubiquitination of ERβ was observed following activation of Akt in 
the presence of CBP establishing the importance of CBP in the degradation of ERβ. CBP’s 
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role in the degradation was further examined by creating a mutant that was non-responsive 
to Akt through the mutation of the threonine residue (Thr 1872) in the C-terminal bromo 
domain of CBP (figure 16). Results show that, not only are the levels of ERβ ubiquitination 
drastically reduced when CBP can no longer respond to Akt, but the interaction between 
Mdm2 and ERβ is affected as well, demonstrating that phosphorylation of ERβ by Akt is 
not sufficient to target its degradation (Chapter 2, section 2 Fig 1A and B). In fact the 
phosphorylation of CBP by Akt is required to trigger the degradation of ERβ. Furthermore 
the selective knockdown of CBP also resulted in a decrease in the ubiquitination of ERβ. 
However the knockdown of MDM2 did not decrease as dramatically the levels of 
ubiquitinated ERβ, signifying the possibility that other E3 ubiquitin-ligases might be 
involved. Indeed, E6-AP was recently uncovered to target ERβ degradation in a ligand-
independent manner which relied on a MAPK-dependent pathway (Picard et al., 2008). 
 
1.4  The hinge region- regulation of transcriptional activity  
ERs are sensitive to post-translational-dependent events, especially in proliferation 
of tumours where their activity, ligand-dependent and independent is often deregulated. 
Several sites for ERα and ERβ have been described to increase their ligand-dependent as 
well as their ligand-independent activity (Figure 12 and 13). These sites were first 
described to be located within the N-terminal AF-1 domain for both receptors; however, 
further examination revealed that the DBD as well as the hinge region have been subject for 
ER control. Indeed, pak1 and PKA target ERα ser-305 (Bostner et al., 2010) promoting its 
transcriptional activation resulting in an increase in cyclin D1 production (Balasenthil et al., 
2004) and a decrease in its sensitivity to tamoxifen (Kok et al., 2010). Phosphorylation of 
Ser-305 prevents the acetylation of the neighbouring lysine residue K303 often mutated in 
breast cancer and leading to an increase in the sensitivity of ERα to E2 (Fuqua et al., 2000). 
ERα’s Thr-311, targeted by p38 promotes its nuclear localization and is linked to an 
increase in its activity (Lee and Bai, 2002). Moreover methylation, within the hinge domain 
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of ERα has led to a decrease in its turnover rate (Subramanian et al., 2008), suggesting that 
ERα can be regulated through modifications of its hinge region.  
 
A recent study has reported the importance of the hinge region for both ERα and 
ERβ’s transcriptional activity involving the AF-1 and AF-2 domains (Zwart et al., 2010). 
Indeed, the length and the composition of the hinge region can affect the capacity for 
transactivation for ERα however these sequences and modifications are not observed in the 
hinge region of ERβ. Results show that the interaction of ERα with SRC-1 together with 
the hinge region, allows full activation potential of ERα in both the presence of the ligand 
and in its absence. This occurrence is not observed for ERβ, which can be a reflection of 
the divergence within the AF-1 domain between both subtypes. Indeed the AF-1 domain of 
ERα is crucial for its E2-dependent activity; however it is not the case for ERβ. We, as well 
as others, have observed that the removal of the N-terminal AF-1 domain of ERβ, strikingly 
improves its response to E2.   
 
For ERα, the hinge region has 43% identity from Homo sapiens to Xenopus laevis, 
and the hinge residues between K302 and S305, immediately before the start of the LBD, 
are approximately 85% conserved between Homo sapiens to Xenopus laevi. This higher 
conservation relative to the rest of the hinge region strongly implies that this region may be 
functionally important. In fact a study showed the importance of the hinge of ERα which is 
necessary for BRCA1 interaction promoting ERα mono-ubiquitination leading to a 
disruption of its activity (Eakin et al., 2007). In effect, mutation of K305 renders breast 
cancer cells hypersensitive for proliferation and has been observed in as many as 34% of 
premalignant breast tumours. The interaction of p300 with ERα and ERβ acetylated only 
the lysine residues 266 and 268 of ERα (Kobayashi et al., 2000b) which increased its 
affinity for DNA (Kim et al., 2006). Alignment sequences have shown that several nuclear 
receptors do conserve these two lysine residues; interestingly ERβ does not contain these 
lysine residues and is therefore not a substrate for p300 acetylation at the hinge region. 
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1.4.1  The hinge of ERβ  
Realising the pressure under which the hinge region of ERs is subjected to in order 
to regulate the receptor, it was of great interest for us to observe that our results also 
revealed a role for the hinge region of ERβ. Most of our studies carried out in chapter 2, 
section 1 and 2 were achieved with the murine isoform of ERβ. Scanning through the 
sequence of murine and human ERβ revealed that only the murine isoform contained a 
perfect and unique consensus site for Akt phosphorylation. However the human isoform 
contains a partial Akt-consensus site where the serine residue has been replaced with an 
aspartic (236) which is followed by a glutamic acid (237) residue. Results from our first 
publication shows that Akt does phosphorylate serine 255 within the hinge region of mERβ 
(Chapter 2, section 1, Figure 2) and the mutation of this serine into an alanine decreased the 
potential for phosphorylation demonstrating that Akt can directly target ERβ. In fact results 
from our laboratory demonstrate that there is a direct interaction between Akt and ERβ 
following the activation of ErbB signaling pathway (data not published). In order to 
understand the impact of Akt phosphorylation on ERβ we looked at the transcriptional 
activity of the mutant mERβ S255A, following Akt activation by Hrgβ1 treatment. 
Surprisingly the transcriptional activity of the ERβ was fully recuperated following the 
mutation of this single site, suggesting that not only is the hinge region important in 
regulating the function of ERβ but in addition this site is of particular interest as, alone, it 
can determine the fate of the receptor given the proper physiological cue.  
 
Due to the high degree of similarity of both biology and sequence between mouse 
and humans, the mouse genome has been receiving considerable attention as a tool for 
cross-species comparison (Battey et al., 1999). This strong similarity has raised doubts 
regarding the general usefulness of human-mouse sequences comparison for distinguishing 
functionally conserved features against a background of recently evolved sequences. In the 
case of ERβ, there is a substitution that has occurred in time which has resulted in a 
variation to the Akt responsive sequence in the hinge region. By examining the response of 
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the hERβ in chapter 2, section 2, we show that although an aspartic residue is present 
instead of a serine residue, its response to the proposed mechanism remains similar to that 
of mERβ. Mutation of the aspartic residue abrogated the decrease in steady-state levels of 
hERβ similar to mERβ suggesting that the negatively-charged environment created by the 
aspartic acid in wild-type hERβ is in all probability mimicking a phosphorylated site, 
therefore the activation of the PI3K/Akt pathway creates a similar environment as the one 
observed with mERβ leading to a decrease in its cellular content with a parallel increase in 
ubiquitination following PI3K/Akt activation in the presence of CBP (chapter 2, section 2, 
fig .6).  
 
Given the importance of the hinge region, we examined how other nuclear receptors 
namely ERα, PR, GR, the three isoforms of ERR (α, β, γ) and PPARγ, respond to the 
activation of the PI3K-akt pathway in the presence of CBP. Our results revealed that only 
those receptors containing within their hinge a consensus site for Akt (GR and ERRβ) 
resulted in a decrease in their transcriptional activity following Akt activation in the 
presence of CBP (Chapter 2, section 1, Figure 7). In addition, this decrease occurred in the 
presence of their respective ligands, suggesting that the activation of the PI3K/Akt pathway 
was able to override the activation displayed by their respective ligand as observed with 
ERβ.   
 
1.5  Influence of ERβ regulation by Akt and CBP in breast 
cancer cells 
It is apparent now that the activation of ErbB2/ErbB3, which preferentially activates 
the PI3K/Akt pathway, targets the degradation of ERβ. Activated Akt has several targets, 
one of which is Mdm2, driving its relocalisation towards the nucleus. Akt can also target 
the phosphorylation of CBP which, in certain cases, allows for an increase in it coactivating 
potential as observed with ERα, PR and PPARγ. Results also demonstrate that all these 
events are subtype specific and while they lead to an acute degradation of ERβ that impact 
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its regulation ERα protein levels remain unaffected and its activity is on the other hand 
stimulated.  
 
1.5.1  Hrgβ1 treatment of breast cancer cell lines 
We next examined if these results were transposable to cells which endogenously 
expressed ERβ. We designed stable breast cancer cell lines which originally did not express 
either ER subtype, to express the mERβ or the mERα in order to discriminate the response 
of each receptor following the activation of the PI3K/Akt pathway. We proceeded to 
examine ERE-regulated genes by RT-PCR experiments which show that the treatment of 
cells with Hrgβ1, which do endogenously express ErbB2/ErbB3 resulted in a decrease in 
the ERE genes regulated by ERβ. Although targets for AP-1 were also available, the results 
were inconclusive. Nevertheless decreasing the amount of ERβ could potentially affect AP-
1 regulated genes in a similar manner to ERE regulated genes. Our laboratory recently 
published that activation of CXCR4 by SDF-1, which activated the MAPK cascade, 
resulted in an upregulation of proximal ERE promoters-regulated SDF-1 itself and PS2 
gene products as well as the PR gene. In addition, AP-1 genes were also looked at, under 
the treatment of tamoxifen, capable of activating ERβ. Similarly to ERE regulated genes, 
tamoxifen was capable of activating AP-1 regulated cyclinD1 and c-myc genes (Sauvé et 
al., 2009). Since we observed a decrease in the genes known to be regulated by the 
activation of ERβ, we next examine the proliferation of breast cancer cell lines.  
 
MCF-7 cells are known to express ERα, and although the expression of ERβ in this 
cell line is still under debate, several publications and our laboratory have been able to 
observe protein expression of hERβ. Similarly to mERβ, hERβ is also degraded following 
the activation of Akt and in the presence of CBP (Chapter 2, section 2, fig.6). The 
proliferation of MCF-7 treated with Hrgβ1 was observed. MCF-7 cells were strongly 
stimulated by the treatment of Hrgβ1 compared to untreated cells. However the selective 
knockdown of Mdm2, proposed to participate in the degradation of ERβ, dramatically 
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affected the rate of proliferation of Hrgβ1 treated MCF-7 cells. Preliminary western 
analysis showed that treatment of Hrgβ1on MCF-7 was capable of decreasing the levels of 
ERβ, which were restored following the knockdown of Mdm2. Measurements of the levels 
of ERα did remain unaffected. Since the decrease in Mdm2 levels could in fact promote 
apoptosis; we looked to see if the steady-state levels of p53 were affected, however we did 
not observe any difference when comparing p53 levels in Hrgβ1-treated MCF-7 vs. 
untreated-cells. This sets forth the premise that we are in fact seeing a regression in 
proliferation rather than an attempt to enter apoptosis. This proposes that the removal of 
ERβ creates a more prolific environment as opposed to its presence, which we can conclude 
that the presence of ERβ might very well regulate the activity ERα and therefore when the 
ratio of ERα/ERβ increases, we observe a greater proliferation, as observed in many cases 
of anti-hormone resistant cancers (Treeck et al., 2009).  
 
There have been reports that have looked at how the ratio of ERα/ERβ can overturn 
an effect observed on ERα. Estrogen-induced MCF-7 survival during treatment with TNF 
can be reduced by the mere reinstatement of ERβ into these MCF-7 cells, or by treatment 
with the SERD, ICI 182,720 (Lewandowski et al., 2005). The presence of ERβ was able to 
reduce the overall activity of ERα and increase the levels of p21 protein, a target of p53. 
The ratio of ERα/ERβ expression in breast tumours is becoming a popular prognostic to 
evaluate the severity of the tumour. Covaleda et al. used T47D-ERβ cell model in which 
the levels of ERβ could be reduced by adding tetracycline. It was shown that the 
proliferative actions in the T47D-ERβ cells were mediated by the ERα, whereas ERβ was 
able to downregulate the effectiveness of ERα-induced proliferation (Covaleda et al., 
2008). It cannot yet be concluded whether the inhibition via ERβ results in a reduced 
transcription of genes involved in cell division or that possibly nongenomic signal 
transduction pathways are induced as well (Figure 20). Addition of ERβ in ovarian cancer 
cell line SK-OV-3 reduced its proliferation following treatment with estrogen (Treeck et al., 
2007). Similarly the expression of ERβ in MCF-7 treated or not with estrogen can have 
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differential impact on gene regulations (Chang et al., 2006). Expression of ERβ in breast 
cancer cell lines T47D reduced tumour growth and angiogenesis (Williams et al., 2008). 
Uncovering the contribution of ERβ in the regulation of breast tumour growth is important 
for the understanding and treatment of this disease.  
 
2 Perspectives         
Many reports have examined the clinicopathologic importance of ERβ expression in 
breast cancers (Esslimani-Sahla et al., 2004; Leygue et al., 1999) although a precise role for 
ERβ has yet to be identified, some common themes are emerging, including the association 
of ERβ expression with ERα, PR, and low tumour grade, factors usually associated with a 
better clinical outcome (Jarvinen et al., 2000; Skliris et al., 2001; Speirs et al., 1999b). 
However, many of these studies executed at the molecular level examine the impact of ERβ 
by incorporating ERβ into cell lines, which might not be an accurate representation of 
endogenous levels and therefore results could be misleading due to overexpression of ERβ.  
 
In endometrial cancer, the development of a specific ERβ agonist caused regression 
of lesions in an experimentally induced model of endometriosis using human tissue (Harris 
et al., 2005) Endometriosis, characterized by the presence of endometrium-like tissue 
outside uterine cavity has been shown to express high level of ERβ and low levels of ERα. 
Selective knockdown of ERβ led to an increase in ERα expression and protein levels 
(Trukhacheva et al., 2009). Furthermore treatment of prostate cancer cell lines with a 
demethylating agent resulted in an increased expression of ERβ implying that methylation 
of ERβ is reversible and a tumour-stage specific process (Zhu et al., 2004). In agreement 
with the above observations, our results propose a mechanism whereby the levels of ERβ 
are important in the control of cellular proliferation and point to an critical regulatory 
region, not only within ERs but of other nuclear receptors as well which can help predict 
the response to the activation of specific (in this case the PI3K/Akt pathway) signaling 
events. However the results presented here can be considered as groundwork and further 
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examination of the pathways involved need to be addressed. First it would be of significant 
value to assign a physiological role to the hinge domain of ERβ in tumoural growth and 
secondly explore the molecular events which take place following a reduction in the levels 
of ERβ.  
 
2.1  An anti-proliferative role for the hinge region 
It would be of great interest to ascribe a functional anti-proliferative role to the 
hinge region of ERβ due to the discriminatory component within its sequence between ER 
subtypes particularly in ERα+/ERβ- tumours. In order to ascertain its role as a potential 
regulator of proliferation, I propose to directly observe the in vivo effect of incorporating a 
mutant ERβ harboring a point mutation at the equivalent site of ser-255 (in humans asp-
236) by lentiviral vector injections into mice models harboring an induced tumour. As our 
model demonstrates the inability of estrogen to either pronounce or reverse the observed 
ERβ degradation, the use of ovariectomized mice would provide a relatively estrogen-free 
environment and tumour growth could be identified as hormone-independent. Therefore 
ovariectomized female nude mice would be xenografted with a breast cancer cell line 
characterized as ER+/ERβ-, ErbB2+/ErbB3+ (known to be very aggressive) 
subcutaneously. Once tumours reach a particular diameter mice would be randomised to 
receive vehicle, lentivirus sh-wt ERβ (possibly targeted towards degradation) or sh-ERβ 
(D236A) (possibly stabilized). Tumour growth would be assessed by caliper measurements. 
Should the hinge region have an effect we could see two possible outcomes: 1- either a 
regression of the tumour indicating a possible tumour-suppressor activity of ERβ or 2- 
deceleration of tumour proliferation as we observed in MCF-7 cells when levels of ERβ 
were reduced by treatment of Hrgβ1.  
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2.1.1  Tumour-suppressor activity 
If we observe a regression of tumour size, we would investigate the possible event 
of cellular apoptosis. Visualizing and quantifying apoptosis on our tumour samples by 
DNA fragmentation (TUNEL assay to visualize apoptotic cells, and DNA laddering on 
agarose gel) and examining the prospect of ERβ binding to promoters of known apoptotic 
inducing markers as previously observed in the overexpression of ERβ in ERα positive 
cells, would suggest that signaling pathways activated by ErbB2/ErbB3 would activate ERβ 
(as observed in our first publication following mutation of the hinge region) and promote 
tumour regression.   
 
2.1.2    Reduction in cellular proliferation 
Should the tumour’s rate of proliferation decrease as observed in MCF-7 cells in our 
second manuscript, we could envision the likelihood of ERβ having a negative role on ERα 
activity. In fact Chang et al. showed that ERβ bound the promoter region of ERα which 
contains a single ERE site but several AP-1/sp-1 sites, following treatment with E2 as well 
as without E2. The binding was only observed in endometriosis and not in normal 
endometrial cells. In addition, ERβ has been shown to affect the gene network regulated by 
ERα in breast cancer cells and ERα down-regulation was noted in the presence of high ERβ 
levels in MCF-7 (Chang et al., 2006). It would be of interest to verify by chromatin 
immunoprecipitation if the tumours from the xenografted mice showed evidence of a 
greater number of ERβ D236A mutants at ERα promoter region and if so which 
coregulatory complexes (corepressors) are involved in order to decrease the transcription of 
the ERα gene. Of course for either outcome aforementioned, we would look at the protein 
levels of ERα, ERβ and ERβ D236A to give us an indication of the environment of the 
tumour and to support our hypothesis of ERβ’s role in breast cancer proliferation.   
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2.1.3  Possible cellular mechanisms at play 
Having demonstrated that the activation of the PI3K/Akt pathway by ErbB2/ErbB3 
leads to the targeted degradation of ERβ and the activation of ERα, then examining the 
molecular mechanisms which are at stake would aid in developing new methodologies to 
reinstate the expression of ERβ in order to decrease the ERα/ERβ ratio, a positive factor in 
breast cancer treatment. As such, developing a peptide derived from protein sequence, 
which would mask the aspartic acid 236 residue, could potentially reduce ERβ targeted 
degradation and reduce the proliferation potential. In addition it would also be of interest to 
understand the function of CBP during the degradation of ERβ. As mentioned previously in 
the discussion, we are still unsure whether CBP exerts an E4-ubiquitin ligase activity or 
acetylation of ERβ is a signal for its degradation. As for its ligase activity, it has been 
previously ascribed to the N-terminal, although neither CBP nor p300 exhibit clear or 
known consensus ligase sequences. Deletion mutants would provide information as to 
which region of CBP is involved and point mutation would determine which sites are 
important. Although inhibiting the function of CBP could be a possibility (chapter 8 HAT 
inhibitors), its vital role in every aspect of cell function implies that drug-specific delivery 
would be necessary in order to reduce non-specific effects on peripheral healthy tissues, 
therefore targeting its possible ligase activity and not its HAT activity might provide a more 
specific approach to inhibit ERβ degradation.  
 
Lastly, most of the information and the propositions stated above involve the use of 
breast cancer cells. We have stated several times the importance of considering every 
aspect of cellular biology (level of proteins expressed, cell-type and promoter context) in 
order to provide a more accurate treatment towards developing hormone-independent 
cancers. On a long-term perspective we would examine the behavior of ERβ C236A in 
other hormone-independent cancers, such as in the endometrium, prostate and colon in 
order to establish whether our observations are tissue-specific or are a general mechanism 
established by ERβ.  
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Conclusion  
 
Studies from rodent models have helped us to understand human physiology and 
propose treatments for human cancers. It is interesting to note that although both mice and 
humans are predisposed to spontaneous breast cancer; it appears that endometrial cancers 
are only spontaneous in humans (Anisimov et al., 2005). Although it is a great 
extrapolation, it would be interesting to investigate the possibility that, at least in the case 
of ERβ, the difference in sequence homology would bring a protective factor in mice as 
opposed to humans. Nevertheless we conclude that the measurement of ERα, ERβ, and 
additional proteins such ErbBs and coregulators in endocrine tumors complementing with 
studies regarding function regulation of these cellular components would provide important 
additional information not only for predicting cellular deregulation incidences but also 
anticipate better and personalized therapeutic responses. 
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From classical gland-based endocrinology to nuclear
hormone receptor biology, tremendous progress has
beenmade in our understanding of hormone responses
underlying cellular communication. Estrogen elicits a
myriad of biological processes in reproductive and per-
ipheral target tissues through its interaction with the
estrogen receptors ERa and ERb. However, our knowl-
edge of estrogen-dependent and independent action
has mainly focused on ERa, leaving the role of ERb
obscure. This review discusses our current understand-
ing of ERb function and the emerging role of intracellu-
lar signals that act upon and achieve estrogen-like
effects through phosphorylation of ERb protein.
Improving our understanding of how cellular determi-
nants impact estrogen receptor actions will likely lead
to treatment strategies for related endocrine diseases
affecting women’s health.
The estrogen receptor ERb – here and for what
purpose?
The unexpected identification of a second estrogen recep-
tor, termed ERb, in the mid-1990s rapidly forced the
scientific field to reassess the classical model of estrogen
action [1]. Originally identified in rat, then in human and
mouse [2–4], ERb was shown to share obvious structural
features and functional responses to estrogenwith its elder
homolog ERa, but also exhibited unique characteristics in
its ability to respond to cellular signals, suggesting ERb
might perform similar as well as distinct functions com-
pared to ERa.
In fact, studies characterizing ERb structure and func-
tion by analyzing ligand binding, recruitment of transcrip-
tional coregulators, interactions with cellular signaling
and the pharmacology of selective estrogen receptor modu-
lators (SERMs) among others, have increased our under-
standing of ERb and helped distinguish its role(s) from
ERa [5–7]. The characterization of mice lacking ERa and/
or ERb has also established that each receptor subtype has
overlapping and unique roles in vivo, revealing the import-
ance of these receptors in a variety of physiological pro-
cesses including male and female sexual differentiation,
fertility, ovarian function, bone formation and cardiovas-
cular aspects (Box 1).
Over the years, the role played by ERb in tissues has
become less ambiguous; however, few studies have focused
on modifications of ERb that control its biological actions.
Therefore, uncovering the molecular mechanisms regulat-
ing the activity of ERb is paramount to understanding its
role in cellular and biological events surrounding gene
regulation.
Transcriptional regulation by ERb
Activation of ERs by hormone is a multistep process rely-
ing on several events including dimerization, ligand bind-
ing, interactionwith cofactors andDNAbinding. It has also
become increasingly clear that phosphorylation of specific
sites on ERs can occur as part of both ligand-induced and
ligand-independent activities. Mostly based on their dis-
tinct and poorly conserved distribution between the two
isoforms, it is predicted that a selective use of these phos-
phorylation sites might contribute to regulate various
aspects of ERb function not always shared with ERa, in
order to complement responses to ligands and/or provide
on their own transcriptional potential.
ERb phosphorylation
Activation of ER by signal transduction pathways, in the
absence of ligand, was first suggested in the early 1990s
when ovariectomized mice were treated with epidermal
growth factor (EGF) leading to nuclear translocation of ER
and transcriptional activation [8]. Since then, the path-
ways involved and the mechanisms supporting ligand-
independent activation of ERa have become clearer
although not fully characterized. The identification of
ERb, however, has added tremendous complexity in our
understanding of potentialmechanisms bywhich estrogen-
dependent and -independent responses can be achieved.
It is nowwidely recognized that the activation of growth
factor signaling cascades can promote hormone-like
responses. Peptide growth factors of the EGF class of
ligands, such as the neuregulins/heregulins and EGF
itself, interact with cell surface receptors of the EGFR/
ErbB family of receptor tyrosine kinases to initiate phos-
phorylation-coupled activation of protein kinases, such as
MAPK/Erk, Jnk, p38 and PKB/Akt [9]. Consensus sites for
these kinases have been functionally characterized within
the N-terminal activation function-1 (AF-1) domain of ERa
and ERb (Box 2). Serines -104, -106 and -118 of ERa were
shown to be phosphorylated by MAPK/Erk [10–12],
whereas Ser-167 was described as a functional Akt site
[13]. Our contribution has allowed the identification of
serines -106 and -124 of ERb as recruiting signals for
transcriptional coactivators to mediate ERb activation
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by EGF and oncogene ras [14,15], thereby providing a
possible mechanism by which AF-1 mediates ERb
responses to ligand-independent signals. These studies
therefore highlight a prominent role of receptor phos-
phorylation through which ligand-independent activation
of ERb can occur [16,17]. A schematic representation of AF-
1 phosphorylation sites of human and mouse ERb that
regulate receptor activity and cofactor recruitment is
shown in Figure 1, as well as the ones characterized in
the hinge region and ligand-binding domain of ERb.
Examples of genes regulated by ERb in a ligand-inde-
pendent manner have been reported. For example, ERb
has a role in regulating cyclooxygenase-2 (COX-2) in feto-
placental endothelial cells, even in the absence of estrogen
[18]. Similarly, ligand-independent phosphorylation of
ERb is associated with increased promoter occupancy
and gene expression of human telomerase reverse tran-
scriptase, a major determinant in telomerase activity,
preventing apoptosis of pancreatic cancer cells [19]. Among
the possible mechanisms involved in ligand-independent
activation of ERb is the selective recruitment of steroid
receptor coactivator-1 (SRC-1) and histone acetyl transfer-
ase CREB binding protein (CBP), following AF-1 phos-
phorylation in response to EGF [14,15]. Although both
coactivators can also be efficiently recruited to ERa, this
process is not enhanced through ERa phosphorylation,
indicating that EGFR/ErbB activation signals might selec-
tively affect each ER isoform. Moreover, the phosphoryl-
ation-initiated ERb/SRC-1 complex is inefficiently
disrupted by SERM tamoxifen in normal and cancer cells
Box 1. ERa versus ERb
In vitro studies have demonstrated redundancy in the roles of ERa
and ERb; however, tissue localization revealed their shared but also
distinct expression patterns of each receptor [59], suggesting that
specific roles are probably observed. ERa is expressed in many
different tissues, including the female and male reproductive tract,
skeletal and cardiac muscle, kidney, liver and hypothalamus. ERb
displays a more limited expression pattern and is predominantly
observed in the ovary, prostate, testis, spleen, lung and areas of
hypothalamus. Further evidence of distinct biological roles for the
two isoforms is suggested by the phenotypes of ERa, ERb and ERa/b
knockout mice [60–63]. In the female aERKO mice, estrogen
insensitivity leading to hypoplasia in the reproductive tract,
hypergonadotropic hypergonadism, lack of pubertal mammary
gland development and excess adipose tissue is observed. In
aERKO males, testicular degeneration and epididymal dysfunction
are the major phenotypes. aERKO and abERKO females are infertile,
and bERKO females are subfertile owing to inefficient ovarian
function. An abnormal vascular function resulting in hypertension
was also reported in bERKO mice [64]. None of these phenotypes
have been linked with receptor phosphorylation owing to the
current lack of appropriate mouse models.
Box 2. The AF-1 and AF-2 of ERb – copartners for a shared
cause
As with other nuclear receptors, the transcriptional competence of
ERb is mediated by two nonacidic activation domains, an
activation function AF-1 located in the N-terminal region and a
ligand-dependent AF-2 located in the C-terminus (Figure 1). The
AF-2 domain is well characterized, with a highly conserved
amphipathic a-helix (H12) essential to mediate hormone-depen-
dent activation of transcription through interaction with cofactors
that facilitate chromatin remodeling and transcription. AF-1
activation is more complex and variable and depends on a wide
region consisting of several phosphorylation sites, mostly con-
sensus Ser–Pro motifs for MAPK, which dictate ERa and ERb
responses to various kinase signaling pathways [4,10,11]. AF-1
activity also depends on the recruitment of coregulators that can
be either similar or unique from those employed by AF-2 [32],
providing AF-1 and AF-2 with synergistic potential in ligand-
activated mechanisms and also with independent functions
related to cell and promoter context [6]. Thus, AF-1 emerges as a
key target for kinase-regulated events to achieve distinct as well as
concerted actions with AF-2.
Figure 1. Targeting estrogen receptor b with phosphorylation. Schematic representation of modified amino acids in human ERb with corresponding residues in mouse
ERb. The difference in numbering is due to a shorter N-terminal form of the human versus mouse isoform. Structural and functional domains of ERb include the
transcriptional activation functions AF-1 and AF-2, the DNA-binding domain (DBD), the hinge region and the ligand-binding domain (LBD). Experimentally supported
phosphorylated residues (red) with their homologous sites (black) are shown, along with the putative kinase and recruiting cofactors involved. Other potential sites (gray)
are derived from sequence homology with reported phosphorylated residues in ERa. References describing phosphorylated residues are as follows: S80 [44], S87 [29], S94
[39], S106 [14,29,39], S124 [14], S255 [16] and Y507 [17].
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[14,20], suggesting that ERb activation could occur in
tumors in which therapeutic resistance ensues.
Despite its properties to behave as an intrinsic acti-
vation domain, the AF-1 of ERb can also complement
hormonal response with AF-2 function, as is the case with
several nuclear receptors, including ERa (Box 2). Follow-
ing estrogen treatment, the expression of TGFb-inducible
early gene (TIEG), anERb target, is shown to be dependent
on the ability of AF-1 to recruit coactivators such as SRC-1
to initiate transcription [21]. Phosphorylation by the p38
pathway has also been linked to the transcriptional acti-
vation of ERb in a ligand-dependent manner, although
specific site(s) targeted by the p38 pathway have yet to be
identified [22]. However, the outcome of ERb phosphoryl-
ation by protein kinases in the presence of estrogen seems
to differ according to cell types, promoter usage and the
identity of the effector. For example, p38 pathway acti-
vation by the ErbB2/ErbB3 heterodimer, a combination
often associated with SERM-resistant breast cancers,
leads to repression of the hormonal response of ERb in
breast cancer cells through an impairment of AF-1 to
facilitate recruitment of coactivators [23]. Interestingly,
activation of ErbB2/ErbB3 induces phosphorylation of
mouse ERb at Ser-255, a site consensus for Akt
(Figure 1), resulting in the disruption of CBP from liganded
ERb, providing a possible mechanism by which ERb
response to hormone is reduced by ErbB2/ErbB3 dimer
activity [16]. Activation of protein kinase A (PKA) by
increasing cAMP intracellular levels through adenylate
cyclase activation with forskolin also stimulates ERa
and ERb activity through selective mechanisms involving
a distinct receptor phosphorylation pattern, although
neither the AF-1 nor cofactor requirement seem to be
involved [24]. Therefore, the diversity of phosphorylated
sites in ERb, their targeting by various signaling pathways
and their intrinsic potential to regulate cofactor usage has
challenged us to understand how ERb integrates numer-
ous incoming cellular signals. An overview of these path-
ways is represented in Figure 2.
ERb regulation by phosphorylation extends to the
chemokine receptor family
Recently, the identification of chemokine receptors as novel
signaling regulators of ERa and ERb has added to the
complexity by which ER-responsive gene transcription
can be regulated by upstream cellular pathways. The che-
mokine receptor CXCR4 and its ligand, the stromal cell-
derived factor SDF-1 (also referred to asCXCL12) havebeen
widely associated with metastasis of several epithelial and
hematopoietic cancers, includingbreast, prostate, ovaryand
Figure 2. Signaling networks targeting ERb. Overview of cellular signals regulating ERb transcriptional competence and degradation. Depicted are kinase pathways elicited
upon activation of growth factor receptors of the EGFR/ErbB family and of G-protein-coupled receptors such as CXCR4, which direct phosphorylation of ERb. Such
phosphorylation, as illustrated by yellow spheres labeled with the letter P, facilitates the recruitment of coactivators, such as SRC-1 and CBP, to promote transcription, and
of E3 ubiquitin ligase E6-AP which favors ubiquitination of the receptor. The Erk pathway has been linked with both processes. SRKs, Src-related kinases; AC, adenylate
cyclase; PDK1, 3-phosphoinositide-dependent protein kinase-1; PI3K, phosphatidylinositol 3-kinase.
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lung cancers [25,26]. Initial studies in breast cancer cells
expressing CXCR4 found that their chemotactic potential
was involved in the dissemination of metastases to SDF-1
producing target tissues, such as lung, liver and bone mar-
row [27]. In linewith a previous report that identifiedSDF-1
as an estrogen-regulated gene in ERa-positive ovarian and
breast cancer cells [28], we found that SDF-1 expression is
not only increased by estrogen through ERa and ERb, but
this ER-produced SDF-1 in turn activates ERa and ERb to
enhance estrogen-regulated proliferating genes and growth
of breast cancer cells [29]. In particular, ERb activation by
the CXCR4/SDF-1 axis relies on AF-1 Ser-87 phosphoryl-
ation by Erk (Figure 1), resulting in enhanced assembly of
ERb at both estrogen-responsive and AP-1 elements of
targeted promoters, including SDF-1 itself. SDF-1-induced
recruitment and activation of ERb at AP-1 sites is insensi-
tive to SERM tamoxifen, providing a way by which ERb
remains competent despite the presence of tamoxifen [29].
These findings establish an autologous regulation of SDF-1
through the ability ofERb to increase gene expression in the
context of enhanced CXCR4 activation (Figure 2), providing
a mechanism by which the CXCR4/SDF-1 axis and ER (a
and b) signaling pathwaysmutually contribute to a positive
autocrine/paracrine feedback loop underpinning breast can-
cer progression. The ER/CXCR4 pathway also opens new
perspectives as to how breast cancer cells might escape
SERM-mediated growth blockade.
A little help for ERb
AsERa and ERb undergo phosphorylation through kinase-
mediated pathways with subsequent effects on their
ligand-independent transcriptional potential, it was pre-
dicted that phosphorylation might serve as a recruiting
signal for coregulators. Candidate coregulators have been
described to interact with ERa in a manner dependent on
Ser-118 phosphorylation to support receptor activation,
such as RNA helicase [30] and splicing factor SF3a120
[31]. It is of interest that AF-1 coactivators for ERa are not
always shared with ERb, at least based on phosphoryl-
ation-directedmechanisms. Indeed, originally identified as
an AF-2 coactivator but also interacting with ERa AF-1 to
strengthen hormonal response [32], we reported that SRC-
1 was potently recruited to ERb AF-1 following phos-
phorylation of Ser-106 and Ser-124 triggered by EGF or
oncogene ras [14], a ligand-independent mechanism which
also allowed for CBP recruitment [15]. This increased
recruitment of SRC-1 and CBP has also been recently
reported to mediate ligand-independent activation of
ERb by hypoxia inducible factor HIF-1a in hypoxic con-
ditions [33]. In addition, a recent report describes ligand-
independent activation of ERb in ovarian granulosa cells
by follicle-stimulating hormone which, by enhancing PKA
signaling, triggers the recruitment of gonadotropin-indu-
cible ovarian transcription factor-4, a bridging factor for
components of the chromatin remodeling SWI/SNF com-
plex [34].
To add further complexity to the interaction of ERbwith
cellular pathways, recent evidence indicates that coregu-
lators serve as points of convergence between ERs and
growth factor signaling pathways by being targets of phos-
phorylation, an event which in most cases contributes to
enhance their transcriptional potential [35]. Whether such
modifications also serve as an interacting interface to
recruit receptors and provide selectivity is highly con-
sidered, but triggering phosphorylation events that afford
the receptor the ability to primarily recruit a coactivator
and then benefit from its enhanced transcription potential
would provide a means by which optimal transcriptional
responses can be achieved through a shared use of incom-
ing activating signals. Such a mechanism is likely to occur
in the activation of unliganded ERb by SRC-1 under
enhanced Erk signaling as SRC-1 contains several con-
sensus Erk phosphorylation sites that confer activation
potential [14,36]. By contrast, a common upcoming signal
that benefits coactivators might serve to attenuate recep-
tor activity in certain conditions. For instance, although
Akt activation confers an intrinsic activation potential to
CBP through phosphorylation of Thr-1872, it reduces the
ability of ERb and the estrogen-related receptor ERRb to
benefit from this CBP activation owing to phosphorylation
of a conserved Akt site in their respective hinge region [16].
In contrast, receptors missing this Akt site, such as ERa
and peroxisome proliferator-activated receptor PPARg,
efficiently respond to CBP coactivation. Therefore, the
availability and ability for second messenger signaling
to regulate ERb might account for the differences in
ERb action in various expressing cells and tissues, provid-
ing a coordinated and organized recruitment and acti-
vation of appropriate coactivators.
Our initial findings regarding the ability of ERb AF-1 to
recruit SRC-1 in a ligand-independent manner revealed
another layer of regulation in the actions of ERb [14]. For
example, the repressive effect of ERb on PPARg activity in
adipose tissue involves the titration of SRC-1 to ERb in a
ligand-independent manner, preventing SRC-1 from facil-
itating PPARg activation and expression of adipogenic
target genes, such as adipocyte protein 2 and adiponectin
[37]. In addition, ERb represses the transcriptional
activity of the nuclear factor of activated T-cell (NFAT3)
in a ligand-independent manner, resulting in downregula-
tion of interleukin-2 promoter activity in breast and kidney
cells [38]. Together, these studies underline the import-
ance of ligand-independent and phosphorylation-mediated
regulation of ERb to coordinate the association and func-
tionality of cofactors in order to affect its own or other
transcription factor-signaling pathways.
A bigger wardrobe for ERb
In addition to phosphorylation, other types of post-transla-
tional modifications influence ERb function. Ubiquitina-
tion, for example, promotes ligand-induced degradation of
ERb by the 26S proteasome system [39,40], a process also
characterized for ERa and essential to confer optimal
response to estrogen through continuous receptor turnover
[41]. The Carboxyl Terminus of Hsc70-Interacting Protein
CHIP, a chaperone-dependentU-box E3 ubiquitin ligase, is
essential for mediating ERb degradation by estrogen
through its interaction with the N-terminal end of ERb
[40]. This interaction switches off the transcriptional
response of ERb to hormone, in contrast to the C-terminal
end which protects unliganded ERb from degradation,
suggesting that receptor degradation is involved in the
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cessation of transcription. SUG1/TRIP1, a regulatory sub-
unit of 26S proteasome, is also involved in ERb degra-
dation in a ligand-dependent manner [40,42]. We recently
reported that ERb phosphorylation also serves as a signal
for receptor ubiquitination and degradation through the
26S proteasome. Indeed, the Angelman syndrome-associ-
ated protein E6-AP, a dual function steroid receptor cor-
egulator/E3 ubiquitin ligase initially described to
participate in the hormonal response of progesterone re-
ceptor and ERa [43], causes proteasome-mediated degra-
dation of ERb in a phosphorylation-dependent manner
[39]. The recruitment of E6-AP to ERb is induced by
Erk phosphorylation of AF-1 Ser-94 and Ser-106, without
a need for estrogen. Together with the ability of phosphory-
lated Ser-106 and Ser-124 to recruit SRC-1 under Erk
activation [14], our findings illustrate a prominent role
for a tight cluster of AF-1 phosphorylated residues (e.g.
Ser-94, Ser-106 and Ser-124) that cooperate in generating
signals to regulate the activation-degradation cycling of
ERb (Figure 1). Phosphorylation of Ser-80 of mouse ERb
has also been reported to regulate ERb degradation
through a competitive interplay with O-b-GlcNAcylation
at the same site (Figure 1). O-GlcNAcylation of ERb was
predicted to prevent Ser-80 phosphorylation resulting in
enhanced degradation and reduced activity of ERb [44].
These mechanisms provide AF-1 domain with an
important and intricate role in responding to signals that
couple ERb activity and degradation. Recently, SUMOyla-
tion, a process by which SUMO (small ubiquitin-like modi-
fier) is covalently linked to target proteins, has emerged as
a new modification of nuclear receptors and associated
coregulators. For ERa, SUMO-1 modifications are linked
with enhanced activity, a process probably also supported
by SUMOylation of SRC-1 [45–47]. Although the functional
significance of this modification remains to be elucidated,
SUMOylation is emerging as an important and highly
dynamic process that adds to the complexity of fine-tuning
nuclear receptor functions. ERb has not yet been described
to be SUMOylated but it will be of interest to analyze
whether and how this modification affects ERb function in
a similar manner.
ERb, an asset or a threat
Although ERa is expressed in a majority of breast cancers,
providing a strong predictive value and first line therapy
using SERMs, the clinical significance of ERb is still under
debate [48–50]. Reductions in ERb protein expression have
been associated with the development of an invasive phe-
notype and poor survival rates during tamoxifen treat-
ment, raising the possibility that loss of ERb encourages
tumorigenesis [51–53]. However, the positive association of
ERb with the proliferation marker Ki-67 might also sup-
port the role of ERb in tumor proliferation [54–56]. The
unfortunate development of acquired resistance to the
SERM tamoxifen is a major clinical problem, and although
tamoxifen has an initial benefit a majority of patients
eventually relapse. These limitations illustrate the need
to better understand the role of ERa andERb in resistance.
Preclinical and clinical studies revealed that upregula-
tion of Erk signaling is associated with failure of endocrine
therapy [57]. Although effective in blocking ER AF-2 func-
tion, tamoxifen does not prevent SRC-1 from activating
ERb in EGF-activated cells [14,20]. Additionally, in the
presence of tamoxifen, SDF-1 maintains the ability to
increase ERb recruitment and expression of AP-1
regulated genes such as cyclin D1 and c-Myc [29], two
genes commonly overexpressed in primary breast tumors
and recognizedmarkers of early steps in breast tumorigen-
esis [58]. The cellular mechanisms by which ER-positive
tumor cells overcome anti-estrogen effects and exhibit
excessive proliferation remain uncertain at present, but
these findings are consistent with the possibility that the
autocrine regulation and coupling between Erk-regulated
pathways and ER signaling might function despite the
presence of tamoxifen. Our observations that both pro-
cesses require Erk activation to phosphorylate ERb Ser-
87 are consistent with a prominent role of the AF-1 region
in sustaining transcription potential by ERb. It is tempting
to speculate that the ability of deregulated cellular signals
to phosphorylate and upregulate AF-1 activity during
tamoxifen exposure might supplant AF-2 as the primary
route of ER activation in tamoxifen-resistant breast cancer
cells. In consonance, the use of ERb protein expression
levels, complemented with its site-specific phosphorylation
status, might represent a valuable biomarker in tumor
screening which, along with ERa protein analysis, has the
potential to indicate therapeutic responses and course/
outcome of disease for breast cancer patients.
Concluding remarks
Phosphorylation emerges as an additional and significant
determinant in regulating ERb transcriptional compe-
tence in response to hormone and ligand-independent
signals. With the extent of upstream signaling pathways
involved, the diversity of sites being characterized and the
high degree of homology of some of them with nuclear
receptor isoforms, it is highly expected that additional
and/or overlapping roles will be revealed for individual
receptor functions. Although specific roles of several of
these sites in ERb have been unveiled, a tremendous task
remains to functionally assign detailed mechanistic
relationships and biological significance to each putative
site in dictating ERb function. Global gene expression
profiling affected by specific site disruption and mouse
knock-inmodels are necessary strategies to address target-
and tissue-specific requirements for ERb phosphorylation.
Future studies are thus needed to further elucidate how
ERb exerts its varying effects.
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